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Abstract+
Addiction treatment guidelines recommend routinely screening for co-
occurring mental disorders. Improvement in the identification of clients with psychiat-
ric comorbidity has been prioritized because of the negative consequences of failing 
to detect it. There is a lack of research on the prevalence of co-occurring mental dis-
orders in residential alcohol and other drug treatment services. There is need for re-
search that validates and compares the short screening measures used to identify co-
occurring mental disorders in alcohol and other drug treatment participants. In Study 
1, the mental disorder status of 278 participants resident in alcohol and other drug 
treatment settings in Australia was estimated using the Addiction Severity Index—
Self Report (Cacciola, Pecoraro, & Alterman, 2008) and the Mental Health Screening 
Form III (Carroll & McGinley, 2001). The estimated rate of diagnosable Axis I men-
tal disorder comorbidity varied from 64% to 71% depending upon the cutoff score 
used. Due to the high estimated rates of comorbid mental disorder the prevalence and 
taxonomy of mental disorder comorbidity in residential alcohol and other drug treat-
ment services was then assessed in Study 2 using a semi-structured interview. Study 2 
involved administration of five commonly used mental disorder screening instruments 
validated against the Structured Clinical Interview for DSM-IV-TR Axis I Disorders 
(First, Spitzer, Gobbon, & Williams, 2002). Participants were 124 randomly selected 
clients with alcohol and other drug problems attending residential recovery services of 
The Salvation Army. Presence of comorbid Axis I mental disorder(s), total scores on 
the Psychiatric Status domain of the Addiction Severity Index, the Mental Health 
Screening Form III, the Self-Reporting Questionnaire 20, the Self-Reporting Ques-
tionnaire 25 and the Modified Mini Screen were recorded. Lifetime prevalence of any 
comorbid Axis I disorder was 87.5% and 30-day prevalence was 73.3%. More than 
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19% of participants met full criteria for a psychotic disorder over the previous 30-
days. Among the short screening measures validated the Modified Mini Screen and 
the Mental Health Screening Form III displayed high sensitivity, high negative pre-
dictive values and high area under the curve scores. Psychiatric comorbidity exists in 
almost eight-out-of-ten clients in residential alcohol and other drug treatment services. 
Psychotic disorders are particularly prevalent when compared to the general popula-
tion (19% vs. 0.45%) (Morgan et al., 2011). The findings suggest a need for integrat-
ed treatment of comorbid disorders, strong linkages between alcohol and other drug 
treatment services and psychological services and training for alcohol and other drug 
treatment workers to better address comorbidity.  
+
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Chapter+1+Introduction+
Screening for co-occurring mental disorders in alcohol and other drug treatment ser-
vices is a formal process that assesses clients for symptoms of comorbid mental dis-
orders. Screening does not determine a mental disorder diagnosis but indicates the 
need for further assessment (Connecticut Department of Mental Health and Addiction 
Services, 2007). Screening for co-occurring mental disorders is needed in alcohol and 
other drug treatment services because the prevalence of co-occurring mental disorders 
is high. Over a 25-year period, epidemiological and service utilization data have con-
sistently shown that mental disorders and addictions co-occur at least as frequently as 
they exist independently of one another (Davidson & White, 2007). The successful 
identification of co-occurring mental disorders using validated screening measures is 
a first necessary step towards improving treatment for the co-occurring disorders pop-
ulation (Croton, 2005b; Ziedonis et al., 2005). 
According to the US Surgeon General, ‘Mental disorders are health conditions 
… characterized by alterations in thinking, mood or behaviour … associated with dis-
tress and/or impaired functioning’ (US Department of Health and Human Services, 
1999, p. 6). The Diagnostic and Statistical Manual of Mental Disorders-IV-TR nosol-
ogises 15 major categories of mental disorder including substance-related disorders 
(American Psychiatric Association, 2000). Substance-related disorders are divided 
into substance use disorders and substance-induced disorders. Substance use disorders 
are further taxonomized into substance abuse and substance dependence. Substance 
abuse is defined as a ‘maladaptive pattern of substance use manifested by recurrent 
and significant adverse consequences related to the repeated use of substances’ 
(American Psychiatric Association, 2000, p. 198). Substance dependence is seen as 
more serious than substance abuse and involves negative sequelae such as physical 
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dependence upon the substance, (tolerance to and/or withdrawal from use), and an 
almost obsessive continuation in using the substance despite negative life conse-
quences (American Psychiatric Association, 2000). There are 11 categories of sub-
stance use disorder under these two heads corresponding to 11 categories of substance 
that can be abused and/or the subject of dependence: alcohol, amphetamines, caffeine, 
cannabis, cocaine, hallucinogens, inhalants, nicotine, opioids, phencyclidine (PCP) 
and sedatives, hypnotics or anxiolytics (American Psychiatric Association, 2000). 
To be diagnosed with a substance-induced, as opposed to a substance use, dis-
order there must be evidence of substance intoxication or withdrawal temporally re-
lated to maladaptive behaviour and any of a wide variety of symptoms characteristic 
of other mental disorders. Symptoms such as, ‘delirium, dementia, amnesia, psycho-
sis, mood disturbance, anxiety, sleep disorders, and sexual dysfunction’ (US 
Department of Health and Human Services, 2007, p. 2). Examples of substance-
induced disorders include substance-induced depression being experienced by some-
one in cocaine withdrawal and substance-induced psychosis being experienced by 
someone intoxicated on crystal methamphetamine (ice).  
Mental disorders that are not substance related include anxiety disorders, 
mood disorders, psychotic disorders and somatoform disorders (American Psychiatric 
Association, 2000). Anxiety disorders occur when people suffer the normal feelings 
experienced in response to danger or stress, but at extreme levels that disrupt daily 
functioning (Queensland Health, 2010). Anxiety disorders include panic disorder, 
generalised anxiety disorder, social anxiety disorder, posttraumatic stress disorder, 
obsessive compulsive disorder and specific phobias. Mood disorders are reported to 
be common among adults and occur when a person’s mood is sufficiently extreme in 
pole and duration to cause clinical impairment in key areas of function such as social 
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or work performance (American Psychiatric Association, 2000; Australian Bureau of 
Statistics, 2007). Mood disorders include major depressive disorder, dysthymic disor-
der and bipolar disorder. Psychotic disorders involve disturbances to perception 
and/or thinking along with negative symptoms such as catatonia and flat emotion that 
result in a disconnection with reality, significant distress and impaired functioning 
(American Psychiatric Association, 2000). Psychotic disorders include schizophrenia, 
schizoaffective disorder, schizophreniform disorder and brief psychotic episode. So-
matoform disorders are when a person experiences symptoms suggestive of a physical 
illness, but these symptoms cannot be fully explained by an identifiable medical con-
dition or the direct effect of a substance, nor are they due to another mental disorder 
(American Psychiatric Association, 2000). Somatoform disorders include conversion 
disorder, somatization disorder, hypochondriasis, body dysmorphic disorder and pain 
disorder.  
The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-5, American Psychiatric Association, 2013), released during the period of this 
study, has approximately the same number of conditions as its predecessor (324 down 
from 374) (Grohol, 2013). Whilst there are some nosological changes and changes to 
form in DSM-5 (see tables 1-2 below and tables 23-24 in Appendix A), very little of 
substance changed that is relevant to this study. 
Table 1. Changes from DSM-IV-TR to DSM-5 (Peele, Goldstein, & Crowel, 2013) 
DSM-IV-TR     DSM-5 
Multiaxial     No axes 
 
Not otherwise specified (NOS) Replaced with “other disorder” or “unspecified 
disorder” 
 
Coded diagnosable conditions, 374 Coded diagnosable conditions, 324 
 
Number of ICD-9-CM’s factors in- Number of ICD-9-CM’s factors influencing 
fluencing health status, V-codes,  health status, V-codes listed, 88 
22 
 
Number of ICD-9-CM’s codes ex- Number of ICD-9-CM’s codes explicating abuse 
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placating abuse (995.xx), 5 abuse (995.xx), 44 abuse codes 
codes 
 
DSM-IV-TR = Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (American Psychiatric 
Association, 2000), DSM-5 = Diagnostic and Statistical Manual of Mental Disorders, fifth edition (American Psychiatric 
Association, 2013), ICD-9-CM = The International Classification of Diseases, Ninth Edition, Clinical Modification (National 
Center for Health Statistics & Centers for Medicare and Medicaid Services, 2010). 
 
Table 2. DSM-IV-TR disorders combined in DSM-5 (Peele et al., 2013) 
DSM-IV-TR     DSM-5 
Expressive language disorder and mixed  Language disorder 
receptive expressive language disorder 
 
Autistic disorder, Asperger disorder, child-  Autism spectrum disorder 
hood disintegrative disorder, and Rett disorder 
 
Shared psychotic disorder and delusional dis- Delusional disorder 
order 
 
Catatonic schizophrenia, disorganized schiz-  Schizophrenia 
ophrenia, paranoid schizophrenia, residual 
schizophrenia, undifferentiated schizophrenia 
 
Bipolar disorder, most recent episode mixed Bipolar disorder I or II (no unique code in DSM-
5) 
 
Panic disorder without agoraphobia and panic Panic disorder 
disorder with agoraphobia 
 
Dissociative fugue and dissociative amnesia Dissociative amnesia 
 
Somatization disorder, undifferentiated somato- Somatic symptom disorder 
form, pain disorder 
 
Primary insomnia and insomnia related to an- Insomnia disorder 
other mental disorder 
 
Primary hypersomnia and hypersomnia related Hypersomnia disorder 
to another mental disorder 
 
Sleepwalking disorder and sleep terror disorder Non-rapid eye movement sleep arousal dis- 
 orders 
 
Vaginismus and dyspareunia Genito-pelvic pain/penetration disorder 
 
Sexual aversion Not listed in DSM-5 
 
Abuse disorder, dependent disorder (alcohol, Use disorders (mild or moderate/severe) 
cannabis, phencyclidine, hallucinogen, in- 
halant, opioid, stimulant, sedative/hypnotic/ 
anxiolytic, and other use disorder 
 
Polysubstance dependence Not listed in DSM-5 
 
DSM-IV-TR = Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (American Psychiatric 
Association, 2000), DSM-5 = Diagnostic and Statistical Manual of Mental Disorders, fifth edition (American Psychiatric 
Association, 2013). 
!
!
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The circumstance where a person is said to meet diagnostic criteria for both 
one or more substance use disorders and one or more mental disorders at the same 
time has been described using a variety of phrases including mentally ill chemical 
abuser (MICA or MICAA), mentally ill substance user (MISA), mentally ill substance 
using (MISU), chemically abusing mentally ill, or chemically addicted mentally ill 
(CAMI), substance abusing mentally ill (SAMI), mentally ill chemically dependent 
(MICD), dually diagnosed, dually disordered, co-morbidity, comorbidity, comorbid 
disorders, complex presentations, concurrent disorders, co-existing disorders and in-
dividuals with co-occurring psychiatric and substance misuse disorders (ICOPSD) 
(Center for Substance Abuse Treatment, 2005; Queensland Health, 2010). Many of 
these terms do not sit well with recovery-oriented approaches that seek to avoid label-
ing people and thereby reducing their human experience and identity to an often stig-
matized mental and/or substance use disorder label. Some of the above terms have 
also been used to refer to different situations causing some confusion and necessitat-
ing a careful examination of the circumstance being described whenever one encoun-
ters any of these terms. For example “co-morbidity” as a neologism in medicine was 
first used by Feinstein in 1970 to describe any co-existing clinical entity to an index 
disease under study and “dual diagnosis” can refer to the co-occurrence of a mental 
disorder and a developmental disorder (Feinstein, 1970). Amongst these variations in 
terminology, according to Croton (2005a) the most longstanding and widely recog-
nised term is ‘dual diagnosis.’ This term has been criticized for failing to 
acknowledge that there may be more than two diagnoses for an individual and for 
portraying individuals in this situation as more homogenous than they are (Drake et 
al., 2001; Howard, Stubbs, & Arcuri, 2007). The term ‘comorbidity’ has currency in 
Australia but has also been criticized by carer groups for its pathological overtones 
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(Croton, 2011). ‘Co-occurring disorders’ is the preferred term in the United States of 
America (Croton, 2005a). Most recently a new phrase, ‘mental health-substance use’ 
has appeared (Croton, 2011). This thesis will use the term ‘co-occurring disorders’ 
(COD), but other terms such as comorbid mental disorder(s) and comorbidity may be 
used synonymously where appropriate.  
A concurrent diagnosis with at least one or more mental disorders and one or 
more substance use disorders is necessary for a person to be said to have “co-
occurring disorders” (Center for Substance Abuse Treatment, 2005). It should be rec-
ognised, however, that whatever the descriptive term employed, it is being appended 
to a functionally and diagnostically heterogenous group with a range of clinical needs 
(Ridgely, Goldman, & Willenbring, 1990).  
In short, the term co-occurring disorder includes a multiplicity of diagnostic catego-
ries, a broad range of severities of disorder, and a potential for confounding between 
severity in one area and diagnosis in another (Flynn & Brown, 2008, p. 38). 
The term “co-occurring disorders” therefore refers to the co-occurrence of all types of 
substance use and mental disorders at all levels of severity (Flynn & Brown, 2008).  
A"Note"on"Aetiology"
An extensive literature has built up attesting to the strong association between sub-
stance use disorders and mental disorders and at least five different models have been 
proposed to explain possible aetiological mechanisms underlying this apparent asso-
ciation (Merikangas et al., 1998). These aetiological models may be categorised as 
secondary psychopathology models, secondary substance abuse models, bidirectional 
models, common-factor models, and a final type of model which proposes the two 
conditions are unrelated (Hall, 1996; Kay-Lambkin, Baker, & Lewin, 2004). Of the 
five, only the final model allows that the rate of co-occurrence could simply be a sta-
tistical phenomenon (Lehman, Myers, & Corty, 1989).  
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Secondary psychopathology models propose mental disorder problems are 
triggered (caused) by substance misuse in individuals who have an existing vulnera-
bility to mental disorder (Dixon, Haas, Weiden, Sweeny, & Frances, 1991; Kay-
Lambkin et al., 2004; Soar, 2003). According to Zubin and Spring who first elucidat-
ed the model, each human is endowed with a degree of vulnerability that under vary-
ing circumstances will express itself as an episode of mental disorder (1977). In the 
context of co-occurring substance misuse with psychosis, the vulnerability model pos-
its substance use as causally related to the onset and relapse of mental disorder 
(Hides, Lubman, & Dawe, 2004). A large number of studies have demonstrated a 
simple association between substance misuse and psychosis (Degenhardt & Hall, 
2001; Hall, 1998; Solowij & Michie, 2007; Tien & Anthony, 1990). In some research 
correlational, cross-sectional and prospective data has suggested causation when there 
is a temporal sequence involved (when substance use, predominantly cannabis, pre-
cedes the onset or relapse of psychosis cross-sectionally or prospectively) (Berglund 
& Ojehagen, 1998). According to Mueser, Drake and Wallach (1998), however, there 
are several reasons why the temporal order of onset does not clearly demonstrate 
causative aetiology. Firstly these authors note that onset is gradual for both mental 
disorders and substance use disorders with no clear demarcation of the moment of on-
set (Mueser et al., 1998). Further, attempts to find demographic or clinical differences 
based upon the order of onset have failed (Mueser et al., 1998). It may also be added 
that epidemiological data support an earlier median age of onset for mental disorders 
than substance use disorders and not the other way around. For example, during 2001-
2003 83.5% of 9, 282 respondents with a lifetime history of comorbidity reported that 
the mental disorder arose before any abuse or dependence upon substances in the na-
tionally representative National Comorbidity Survey Replication conducted in the 
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United States of America (Kessler, Berglund, Demler, Jin, & Walters, 2005; Kessler 
et al., 1996). Additionally, no aetiological mechanisms underlying any proposed 
causative process or processes have been elaborated by researchers who support this 
model. It would seem equally possible it is a common vulnerability underlying both 
the substance use and the mental disorder(s) as it is one disorder causing the other. 
Given that rates of mental disorder (including psychosis) have been relatively stable 
or perhaps even fallen in the general population while rates of substance misuse have 
increased significantly during the same time period, a directly causal relationship 
seems less likely (Degenhardt, Hall, & Lynskey, 2003; Der, Gupta, & Murray, 1990; 
Jablensky, 1995 for a review; Joyce, 1987). A number of reviews of the available evi-
dence have been unable to reach any strong conclusions on causality (Hall, 1998; 
Hall, Degenhardt, & Teesson, 2004; Thorncroft, 1990). 
Secondary substance misuse models posit that mental disorder increases a per-
son’s susceptibility to substance misuse or given an alternate formulation that mental 
disorder symptoms lead to substance misuse (Kay-Lambkin et al., 2004; Soar, 2003). 
Based upon psychodynamic work in the 1970s early formulations of this theory estab-
lished a self-medication hypothesis whereby susceptible (mentally disordered) indi-
viduals were drawn to substance misuse by the specific psychotropic effects of sub-
stances intentionally chosen to alleviate the symptoms and general malaise of their 
mental disorder (Khantzian, 1985). In the context of psychosis and substance misuse, 
Hides and others refer to this theory as the self-medication (coping) model (2004). 
The basic premise of this model is that people with mental disorder symptoms self-
medicate to provide relief from the accompanying general symptoms of dysphoria and 
therefore to help cope with the debilitating effects of chronic mental disorder (Hides 
et al., 2004). Relying upon correlational, time sequenced cross-sectional and prospec-
! 24!
tive data, some researchers assert there is little evidence for the self-
medicating/coping model (Hides et al., 2004; Mueser, Yarnold, & Bellack, 1992). 
Other researchers think there is evidence (Berglund & Ojehagen, 1998; Brady et al., 
1990; Deykin, Levy, & Wells, 1986; Dixon et al., 1991) and argue the self-medication 
model is one of the most compelling reasons why people with a mental disorder use 
drugs (Khantzian, 1985). 
Bidirectional models assert that mental disorders and substance misuse disor-
ders interrelate. Thereby either or both disorders may influence the other(s) (Soar, 
2003). According to this model multiple different factors may be involved in causing 
mental disorder problems and substance misuse problems (Kay-Lambkin et al., 2004). 
In 1998 commentators stated that despite intuitive appeal, bidirectional models re-
mained largely untested and theoretical (Mueser et al., 1998). However, one example 
of a bidirectional model did find that personality traits are both influenced by, but also 
play a role in, the development of a lifetime history of alcohol dependence and abuse 
and also of anxiety and depression (Ostlund, Spak, & Sundh, 2004).  
Common factor models involve one or more common factors thought to in-
crease the risk of both mental and substance use disorders. Possible common factors 
include personality disorder(s), genetic factors, neurobiological problems and stress-
ful events (Kay-Lambkin et al., 2004). There is moderately strong evidence Antisocial 
Personality Disorder is a common factor that contributes to increased rates of COD 
(Mueser et al., 1998). Other factors that have been proposed include socioenviron-
mental stress (e.g., poverty, unemployment), poor social competence (Soar, 2003) so-
cioeconomic status and cognitive functioning (Mueser et al., 1998). A number of 
studies may be cited as evidence that shared genetic factors do not account for in-
creased rates of comorbidity (Mueser et al., 1998), however, one example of a com-
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mon factor model based upon genetics is provided by Wilhelm, Wedgwood, Niven 
and Kay-Lambkin (2006). In the case of smoking/nicotine dependence these authors 
opine that a common genetic vulnerability could increase both the likelihood of expe-
riencing depression and the likelihood of experiencing the positive effects of nicotine 
(an elevation in mood, subjective increases in wellbeing and even anti-depressant 
properties through excitation of the serotonergic system) (Wilhelm et al., 2006).  
Finally the unrelated model suggests mental disorders and substance use dis-
orders may be unrelated (Kay-Lambkin et al., 2004). A personality model provides an 
example of one of these “unrelated” models (2004). This personality model proposes 
two different enduring personality characteristics as causative of substance misuse in 
those with mental disorder (psychosis). Neuroticism (habitually negative mood states, 
low stress tolerance and control of one’s mood) and impulsivity (sensation-seeking, 
risk taking and behavioural disinhibition) (Hides et al., 2004). Essentially the model 
suggests that people with high neuroticism and impulsivity do not deal well with 
stress when it is encountered, choosing harmful ways to deal with it (substance mis-
use). Although initially unrelated, disorders may still interact and exacerbate each 
other under the unrelated model (Lehman et al., 1989). 
Comorbid psychiatric disturbance can arise prior to, concurrently with, or fol-
lowing the commencement of substance abuse. There is an additive effect, a cumula-
tive interaction between the two disorder types, but there is no persuasive evidence to 
suggest one model should be adopted over others to explain any possible association 
between the aetiology of the two (Howard et al., 2007; Wilhelm et al., 2006). Instead 
researchers assume no single model accounts for all cases of comorbidity and allow 
both that different models may explain comorbidity in different COD subgroups and 
that more than one model may apply to an individual (Lehman et al., 1989; Mueser et 
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al., 1998; Wilhelm et al., 2006). It should be recognised that ‘[a]s in other areas of 
medicine, monolithic theories about etiology, coupled with simplistic approaches to 
treatment, spells disaster for patients with complicated problems’ (Mirin, 1988, p. 
154). !
Costs"and"Consequences"of"Co4occurring"Disorders"
Substance use disorders and mental disorders are significant personal and societal 
problems. Monetarily, estimates vary as to the exact annual cost to society of sub-
stance-related problems, but all the estimates agree that it is a huge amount of money. 
For example, whilst it has been asserted the annual estimated cost to society of sub-
stance-related problems worldwide is more than US$200 billion (Fabricius, Langa, & 
Wilson, 2008), there are also estimates of US$600 billion and more recently US$700 
billion that cover the United States alone (National Institute on Drug Abuse, 2012, 
2015). The social cost of alcohol and drug abuse in Australia alone was estimated at 
AUD$55.2 billion during the 2004/2005 financial year (July 1, 2004 to June 30, 2005) 
(Collins & Lapsley, 2008). Such figures suggest the worldwide US$200 billion figure 
is likely to be a gross underestimation. The AUD$55.2 billion total cost of alcohol 
and drug abuse in Australia during 2004/2005 consisted of AUD$15.3 billion due to 
abuse of alcohol (27.3%), AUD$31.5 billion due to tobacco (56.2%) and AUD$8.2 
billion due to the abuse of illicit drugs (14.6%) (Collins & Lapsley, 2008). Irrespec-
tive of the exact accuracy of what are very large figures, the monetary costs of alcohol 
and drug misuse are significant and they are on the rise, having risen by 23% in Aus-
tralia from 1998/99 to 2004/05 in adjusted dollars (Collins & Lapsley, 2008).  
Like substance use disorders, there is no question mental disorders in and of 
themselves are an enormous burden on the individual and society as a whole. Mental 
disorders caused more than 18% of disability worldwide according to the Global Bur-
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den of Disease study conducted by the World Health Organization (Lopez & Murray, 
1998). Measured by the number of years living with a disabling condition, depression 
has been reported as the leading cause of disability worldwide (Edward, Hearity, & 
Felstead, 2012; Murray & Lopez, 1996). The burden of mental disorders even exceeds 
the burden of disease caused by all cancers (Alonso et al., 2004). In Australia in 2004, 
mental disorders were the leading cause of the nonfatal burden of disease and injury 
and third only to cancer and cardiovascular disease as the leading overall cause of the 
burden of (fatal and nonfatal) disease and injury (Begg et al., 2007). 
Comorbidity or suffering both substance use and mental disorders at the same 
time also has important consequences for society and the individual. Problems facing 
people with CODs include poorer treatment response (Grella & Stein, 2006; Hasin et 
al., 2002), increased incidence of relapse (Hasin et al., 2002; Mueser et al., 1998; 
Swofford, Kasckow, Scheller-Gilkey, & Inderbitzin, 1996), an inability to maintain 
functional stability (Ziedonis & Stern, 2001), family difficulties and limited social 
relationships (Ziedonis & Stern, 2001), increased unemployment (Ziedonis & Stern, 
2001), victimization (Goodman, Rosenberg, Mueser, & Drake, 1997), incarceration 
(Abram & Teplin, 1991), violence (M. S. Swartz et al., 1998), depression, suicidal 
behaviour (Bartels, Drake, & McHugo, 1992), homelessness (Drake, Osher, & 
Wallach, 1991), hospitalization (Haywood et al., 1995), HIV (Adams, 2008; Brunette, 
Mueser, & Drake, 2004), and Hepatitis C (Rosenberg et al., 2001). On a systemic-
basis undetected comorbidity leads to higher service utilization and costs (Dickey & 
Azeni, 1996). Combined data from 2010-2011 in the United States of America 
showed that 44.7% of past year emergency room visits in that country were from 
adults with co-occurring mental and substance use disorders (Substance Abuse and 
Mental Health Services Administration, 2013). In 2005, in most cases in Australia 
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where a mental or behavioral disorder was recorded as the underlying cause of death, 
the abuse of psychoactive substances such as alcohol and heroin was also involved 
(Australian Institute of Health and Welfare, 2008).!
The"Clinical"Emergence"of"Co4Occurring"Disorders"
Internationally, the problem of co-occurring disorders was first highlighted by clini-
cians who identified “young mentally disordered vagrants” and “young adult chronic 
patients” in the mid 1970s to early 1980s (Bachrach, 1982; Bassuk & Gerson, 1980; 
Caton, 1981; Pepper, Kirshner, & Ryglewicz, 1981; Robbins, Stern, Robbins, & 
Margolin, 1978; Segal, Baumohl, & Johnson, 1976-1977; S. R. Swartz & Goldfinger, 
1981). The young adult chronic patients, as opposed to older deinstitutionalized pa-
tients, were the first of the post-deinstitutionalization generation of people with chron-
ic mental disorder who had never been institutionalised in asylums for a significant 
period of time (S. R. Swartz & Goldfinger, 1981). These quite quickly came to be de-
scribed as ‘a problem of considerable dimension, one seriously compromising the op-
eration of the mental health system’ (Galanter, Castaneda, & Ferman, 1988, p. 231). 
When the asylums were progressively closed from the 1950s onwards, people with 
chronic mental disorders were moved out of institutions into the world to face all the 
demands and pitfalls of daily living including access to substances of abuse. At the 
same time as these past institutionalised patients were being disinterred from the insti-
tutions, a new generation of people with serious mental disorder also arrived who 
twenty or thirty years previously would have been long-term asylum patients, but in-
stead were now supposed to be managed in the community (Bachrach, 1982). Accord-
ing to some with the benefit of hindsight this era of deinstitutionalization into a socie-
ty with high availability of substances set the scene for the co-occurrence of substance 
use and mental disorder becoming a serious social concern (Mueser et al., 1998). The 
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heavy patterns of ineffective service utilisation characteristic of this new population 
were of great concern to early commentators (Ridgely et al., 1990). These patients 
were quickly known as regulars at hospital emergency departments and psychiatric 
units and according to some authors it was particularly those with histories of drug 
abuse who evidenced a service utilisation pattern described as intensively ‘heavy, dis-
continuous, and episodic’ (Richardson, Craig, & Haugland, 1985, p. 104). 
Segal and Baumohl (1980) and Prevost (1982) give two early summaries of 
the system-stressing characteristics of the co-occurring disorder population:!
The chronically dysfunctional have long histories of unemployment and minimal oc-
cupational skills. They show consistently poor judgment in the management of their 
finances and social relationships and have long-standing psychological problems that 
have resulted in multiple hospitalizations and frequent minor entanglements with the 
law. They are often said to be drug or alcohol abusers and are described as “minimiz-
ing,” “denying,” and “projecting” responsibility for their problems. Characteristically 
they do not follow through on treatment plans (Segal & Baumohl, 1980, p. 359). 
 
We do know that although these patients do not make up a diagnostically homogene-
ous population, they have certain characteristics in common. They have difficulty 
forming stable relationships and have little or no natural support systems. Socially 
and psychologically fragile, and often psychotic, they are acutely vulnerable to stress. 
They frustrate our treatment efforts, resist ongoing affiliation, and frequently choose 
a sporadic semi-involvement during recurring crisis periods in their lives (Prevost, 
1982, p. 173). 
In the thirty-five years since this description three research findings have con-
sistently come out of studies into this population: 1) the co-occurrence of substance-
related disorders and mental disorders is common, indeed in clinical settings co-
occurring disorders are expected to be the rule, not the exception (Ridgely et al., 
1990); 2) comorbidity is associated with a plethora of negative outcomes (already 
noted above), and 3) the parallel but separate mental disorder and substance misuse 
treatment systems have delivered fragmented and ineffective care to this population 
(Drake et al., 2001).  
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The"Emergence"of"Co4Occurring"Disorders"in"Research"
Knowledge of co-occurring disorders originally emerged as an unexpected feature of 
research into the epidemiology of mental disorders in the United States of America. 
Internationally, epidemiological surveys of the population prevalence of CODs are 
dominated by two large studies done in the United States, the National Epidemiologi-
cal Catchment Area (ECA) Study and the National Comorbidity Survey (NCS). Be-
tween them the Ecological Catchment Area Study and the National Comorbidity Sur-
vey established the methods of modern psychiatric epidemiology (Insel & Fenton, 
2005). It was these population-based surveys, and others that subsequently mirrored 
them internationally, (including Australia’s 1997 and 2007 National Surveys of Men-
tal Health and Wellbeing), that brought to light the size and scope of the co-occurring 
disorders problem on an international, population-wide basis. It is because of these 
studies that we know the prevalence of CODs among the general population is high 
(Kessler et al., 1996). 
The National Institute for Mental Health’s multisite Ecological Catchment Ar-
ea study (ECA) aimed to estimate the prevalence rates of mental disorders in the 
United States population. It became ‘the largest, most comprehensive survey of men-
tal disorders ever conducted in the United States’ (Bourdon, Rae, Locke, Narrow, & 
Regier, 1992, p. 663). A collaborative research project, the ECA was conducted from 
1980 to 1984 by five university research teams sponsored by the National Institute for 
Mental Health (NIMH): Yale University (New Haven), Johns Hopkins University 
(Baltimore), Washington University (St Louis), Duke University (North Carolina) and 
the University of California at Los Angeles (UCLA) (Los Angeles) (Bourdon et al., 
1992; Regier et al., 1990). The five geographically-defined catchment areas had popu-
lations ranging from 270,000 to 420,000 (Regier et al., 1988). From these, the ECA 
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study originally surveyed a total of 18,571 household and 2,290 institutional residents 
personally or by proxy means (Bourdon et al., 1992). Whilst the ECA study was con-
sidered the largest and most comprehensive survey of mental disorders ever conduct-
ed at the time, the methodology the study employed involved surveying people from 
five distinct areas only – instead of surveying a nationally representative sample. This 
method has subsequently been criticized as being a significant flaw that resulted in the 
study not being generalizable (Helzer & Pryzbeck, (1988). The sample reported on 
and used for the prevalence rates cited below excludes the proxy interviews, leaving a 
total of 20,291 participants. These participants went through two interviews one-year 
apart with a telephone interview in between (Bourdon et al., 1992). They were as-
sessed for current disorders according to the third edition of the Diagnostic and Statis-
tical Manual for Mental Disorders (American Psychiatric Association, 1980) over the 
past month, past six-months, past year and over their entire lifetime using the NIMH 
Diagnostic Interview Schedule (Robins, Helzer, Croughan, & Ratcliff, 1981) 
(Bourdon et al., 1992; Regier et al., 1990). The prevalence of mental disorders rec-
orded by the ECA study is reported in Table 3 below. 
Table 3. Ecological Catchment Area Survey Disorder Prevalence Rates (Regier et al., 
1990).!!
Drug/Disorder   1 Month   6 Months  Lifetime 
Type    Prevalence  Prevalence  Prevalence 
Any Disorder   15.7%   19.5%   32.7% 
 
Mental Disorders   13%   15.1%   22.5% 
 Anxiety   7.3%   8.9%   14.6% 
 Affect   5.2%   5.8%   8.3% 
 Schizophrenic  0.7%   0.9%   1.5% 
 
Substance Use Disorders  3.8%   6.1%   16.7% 
 Alcohol   2.8%   4.8%   13.5% 
 Other Drug  1.3%   2%   6.1% 
 
Substance use disorders accounted for a high proportion of the disorders de-
tected by the ECA study. Alcohol disorders were the most frequently detected disor-
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der and other drug disorders were the third most frequently detected disorder (Helzer 
& Pryzbeck, 1988). The median age of onset for disorders as a whole was 16 years, 
the median duration people experienced disorders as a whole 10.4 years and 75% of 
all disorders had their onset before 24 years of age (Hall, 1996). The median age of 
onset for anxiety disorders was 15 years, for drug disorders 19 years and for alcohol 
disorders 21 years (Christie et al., 1988). 
The ECA study’s figures on comorbidity concentrate on lifetime comorbidity, 
or the experience of a person having one or more disorders over the course of their 
lives, (not necessarily concurrently) (Regier et al., 1990). More than 60% of the 33% 
of ECA respondents with at least one lifetime disorder had two or more disorders 
(Kessler et al., 1994). Of the 22.5% who had a lifetime prevalence for a non-
substance-related mental disorder, 16.2% had mental disorders only, 3.1% had mental 
and alcohol disorders, 1.5% had mental and other drug disorders and 1.7% had disor-
ders from all three categories combined (Regier et al., 1990). Eighty percent of these 
respondents with multiple disorders reported onset before the age of 20 (Christie et 
al., 1988). Those with a lifetime history of alcohol disorder were almost twice as like-
ly to have a (comorbid) mental disorder (37%) than the general population (Regier et 
al., 1990). Perhaps most significantly, 53% of those with a drug other than alcohol 
disorder also had a lifetime history of comorbid mental disorder, a rate more than 
double that found in the general population (Regier et al., 1990).  
A methodological advantage that the ECA study enjoyed over predecessor 
community studies was its measurement of base-rates for positive and negative 
groups on a disorder-by-disorder basis (Regier et al., 1984; Weissman, Myers, & 
Harding, 1980). This allowed proper odds ratios to be calculated reporting on the in-
creased risk of having a comorbid disorder given the presence of an initial disorder 
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(Regier et al., 1990). The adjusted odds ratios or increased risks of having a comorbid 
mental or alcohol and other drug disorder for those with, as opposed to those without 
specific disorders are reported in Table 4 below: 
Table 4. Odds Ratios For Comorbidity On a Disorder-by-Disorder Basis (Regier et 
al., 1990) 
Initial Disorder   Odds Ratio  Odds Ratio 
    Comorbid Mental Comorbid Substance 
Alcohol    2.3* 
 
Other Drug   4.5* 
 Marijuana  3.8 
 Cocaine   11.3 
 Opiate   6.7 
 Barbiturate  10.8 
 Amphetamine  6.2 
 Hallucinogen  8.0 
 
Mental       2.2 
 Anxiety      1.7 
Schizophrenia     4.6 
*Significant at p < .001 
!
These figures revealed for the first time those with an alcohol disorder were 2.3 times 
more likely to have a comorbid mental disorder than those without an alcohol disor-
der. Those with a drug other than alcohol disorder were 4.5 times more likely to have 
a comorbid mental disorder than those without a drug other than alcohol disorder 
(Regier et al., 1990). These figures agreed with other studies conducted around the 
same time that reported when drug problem severity increases, likelihoods for comor-
bid disorders also increase (Flynn, Craddock, Luckey, Hubbard, & Dunteman, 1996; 
H. E. Ross, Glaser, & Germanson, 1988). On a disorder-by-disorder basis, some of 
the odds ratios of suffering a comorbid mental disorder given a certain substance use 
disorder were quite remarkable: for example those with cocaine disorders had 13.2 
times as many schizophrenia disorders as those without cocaine disorders (Regier et 
al., 1990). 
Examined from the reverse standpoint of those with a mental disorder, indi-
viduals with a lifetime history of a mental disorder were 2.2 times as likely to have a 
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substance use disorder (with a lifetime prevalence of substance use disorders of 
28.9% against a general population rate of 16.7% and a rate of 13.2% among those 
who did not have a mental disorder) (Regier et al., 1990). Forty-seven percent of 
those with a schizophrenia disorder had a comorbid substance use disorder, 4.6 times 
as many as those without a schizophrenia disorder (Regier et al., 1990). Those with an 
anxiety disorder were 1.7 times more likely to have a substance use disorder as those 
without an anxiety disorder (Regier et al., 1990). 
Finally, it was also notable that with alcohol use disorders, there was a strong 
association between alcohol disorders and gender (Hall, 1996). The lifetime preva-
lence of alcohol disorders was 24% for men and 5% for women while the 12-month 
prevalences were 12% for men and only 2% for women (Hall, 1996). Men also re-
ported a significantly higher lifetime prevalence of mental, alcohol and other drug 
disorders overall (35.4% for men vs. 30.0% for women, p < .01) (Bourdon et al., 
1992). The extent of comorbidity revealed by the landmark ECA study provided the 
impetus for a follow-up NIMH-supported National Comorbidity Survey (NCS) 
(Bourdon et al., 1992). The mental disorder screening measure used in the ECA, the 
Diagnostic Interview Schedule, was also developed by an international taskforce aus-
piced by the World Health Organisation into the Composite International Diagnostic 
Interview (CIDI) (Bourdon et al., 1992; Robins et al., 1988). 
The National Comorbidity Survey (NCS) was a congressionally-mandated 
study into the comorbidity between substance-related mental disorders and non-
substance-related mental disorders conducted between September 14, 1990 and Feb-
ruary 6, 1992 (Kessler et al., 1994).  The NCS was the first time a structured psychiat-
ric interview had been administered to a nationally-representative sample (Kessler et 
al., 1994). For this collaborative, epidemiologic investigation, 8098 respondents com-
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prised a ‘stratified, multistage area probability sample of persons aged 15 to 54 years 
in the noninstitutionalized civilian population in the 48 coterminous states’ (Kessler et 
al., 1994, p. 18).  
The NCS had several advantages over the Ecological Catchment Area study: 
1) countering some criticisms of the ECA study (e.g., made by Helzer and Pryzbeck 
(1988)), the NCS sample was a genuinely nationally representative sample; 2) NCS 
diagnoses were based upon the revised third edition of the Diagnostic and Statistical 
Manual for Mental Disorders (American Psychiatric Association, 1987), an update 
from the third edition; and 3) in addition to prevalence and incidence, the NCS fo-
cused in upon risk factors as well (Kessler et al., 1994). 
The NCS used a modified version of the newly developed Composite Interna-
tional Diagnostic Interview (CIDI) (Robins et al., 1988) to report upon the lifetime 
prevalence and 12-month prevalence of 14 DSM-III-R disorders (Kessler et al., 
1994). Major depression, mania, dysthymia, panic disorder, agoraphobia, social pho-
bia, simple phobia, generalized anxiety disorder, alcohol abuse, alcohol dependence, 
drug abuse, drug dependence, antisocial personality disorder and nonaffective psy-
chosis (NAP) were assessed. NAP was a summary category for schizophrenia, schiz-
ophreniform disorder, schizoaffective disorder, delusional disorder and atypical psy-
chosis (Kessler et al., 1994). “Severe disorders” were defined as ‘(1) 12-month mania 
or NAP, (2) lifetime mania or NAP with 12-month treatment or role impairment, or 
(3) 12-month depression or panic disorder with severe impairment (hospitalization or 
use of antipsychotic medication)’ (Kessler et al., 1994, p. 9). Any respondent who re-
ported psychotic symptoms was re-interviewed by experienced clinicians using an 
adapted version of the Structured Clinical Interview for DSM-III-R (Spitzer, 
Williams, Gibbon, & First, 1988, 1992) due to this instrument’s reliability in the di-
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agnosis of schizophrenia (Kessler et al., 1994; Williams et al., 1992). NCS diagnoses 
of NAP were based upon these clinical re-interviews, not the CIDI (Kessler et al., 
1994). Table 5 below contains the prevalence rates reported by the nationally repre-
sentative National Comorbidity Survey and also notes the comparable ECA study life-
time prevalence. 
Table 5. National Comorbidity Survey Disorder Prevalence Rates (Kessler et al., 
1994; Regier et al., 1990) 
Drug/Disorder   NCS 12-Month NCS Lifetime ECA Study Lifetime 
Type    Prevalence Prevalence Prevalence 
Any Disorder   29.5%  48%  32.7% 
Substance Use Disorder  11.3%  26.6%  16.7% 
Anxiety Disorders  17.2%  24.9%  14.6% 
Affective Disorders  11.3%  19.3%  8.3% 
Psychosis   0.5%  0.7%  1.5% 
NCS = National Comorbidity Study, ECA = Ecological Catchment Area Survey. 
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The prevalence figures for substance use disorders reported by the NCS sug-
gested slightly more than one-in-four Americans would experience a substance use 
disorder in their lifetime and that more than one-in-ten Americans were currently ex-
periencing a substance use disorder at any given time. The retrospectively reported 
median age of onset for mental disorders was 11-years-old and for substance use dis-
orders 21-years-old (Kessler et al., 1996). Anthony and colleagues published a report 
that included both the incidence and prevalence of any non-medical use of each sub-
stance as recorded by the NCS (Anthony, Warner, & Kessler, 1994). The figures are 
reported in Table 6. 
Table 6. Prevalence of non-medical lifetime use and dependence on substances 
(Anthony et al., 1994) 
Substance   Lifetime   Dependence 
    Use (%)   (%) 
Alcohol    91.5%   14.1% 
Cannabis   46.3%   4.2% 
Cocaine    16.2%   2.7% 
Stimulant (Amphetamine)  15.3%   1.7% 
Anxiolytic/Sedative/Hypnotic 12.7%   1.2% 
Analgesic   9.7%   0.7% 
Psychedelic   10.6%   0.5% 
Heroin    1.5%   0.4% 
Inhalant    6.8%   0.3% 
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Notably for comorbidity; of the 48% of respondents who reported a lifetime 
history of disorder, 21% had one disorder, 13% had two disorders and 14% had three 
or more disorders (Kessler et al., 1994). These figures revealed for the first time on a 
population-wide basis that 56% (or more than half) of Americans who had a lifetime 
history of disorder, had more than one disorder in that lifetime (or that comorbidity 
was more likely than not) (Kessler et al., 1994). The rates of co-occurring mental dis-
orders in those with a substance-related disorder were also high. Of those with a life-
time substance-related disorder 51.4% also had at least one lifetime mental disorder 
(Kessler et al., 1996). Of those with a 12-month substance-related disorder 42.7% also 
had at least one 12-month mental disorder (Kessler et al., 1996). Conversely among 
those with a lifetime mental disorder, 50.9% also had at least one lifetime substance-
related disorder and among those with a 12-month mental disorder, 14.7% also had at 
least one 12-month substance-related disorder (Kessler et al., 1996). These figures 
revealed that at any given point in time (12-month prevalence) the rate of co-
occurrence of mental disorders in those with a substance-related disorder was much 
higher than the co-occurrence of a substance-related disorder in those with a mental 
disorder (42.7% vs. 14.7%). That is, a co-occurring disorder of the other type was 
much more common among the substance-disordered than the mentally disordered 
(Kessler et al., 1996). Another interesting measurement relevant to comorbidity the 
NCS offered was a temporal analysis of which type of disorder occurred first in those 
with comorbidity. This analysis revealed that among respondents with a lifetime his-
tory of comorbidity 83.5% retrospectively reported that the mental disorder arose be-
fore any abuse or dependence upon substances (Kessler et al., 1996). Among the 12-
month co-occurring disordered, 89.3% retrospectively reported the mental disorder 
arose before the substance use disorder (Kessler et al., 1996). 
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A major finding of the NCS was that the great majority of current (12-month) 
psychiatric burden in society was concentrated in a highly comorbid 14% of respond-
ents who had a lifetime prevalence of three or more disorders (Kessler et al., 1994). 
This highly comorbid sixth of the population suffered six-of-every-ten (58%) 12-
month disorders and nearly nine-of-every-ten (89%) severe 12-month disorders rec-
orded in the survey (Kessler et al., 1994). It is to this highly comorbid sub-population 
this thesis will return when it examines co-occurring disorders among those in resi-
dential treatment. 
The NCS figures on the population prevalence of mental disorders and the 
population prevalence of the co-occurrence of mental disorders and substance use 
disorders represented significant increases on those reported by the ECA study 
(Kessler et al., 1996). The figures on substance use disorders were generally similar, 
except for an increase in cocaine disorders (Anthony et al., 1994). The NCS found 
that 51% of those with a lifetime history of substance-related disorder also had a life-
time history of mental disorder compared to the Ecological Catchment Area study 
figure which was only 38% (Kessler et al., 1996). As a result of the NCS the lifetime 
prevalence of any disorder among the United States population was now estimated at 
just under one-in-two people and the 12-month prevalence for current disorder was 
nearly one-in-three Americans (Kessler et al., 1994). Fifty-one percent or one-in-two 
Americans had tried an illicit drug over their lifetime and the rate of drug dependence 
was the highest of any country on record (Anthony et al., 1994). Comorbidity of sub-
stance-related and non-substance-related disorders was also now known to be more 
likely than not on a population-wide basis (Kessler et al., 1994). For some commenta-
tors the implications of the NCS results were clear, Hall stated: 
We need to improve our ability to treat people who have co-morbid mental and sub-
stance use disorders. Specialist mental health services need to be better at recognizing 
and treating co-morbid substance use disorders among their clients. … Specialist 
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drug and alcohol staff have a similar responsibility to recognize mental health disor-
ders among their clients (Hall, 1996, p. 168). 
Kessler agreed, saying: 
These results have a number of implications for treatment. Perhaps the most obvious 
is that special assessment and treatment procedures are needed for patients who pre-
sent with co-occurring addictive and mental disorders. … In addition, clinicians 
should routinely consider the possibility of a co-occurring disorder [and] [a]mong pa-
tients with only one type of disorder … clinicians should be aware that these patients 
are at increased risk of the subsequent occurrence of later disorders … making them 
prime candidates for preventive interventions (Kessler et al., 1996, p. 29). 
The figures and findings reported by the nationally-representative NCS have 
subsequently been mirrored throughout the world in epidemiological studies conduct-
ed over the past two decades (Australian Bureau of Statistics, 2007; Merikangas et al., 
1998; WHO International Consortium in Psychiatric Epidemiology, 2000). The Na-
tional Institute of Mental Health Epidemiologic Catchment Area study and the Na-
tional Comorbidity Survey were formative to the field of psychiatric epidemiology, 
but they are not without limitations and nor have they gone without criticism. Both 
studies (and subsequent epidemiological studies) have been criticised for not proceed-
ing beyond merely describing a range of demographic correlates associated with men-
tal disorder to clarifying how such factors may operate (Weissman, 1987). In this 
sense they were thought by some to present findings with little utility to the mental 
health of ill people (Weissman, 1987). The methodology the two studies employed 
has also been criticised for using a cross-sectional, single point in time retrieval of 
lifetime psychopathology approach that is heavily reliant upon long term recall 
(Anthony, Eaton, & Henderson, 1995; Giuffra & Risch, 1994). This methodology that 
relies upon memory has been criticised as severely underestimating the effects of for-
getting and is therefore thought to underestimate the rates of lifetime prevalence 
(Giuffra & Risch, 1994; Simon & VonKorff, 1995). In this regard the ECA and NCS 
studies have been criticised for presuming the accuracy of long-term recall even 
though autobiographic memory is often affected in numerous psychiatric disorders 
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(Simon & VonKorff, 1995). Follow-up interviews conducted 12-months after the 
ECA study found significant discrepancies in the 12-month and lifetime psychiatric 
histories self-reported by respondents when both original and follow-up diagnostic 
information was considered. Twelve-month disorder rates rose from 20% to 28% and 
lifetime rates from 32% to 44% (Regier et al., 1998). A study that simulated an 
ECA/NCS type study but instituted a constant rate of forgetting among respondents 
produced the exact cohort effects seen in the ECA and NCS studies (where the rates 
of mental disorders were higher in younger cohorts than older cohorts who have had 
more time to forget earlier incidences of disorder in their lives). In the ECA study, for 
example, the 25-44 year old cohort had a higher lifetime prevalence than the 65-and-
over cohort on 64 of 68 symptoms used to diagnose disorders (Giuffra & Risch, 
1994). The authors involved in this study with simulated rates of forgetting stated for-
getting could have a confounding role in producing cohort differences (Giuffra & 
Risch, 1994). Whether the results reported by the ECA and NCS studies represented 
genuine cohort effects or were due to the confounding effect of forgetting is therefore 
unknown due to the methodology used. The authors of the simulated study concluded 
the ECA/NCS results strongly suggest methodological flaws in data collection 
(Giuffra & Risch, 1994). 
The two Australian versions of the ECA/NCS-type studies were completed in 
1997 and 2007. Figures on population-wide comorbidity from the first Australian ver-
sion of this study, the National Survey of Mental Health and Wellbeing were con-
sistent with the rest of the world and are reported in Table 7 below with the NCS fig-
ures for comparison (Andrews, Slade, & Issakidis, 2002; Burns, Teesson, & Lynskey, 
2001; Teesson & Burns, 2001; Teesson & Proudfoot, 2003).  
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Table 7. Epidemiology of Australian Mental Disorders with US Comparison 
(Henderson, Andrews, & Hall, 2000; Kessler et al., 1994; Teesson, Hall, Lynskey, & 
Degenhardt, 2000) 
Drug/Disorder   NSMHWB 12-Month NCS 12-Month 
Type    Prevalence (%)  Prevalence (%) 
Any Disorder   17.7%   29.5% 
Anxiety Disorder  9.7%   17.2% 
Affective Disorder 5.8%   11.3% 
 
Substance Use Disorder  7.7%   11.3% 
Alcohol   6.5%   9.7% 
Other Drugs  2.2%   3.6% 
NSMHWB = National Survey of Mental Health and Wellbeing, NCS = National Comorbidity Study.!
 
 The second Australian epidemiological study, the National Survey of Mental 
Health and Wellbeing 2 conducted in 2007, also reported results similar to those re-
ported all over the world (Slade et al., 2009). Nearly half (45.5%) of Australians aged 
16-85 years had experienced a lifetime anxiety, affect and/or substance use disorder 
(Slade et al., 2009). One-in-five (20%) had experienced a disorder in the 12-months 
prior to the survey interview (Slade et al., 2009). These results are reported in Table 8 
below with the first Australian national survey as a comparison: 
Table 8. Epidemiology of Australian Mental Disorders in 1997 and 2007 (Henderson 
et al., 2000; Slade et al., 2009; Teesson et al., 2000) 
Drug/Disorder   NSMHWB 1997  NSMHWB 2007 
Type    12-Month Prev.  12-Month Prev. 
Any Disorder   17.7%   17.0% 
 Anxiety Disorder  9.7%   14.4% 
 Affective Disorder 5.8%   6.2% 
 
Substance Use Disorder  7.7%   5.1% 
 Alcohol   6.5%   4.3% 
 Other Drugs  2.2%   1.5% 
NSMHWB 1997 = National Survey of Mental Health and Wellbeing 1 conducted in 1997, NSMHWB 2007 = National Survey of 
Mental Health and Wellbeing 2 conducted in 2007, 12-Month Prev. = 12-month prevalence. 
 
The Australian epidemiologic surveys utilised the same basic methodology as the 
ECA and NCS studies. They are therefore susceptible to the same criticisms of the 
limitations and possible flawed methodologies utilised by these studies. The Australi-
an epidemiological surveys found, for example, cohort effects indicating the preva-
lence of mental disorder declines with age where this may not actually be the case. 
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The"Prevalence"of"Co4Occurring"Disorders"in"Treatment"Popula4
tions"
In the period between the Ecological Catchment Area study and the National Comor-
bidity Survey, commentators stated that, ‘Given the apparent magnitude of the dual 
diagnosis problem, it is notable that there are so few recent studies on the epidemiolo-
gy of this syndrome’ (Galanter et al., 1988, p. 220). The epidemiology or population-
wide prevalence of COD has been well studied and reported since this lament. At the 
same time as epidemiological research highlighted the population-wide prevalence of 
co-occurring disorders during the 1990s and 2000s, research into comorbidity among 
those seeking treatment for mental and alcohol and other drug disorders was also un-
dertaken. This research noted the poorer treatment response and outcomes experi-
enced by those who suffer COD in treatment settings compared to those diagnosed 
with one disorder alone in such settings, (as noted above). Researchers also investi-
gated whether sequential, parallel or integrated treatment produced better outcomes 
for the COD population – a question still the subject of debate although commentators 
favour integrated treatment (Flynn & Brown, 2008). Twenty-five years of COD re-
search in treatment populations later, what has not improved is research into the 
screening, prevalence and nature of comorbidity in the treatment/clinical population. 
This is despite the realisation that, 
While much is still to be learned about what constitutes effective treatment, there is 
general agreement that, in order to provide any treatment, it is first necessary for 
treating clinicians and agencies to recognize that a co-occurring disorder exists 
(Croton, 2007, p. 2). 
In 2008 Flynn and Brown stated, 
There is [still] a need to clarify the rates of COD and, more specifically, the rates of 
mental disorder among substance abuse treatment clinics. While prevalence for the 
general population can be seen as having obvious significance for national planning, 
prevalence in substance abuse treatment programs is the immediate concern of the 
substance abuse treatment field and constitutes the demand we are required to address 
(p. 37). 
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Among researchers it is recognised that, ‘Planning processes need to be in-
formed by accurate estimates of the prevalence of co-occurring disorders and identifi-
cation of best practice responses’ (Croton, 2005b, p. 3). It is generally accepted that 
the prevalence of COD in alcohol and other drug (AOD) “treatment-seeking” popula-
tions is even higher than that found in the population-wide epidemiological studies 
(H. E. Ross et al., 1988; Whiteford & Groves, 2009). Internationally, however, esti-
mates of the proportion of AOD clients across all treatment modalities who also suffer 
from a comorbid mental disorder vary as widely as the methods used to obtain the in-
formation. One overview summarized the literature by suggesting that comorbid life-
time mental disorder prevalence in treatment populations is between 50% and 75% 
(Center for Substance Abuse Treatment, 2007). Figures from 35%-90% are common 
(Fabricius et al., 2008), with 42-60% estimated in Australia (Cole & Sacks, 2008), 
57% in South Africa (Fabricius et al., 2008), just over 50% in the United States 
(Watkins et al., 2004) and 35%-53% in the United Kingdom (Weaver et al., 2001). 
The experimental variation used to obtain the above figures, however, renders the re-
search base covering the prevalence of COD in treatment populations largely incom-
parable and inadequate. See Appendix B for detailed information on the database 
searches conducted to inform this thesis. 
Perhaps the largest dataset that speaks to comorbidity in substance abuse 
treatment populations in general is the National Survey of Substance Abuse Treat-
ment Facilities (N-SSATS) conducted by the Substance Abuse and Mental Health 
Services Administration (SAMHSA) in the United States of America (Substance 
Abuse and Mental Health Services Administration, 2014). In the most recent example 
of this survey 14,148 of 14,630 treatment facilities responded. This provided a one-
day census of 1,249,629 clients enrolled in substance abuse treatment on March 29, 
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2013. This survey estimates that 563,071 or 45.1% of those 1,249,629 consumers 
were suffering co-occurring mental disorders on that day (Substance Abuse and 
Mental Health Services Administration, 2014). Methodologically, however, this fig-
ure is based upon each of 14,148 treatment services across the United States of Amer-
ica “estimating” what proportion of their clientele suffered a co-occurring mental dis-
order without giving any information about how this “estimate” is reached at any of 
the system, service or individual levels.  For example, the estimates of comorbidity in 
the survey could be made on the basis of existing official diagnoses only. The esti-
mates could be made on the basis of completely different methodologies from one 
service to the next. Against this uncertain methodological background, variation be-
tween the estimated rates of comorbidity reported by the survey ranged from a low of 
35.8% in “Other” US Federal Government treatment services to a high of 66.7% in 
“Department of Veterans Affairs” US Federal Government treatment services. Varia-
tion between different facility operations that contain different treatment modalities is 
to be expected (a topic that will be discussed in significant detail below). But varia-
tion across states from a low estimate of 27.6% of all clients in Hawaii to a high esti-
mate of 73.1% of all clients in New Hampshire is unexpected and difficult to explain 
except through methodological variability. Given the lack of a consistent method of 
estimating comorbidity being prescribed by the study, such variation on an overall 
state-to-state basis is likely due to low reliability in the methods used for estimating 
comorbidity rates. As a result, the overall 45.1% figure is unreliable. 
In the case of the residential alcohol and other drug treatment modality up-to-
date research on the prevalence of co-occurring disorders in this treatment context 
simply does not exist. This is because much of the previous research into the preva-
lence of COD in “treatment” populations reports on collective samples sourced from 
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mixed treatment modalities. Compton and others (2000), for example, report on a 
sample aggregated from public outpatient methadone clinics, outpatient and inpatient 
drug-free programs, outpatient programs for drug-abusing prostitutes and residential 
recovery shelters for women. Ross and others (1988) and Rush and others (2013) also 
use a similar mixed-modality aggregated approach. This approach wrongly assumes 
comorbidity across different treatment modalities is monolithic and that co-occurring 
disorder sufferers are homogenous. The Committee for the Substance Abuse Cover-
age Study explains that: 
The modalities, [however,] were designed for different types and severities of prob-
lems, and prospective clients often have very set ideas about what type of treatment 
they want. As a result, the profiles of clients admitted to the major modalities are 
quite different, and one cannot compare the performance or results of each modality 
with the others as if they were all simply interchangeable (Gerstein & Harwood, 
1990, p. 12). 
Residential treatment services, for example, are designed for clients ‘with major im-
pairments and social deficits, including histories of serious criminal behaviour’ 
(Gerstein & Harwood, 1990, p. 188). The overall level of treatment intensity in differ-
ent treatment modalities increases from a starting point in the outpatient treatment 
modality to its highest intensity in the residential treatment modality and in theory this 
should match the levels of problem severity or disability. Clients in different treat-
ment modalities should not have homogenous comorbidity needs and research over a 
long period of time confirms this is the case (Gerstein & Harwood, 1990; J. Ross et 
al., 2005). In one large study that countenanced 30-years of research into substance 
abuse treatment populations using three large datasets that covered several million 
substance abuse treatment episodes, the authors found across-modality population dif-
ferences that remained stable over decades (Craddock, Rounds-Bryant, Flynn, & 
Hubbard, 1997). Craddock and colleagues stated: 
Perhaps most importantly, each modality … [serves] distinctly different clients. [For 
example, c]ompared with the other clients in other treatment modalities, long-term 
residential clients… were most likely to be male, most likely to have illegal sources 
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as their major source of income, least likely to be employed full-time, and most likely 
to be involved in a criminal lifestyle in the year prior to treatment. … These com-
monalities across decades indicate that the distinctiveness of client characteristics 
held up over time, thus supporting the importance of studying differences among cli-
ents in various treatment modalities. Outcomes from treatment must be interpreted 
within the context of these modality differences (1997, p. 56). 
 More recently, Ross and others (2005) examined heroin users not seeking treatment 
and heroin users seeking treatment across three different treatment modalities (detoxi-
fication units, residential rehabilitation facilities and outpatient metha-
done/buprenorphine maintenance agencies). These authors found heroin users in resi-
dential treatment services had significantly higher levels of psychological distress, 
suicide history, Axis I and Axis II disorders (J. Ross et al., 2005). It was concluded 
that heroin users in residential treatment represented a hard core compared with those 
in other treatment modalities (J. Ross et al., 2005). A comprehensive review ap-
proaching the topic of comorbidity from the reverse standpoint of the prevalence of 
comorbid alcohol and other drug disorders among those in mental health services also 
found that the prevalence of comorbidity differed across service settings and geo-
graphical areas (Carra & Johnson, 2009). In the light of such research, assuming all 
co-occurring disorder sufferers across all treatment modalities are homogenous is un-
justified and likely to produce inaccurate results, especially where screening instru-
ment validation is concerned, as we will read below. Treating clients from different 
modalities as an aggregate for the purposes of research does not adequately deal with 
across-modality client differences. Prevalence research needs to be service-modality-
specific to accurately record the needs of clients in each service modality. The popu-
lation should not be treated as a monolith and results from studies that employ this 
methodology should be viewed as suggestive only. 
The dearth of contemporary data about mental disorder comorbidity in the res-
idential AOD treatment modality is evident in recent reviews (Center for Substance 
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Abuse Treatment, 2007; Mills et al., 2010). Sources of prevalence rates for mental 
disorder comorbidity specifically in the residential AOD treatment modality cited in 
recent reviews are based on research conducted by Nancy Jainchill 30-to-40 years ago 
in the United States of America (Jainchill, 1994). This research conducted between 
1974 and 1984 within therapeutic communities reported a lifetime COD rate of 82% 
and a 30-day prevalence of just 45% (Jainchill, 1994). But both mental disorder and 
AOD treatment environments, diagnostic systems and drugs of abuse have changed 
since this time. This research was also conducted before the emergence of 
pseudoephedrine-based amphetamines and the drug ice, as well as cannabis of far 
greater potency, all of which are thought to have a role in psychosis. Additionally, 
Jainchill's (1994) review identified a 10-year pattern of worsening psychiatric symp-
toms among those entering treatment for substance use disorders during 1974 to 1984. 
It is currently unknown whether this worsening trend has continued. 
The little research that has been conducted in recent years has tended to focus 
on samples with specific drug-problem types. For example, research on heroin-taking 
populations that only investigated the co-occurrence of anxiety and depression (Darke 
& Ross, 1997) and outpatient clients on methadone maintenance (Callalay, Trauer, 
Munro, & Whelan, 2001). Or research into the psychological profile of people admit-
ted to a methamphetamine detoxification program (Dyer & Cruickshank, 2005). In 
2005 heroin users were again studied, but only depression and posttraumatic stress 
disorder were assessed (J. Ross et al., 2005). Such subpopulations specifically linked 
to opioid or amphetamine dependence alone are not generalizable to the broader sub-
stance use disorder treatment population. 
More recently when Axis I mental disorder comorbidity has been assessed, it 
has either been among treatment modalities other than residential treatment or across 
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a multitude of modalities mistakenly treated as a monolith. For example, Axis I men-
tal disorder comorbidity has been assessed, but only among outpatients and limited to 
youth (Hides, Lubman, Elkins, Catania, & Rogers, 2007). In a second study Axis I 
mental disorder comorbidity was again assessed, but this time across specialized as-
sessment, withdrawal management (detox), residential and non-residential treatment 
modalities sourced from a teaching hospital, a general hospital and a community 
agency all treated as homogenous (Rush et al., 2013).  
Despite several decades of research into co-occurring disorders significant 
gaps in the literature remain. Little is known about the prevalence or taxonomy of co-
occurring disorders in the residential alcohol and other drug treatment modality. Ex-
perts have long opined that, !
Plans at the national, state, treatment service and clinician levels need to be informed 
by accurate data on the prevalence, nature and harms of co-occurring disorders within 
each of the treatment systems. Such data will hone the planning of resource alloca-
tion, program design, policy needs, clinical practice needs, and competency needs 
(Croton, 2005b, p. 3). 
In the absence of such data, treatment for those with CODs may be suboptimal result-
ing in higher service utilisation and costs as well as all the harms known to attend un-
detected, untreated CODs (Wilhelm et al., 2006). Study 1 of this thesis addresses this 
gap in the literature and aims to provide estimates of the prevalence of co-occurring 
mental disorders within the residential alcohol and other drug treatment modality in 
Australia. The questions investigated by Study 1 include: What is the prevalence of 
co-occurring Axis I mental disorders in residential AOD treatment services? Has 
mental disorder comorbidity worsened in those presenting to residential AOD treat-
ment services since the last known figures taken from the 1970s and 1980s? Has the 
rate of psychotic-based disorders increased in residential AOD treatment services? 
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The"Need"for"Validated"Screening"Instruments"
As government, clinical and research awareness of CODs have increased so has the 
realisation the accurate identification of comorbidity is an important first step towards 
improving treatment and effectively managing this population (Ziedonis et al., 2005). 
One Australian expert put it succinctly in 2005 stating that, ‘The first, necessary step 
towards responding more effectively to co-occurring disorders is to improve the de-
tection of any co-occurring disorder’ (Croton, 2005b, p. 6). Accordingly, both Aus-
tralian and international guidelines have come to advocate routine screening for 
CODs (Center for Substance Abuse Treatment, 2005; Dawe, Loxton, Hides, 
Kavanagh, & Mattick, 2002; Gordon, 2008; Hawkings & Gilburt, 2004; Health 
Canada, 2002; Institute of Medicine, 2006; Mills et al., 2010; NSW Health, 2000; 
Substance Abuse and Mental Health Services Administration, 2002). Many govern-
ment initiatives have also been aimed at improving the identification and treatment of 
those suffering both a substance use disorder and a mental disorder in treatment set-
tings. In Australia, for example, the National Comorbidity Project 1998-2003 devel-
oped as a response to the National Strategic Drug Framework 1998-2003 and the Se-
cond National Mental Health Plan 1998-2003 (Croton, 2011). This project had a 
threefold aim: 1) to identify what comorbidity is; 2) to identify effective treatments 
for comorbidity; and 3) to identify how the overall response to the issue of comorbidi-
ty can be improved (Croton, 2011). The National Comorbidity Project was followed 
by the National Comorbidity Initiative 2003-2010 which aimed to: 1) raise awareness 
of comorbidity amongst health professionals; 2) promote examples of good practice; 
3) support general practitioners and other health professionals to improve treatment 
outcomes; and 4) facilitate resources and information for individuals needing care 
(Croton, 2011). National Comorbidity Guidelines that advocated routine screening for 
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CODs released in 2010 were one facet of the National Comorbidity Initiative (Mills et 
al., 2010).  
Despite the release of guidelines, government initiatives, and increasing 
awareness of the poor outcomes associated with COD, the ongoing failure to identify 
and thereafter treat co-occurring mental disorders in substance misuse treatment is 
well documented (Flynn & Brown, 2008). In one large 3-year study that assessed the 
rates of detection of CODs in the New Jersey addiction treatment system, CODs were 
only detected in 22% of actual cases (N = 47,379; Hu, Kline, Huang, & Ziedonis, 
2006). In another significant study counselors failed to identify 32% of 2,128 clients 
who reported psychiatric symptoms as needing mental health services (Mericle, 
Martin, Carise, & Love, 2012). Clinicians often miss the co-occurrence of mental dis-
orders and substance use disorders because of an absence of routine screening 
(Croton, 2007; Donald, Dower, & Kavanagh, 2005; Hu et al., 2006; Lubman, Hides, 
& Elkins, 2008; Watkins et al., 2004). A number of commentators assert that in the 
United States half of those with COD receive no treatment (Alexander, Haugland, 
Lin, Bertollo, & McCorry, 2008; Kessler et al., 1996). Among those who do receive 
treatment, both disorders are addressed for only 6% (Alexander et al., 2008), 19% (J. 
A. Swartz & Lurigio, 2006) or 50% (Watkins et al., 2004) of clients according to var-
ious commentators. 
Over recent years it has been acknowledged that clients with COD have re-
ceived poor care due to gaps in service provision (Adams, 2008; Harris & Edlund, 
2005) and that the failure to detect (and therefore treat) mental disorder comorbidity 
‘contributes to some of the most expensive and intractable social problems’ (Davis et 
al., 2006, p. 263). Put simply unrecognised and untreated comorbidity leads to high 
costs and poor outcomes. (Alexander et al., 2008). Yet serious under-identification of 
! 51!
COD continues, at least in part due to the use of diagnostic tools being ‘usually the 
exception rather than the rule’ (Mericle et al., 2012, p. 225). A number of barriers to 
the detection and treatment of COD have been identified by commentators including a 
lack of integration with and/or access to psychiatric support staff and services, a lack 
of routine mental health assessments and a relative dearth of screening measures 
available (Hides et al., 2007; Kavanagh, Baker, & Teesson, 2004; McGovern, Xie, 
Segal, Siembab, & Drake, 2006). A significant additional barrier to improving the 
identification of COD is the paucity of validation research into the various screening 
instruments that are currently available to detect COD in AOD treatment systems. 
Study 2 of this thesis addresses this latter barrier to the effective identification of 
CODs and validates a number of screening measures for use in this population. 
Validation"of"Screening"Instruments"
Resources have been published that review the screening measures currently available 
to detect co-occurring mental disorders (Center for Substance Abuse Treatment, 2005; 
Croton, 2007; Dawe et al., 2002). Some measures, such as the Alcohol Use Disorders 
Identification Test (AUDIT) and the Drug Abuse Screening Test (DAST) are de-
signed to detect alcohol and other drug use disorders (respectively) and may be used 
in psychiatric populations to identify co-occurring disorders. These are different to 
measures designed to detect psychological comorbidity. When selecting measures for 
review and recommendation, experts have been mindful that, ‘time, cost and effort 
[are] severe initial barriers to implementing anything new into a treatment service sys-
tem’ (Center for Substance Abuse Treatment, 2005, p. 497). For that reason screening 
measures selected had to be widely used, ideally free and in the public domain, re-
quire no qualifications to possess or administer, cost nothing for instructions, repro-
duction or administration, be short in duration and be easy to use, requiring minimal 
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staff training (Center for Substance Abuse Treatment, 2005; Dawe et al., 2002). The 
same requirements were considered when selecting screening measures to be validat-
ed in the second study of this thesis. Measures had to be widely used, free and in the 
public domain, short and easy to administer with minimal staff training required of 
treatment services. 
There are a number of measures available to the AOD treatment industry to 
screen for co-occurring mental disorders (Center for Substance Abuse Treatment, 
2005; Dawe et al., 2002). What is not available is adequate validation research to 
guide treatment services in their choice of measure. Screening measures used to iden-
tify COD in AOD treatment systems have been recommended before psychometric 
validation research into the instruments’ sensitivity, specificity and overall accuracy 
has been undertaken (e.g., the Mental Health Screening Form-III, Carroll & 
McGinley, 2001; recommended in  Center for Substance Abuse Treatment, 2005; see 
also the Self-Reporting Questionnaire 20 before 2010, Lee & Jenner, 2010; 
recommended by Croton, 2007). Screening measures are often only validated once in 
a particular subpopulation by the measure’s creators without further validation in oth-
er subpopulations despite evidence that rates of disorders and their severity likely 
vary between settings (Carra & Johnson, 2009; J. Ross et al., 2005) and that this var-
iation reduces the appropriateness of validation data (Castel, Rush, & Scalco, 2008), 
(for e.g., see the Modified Mini Screen until 2008, Brandau, Alexander, & Haugland, 
2005; Alexander, Haugland, Lin, Bertollo, & McCorry, 2008). It is preferable for 
screening instruments to be validated with data obtained from the population in which 
they will be used (Castel et al., 2008). This is necessary to guide treatment services in 
an appropriate choice as to the best measure for their service and to know at what cut-
off score the measure should be used.  
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Currently there is an absence of adequate research evidence upon which 
treatment services can base and improve their practices to identify COD. Studies that 
compare the performance of multiple measures’ are rare and have not been conducted 
within residential treatment services. Additionally, much of the research that has been 
done has involved instruments that cost money to possess and administer (for e.g., the 
Psychiatric Diagnostic Screening Questionnaire) or require administration by a regis-
tered psychologist (for e.g., the Symptom Checklist-90-R). Costs and/or qualification 
requirements often reduce the use of these measures amongst substance misuse treat-
ment organisations that may have limited resources and/or staff who do not have the 
required level of training. Instead these organisations require freely available, easily 
administrable measures so no further cost or training burden is imposed.  
Often research that has been conducted into the screening instruments availa-
ble to detect CODs has involved instruments being ‘tested against different reference 
standards, using samples drawn from different populations, and employing different 
procedures’ (Rush et al., 2013, p. 375). The following literature review highlights the 
changes in method, criterion and population evident in the literature and the differing 
results these methodological variations have produced, sometimes with the same 
measure in a similar population. 
Early research validated measures through correlational studies that evidenced 
a measure’s concurrent validity with other measures. McLellan and others original 
(1980) validation of the Addiction Severity Index (ASI) “severity ratings” is an ex-
ample of this early methodology. The initial version of the ASI covered six domains: 
chemical abuse, medical, psychological, legal, family/social, and employment support 
(McLellan et al., 1980). The severity ratings were an unanchored scale scored from 0-
9 for each domain based upon a combination of objective questions including the 
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number, intensity and duration of problem symptoms and each participant’s self-
assessment of their need for additional treatment in the given domain (McLellan et al., 
1980). The ratings cover the previous 30-days with the higher the number, the greater 
the impairment. The validity of the ASI psychological severity rating was determined 
by reporting its correlations with other like measures. Among 524 male veteran sub-
stance abuse clients the ASI psychological severity scale correlated .64 with the 
Maudsley Neuroticism scale, .61 with the Beck Depression Inventory, and .58 with 
the Hamilton Depression scale (n = 111) (McLellan et al., 1980). A cluster analysis 
was also performed on a random sample of 150 participants to determine whether the 
ASI could differentiate respondents into subgroups. This cluster analysis produced six 
clusters that significantly differed from one another, however, these clusters did not 
neatly cover the six domains proposed for the instrument, nor was there any one men-
tally disordered vs. not mentally disordered cluster. To the contrary there were several 
statistically different clusters with and without high expressed need for additional 
psychiatric treatment so this cluster analysis did not support the use of the ASI as a 
valid screen for mental disorder amongst a substance-abuse-treatment-seeking sample 
of veterans (McLellan et al., 1980). 
Kosten and others’ (1983) also tested the concurrent validity of the Addiction 
Severity Index but used a criterion-type measure. The Addiction Severity Index was 
administered to a sample of 204 male and female treatment-seeking opiate “addicts” 
(Kosten et al., 1983). A correlational and “categorical” analysis was undertaken, with 
the latter involving a comparison and then cluster analysis of ASI performance in 
three different pre-defined groups (anti-social personality, current depression and no 
disorder) based on the Research Diagnostic Criteria (RDC, Spitzer, Endicott, & 
Robins, 1978). Information for making RDC diagnoses was gathered using the 
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Schedule for Affective Disorders and Schizophrenia – Lifetime version (Endicott & 
Spitzer, 1978). Concurrent validity was reported with highly significant correlations 
between the Addiction Severity Index Psychiatric Severity scale and the Beck De-
pression Inventory (.51), the Global Assessment Scale (–.42) and the Maudsley Per-
sonality Inventory (.55) (all p<.0001) (Kosten et al., 1983). The ASI Psychiatric Se-
verity scale and Beck Depression Inventory (BDI) scores were then compared for 
those with and without a current RDC depressive disorder. T-tests revealed signifi-
cantly higher (more impaired) mean scores for those with, compared to those without, 
a depressive disorder for both the ASI (t = 12.3, df = 101, p<.0001) and the BDI (t = 
13.9, df = 101, p<.0001) (Kosten et al., 1983). Kosten and others (1983) stated a sen-
sitivity and specificity analysis was undertaken but no receiver operating characteris-
tic curve analysis was provided. At a cut off score of 3, the ASI Psychiatric Severity 
scale was reported to have 89% sensitivity and 67% specificity (Kosten et al., 1983). 
A similar analysis was done with the ASI Psychiatric Severity scale and the Global 
Assessment Scale, but this time comparing means for those with and those without 
any non-substance abuse RDC mental disorder (not just depression) (Kosten et al., 
1983). Respondents without any other psychiatric disorders had significantly lower 
mean ASI and GAS scores (less impaired) when compared to those with other psychi-
atric disorders (ASI: t = 9.7, df = 101, p<.0001, GAS: t = 2.5, df = 101, p<.05) 
(Kosten et al., 1983). Sensitivity (63%) and specificity (83%) scores were again re-
ported at the same cut off score (Kosten et al., 1983). Lastly a cluster analysis of all 
the ASI domain scores was performed with the authors reporting four clusters; a nor-
mal cluster, an anti-social cluster, a depressed cluster and a medically impaired cluster 
(Kosten et al., 1983). From the dispersion of RDC diagnoses across these cluster 
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groups, the authors concluded the ASI was able to distinguish between these diagnos-
tic groups (Kosten et al., 1983). 
In 1989 Weiss and others (1989) compared the Beck Depression Inventory 
(BDI, Beck, Ward, Mendelson, Mock, & Erbaugh, 1961), the Hamilton Rating Scale 
for Depression and the depression subscale of the Symptom Checklist 90 (SCL-90, 
Derogatis, Meyer, & King, 1981) among 149 cocaine abusing private psychiatric hos-
pital clients. These measures’ abilities to identify major depression were tested by 
comparing their results with the independent diagnoses of two psychiatrists. One was 
a ward psychiatrist making discharge diagnoses on the basis of interviews and obser-
vations of ward behaviour (using DSM-III criteria (American Psychiatric Association, 
1980)). The other was an independent psychiatrist. A consensus diagnosis was pro-
vided where the two were in disagreement.  Thirteen of the clients,  (9% of the sam-
ple), were diagnosed with major depression. Sensitivity and specificity were reported 
based upon data gathered at three different times: admission, 2 weeks after admission 
and 4 weeks after admission. Results are reported in Table 9 below. 
Table 9. Sensitivity and specificity of three depression rating scales at three times in 
detecting major depression in 149 hospitalized cocaine abusers (Weis et al., 1989) 
Scale      Sensitivity  Specificity 
Beck Depression Inventory ≥ 12 
   Admission  100%   35% 
   2 weeks   40%   77% 
   4 weeks   20%   91% 
 
Hamilton Rating Scale for Depression ≥ 17 
   Admission  85%   49% 
   2 weeks   69%   79% 
   4 weeks   38%   89% 
 
Symptom Checklist 90 Depression Subscale ≥ 0.9 
   Admission  100%   26% 
   2 weeks   70%   58% 
   4 weeks   70%   83%  
+
The authors favoured the BDI’s performance and noted it was shorter than the SCL-
90 and did not require a trained person for administration like the HDRS. Two other 
! 57!
findings were of note. First the unacceptably low specificity scores of all the measures 
when used at cut off scores that gave acceptable sensitivity at admission. Second the 
rapid decline in sensitivity scores over time. These results led the authors to conclude 
these measures may be more useful at identifying clients without major depression 
than identifying those with the disorder. This conclusion was reached despite these 
authors expressly naming sensitivity the more important characteristic when the utili-
ty of a screening measure is being assessed on the grounds that a comprehensive psy-
chiatric assessment following screening can provide the required specificity (Weiss et 
al., 1989). 
A Dutch-translation version of the Addiction Severity Index (ASI)!(Hendriks, 
Kaplan, Limbeek, & Geerlings, 1989) was also tested against the Beck Depression 
Inventory (BDI, Beck et al., 1961), the Symptom Checklist-90 (SCL-90, Derogatis, 
Lipman, Rickels, Uhlenhuth, & Covi, 1974) and DSM-III diagnoses of major depres-
sion made on the basis of the third version of the Diagnostic Interview Schedule (DIS, 
Robins et al., 1981). One hundred and forty-two detoxification clients at the Hague 
were administered these measures within two days of admission. Correlations of .55 
with the BDI, .54 with the SCL-90 total score, (including .35 with the SCL-90 soma-
tization sub-scale, .48 with the SCL-90 depression subscale, and .52 with the SCL-90 
anxiety subscale), evidenced the concurrent validity of the ASI Psychiatric Status Se-
verity scale (Hendriks, Kaplan, Limbeek, & Geerlings, 1989). Sensitivity and speci-
ficity figures were cited for the ASI Psychiatric Status Severity scale’s ability to cor-
rectly identify those with and without DSM-III depression diagnoses according to the 
DIS in a subsample of 84 respondents. At a cut off score of 4, sensitivity was 86% 
and specificity 42%. At a cut off score of 5, sensitivity was 72% and specificity 56%. 
The statistical technique used to arrive at these figures was not specified, although the 
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authors did note that even at the more sensitive cut off score the ASI still failed to 
identify 14% of depression cases (Hendriks et al., 1989). 
Different procedures, reference standards and population samples produced 
conflicting, as well as incomparable, results in another validation study on the Dutch 
version of the Addiction Severity Index (Eland-Goossensen, Goor, Garretsen, & 
Schudel, 1997). Three-hundred and twenty-seven heroin and methadone addicted in-
dividuals were researched in three treatment groups: a low threshold methadone pro-
gram (n = 91), a clinical detoxification program where participants did not continue 
their treatment (n=72) and the same clinical detoxification program where participants 
continued their treatment in a therapeutic community (n = 77). Additionally 83 re-
spondents were not in treatment and had not received treatment for more than two 
weeks over the past two years (Eland-Goossensen et al., 1997). The Addiction Severi-
ty Index Psychiatric Status Severity scale and the (still current) Addiction Severity 
Index Psychiatric Status Composite Score were validated against the Composite In-
ternational Diagnostic Interview (CIDI, Robins et al., 1988). The authors did not use 
ROC curve analysis but stated, ‘cut-off points can be used to distinguish between re-
spondents with and without … problems. The choice of such a cut-off point is based 
more often on intuition than on empirical data’ (Eland-Goossensen et al., 1997, p. 
587). Sensitivity scores (but not specificity scores) were reported for the Severity 
scales at cut off scores of 6, 5 and 4 among 99 respondents with anxiety, affect or 
psychotic disorders (sensitivity was 43%, 59%, and 73% respectively) (Eland-
Goossensen et al., 1997). Eland-Goosensen and colleagues opined that a cut off score 
of 6 was optimal, (where only 43% of cases were identified), and stated ‘[t]hat the 
data … are not totally compatible with the DSM-III-R data’ (Eland-Goossensen et al., 
1997, p. 587). The Composite Score performed less well than the Severity scale, with 
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the largest number of respondents with disorders from all four categories, (affective 
disorder, anxiety disorder, psychotic disorder, anti-social personality disorder), scor-
ing a middle-range Composite Score, not a high-range score as expected, bringing 
into question what was being measured and how, along with what cut off score truly 
best represented a positive result (Eland-Goossensen et al., 1997). Earlier researchers 
had warned against using arbitrary approaches to cut off score selection like “intui-
tion”. Murphy and others (1987) had lamented a decade before that: 
At the present time … sensitivity and specificity are often reported as unalterable fea-
tures of a test. A potential user must accept an a priori and often arbitrary decision 
about the criterion threshold that led to these values. … While it has been appreciated 
that changing the threshold can affect the performance of a test, a standard method 
for assessing the complete information needed for a threshold decision has not yet 
become a regular part of the procedures used by psychological researchers for as-
sessing diagnostic and screening tests (p. 551). 
Both the Eland-Goossensen and others (1997) study and the Hendriks and others 
(1989) study that preceded it, tested Dutch-translation versions of the Addiction Se-
verity Index. The results of the two studies, however, were significantly different and 
incomparable due to being set in different populations, using different reference 
measures and statistical techniques to generate their results. This experimental varia-
tion is representative of the early validation literature.  The study by Eland-
Goossensen and others (1997) was also an example of where more sophisticated sta-
tistical analyses were necessary to better analyze test performance across a range of 
cut off scores. 
Receiver+Operating+Characteristic+Curve+Analysis+
Described as new to psychiatry in 1989 (Hsiao, Bartko, & Potter, 1989), Receiver 
Operating Characteristic (ROC) curve analyses provide a number of statistics on a 
measure’s performance at a certain cut off score including sensitivity, specificity, ac-
curacy, positive and negative predictive values, and positive and negative odds ratios. 
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Additionally, ROC curve analyses provide an Area Under the Curve (AUC) score in-
dicative of a measure’s performance across all cut off scores. 
The sensitivity of an instrument is a measure of an instrument’s ability to iden-
tify illness among the ill (Murphy et al., 1987). Sensitivity is calculated by dividing 
the number of true-positives detected by the instrument by the number of all diseased 
participants (Schmitz, Kruse, Heckrath, Alberti, & Tress, 1999). The specificity of an 
instrument is a measure of an instrument’s ability to correctly identify the absence of 
an illness or condition among those who do not have that illness or condition (Murphy 
et al., 1987). Specificity is calculated by dividing the number of true-negatives detect-
ed by the test by the number of all non-diseased participants (Schmitz et al., 1999). 
Both sensitivity and specificity are measured on the basis of a division of the test’s 
score range by a criterion threshold or cut point (Murphy et al., 1987). When an in-
strument’s sensitivity (in this case its ability to correctly identify those with a mental 
disorder) and its specificity (its ability to correctly identify those without a mental 
disorder) are combined, the result is described as the instrument’s overall accuracy, 
also known as its efficiency (Harrington & Newman, 2007). By way of example, if in 
a population of 200 there were 100 participants with a certain condition and 100 par-
ticipants without that condition and at a certain cut off score a measure correctly iden-
tified 80 of the 100 participants with that condition as having that condition and 70 of 
the 100 participants without the condition as not having the condition, the measure’s 
sensitivity would be 80/100 (80%), its specificity 70/100 (70%) and its overall accu-
racy 75%.  
The positive predictive accuracy or value is the proportion or percentage of 
cases screening positive that are truly positive for mental disorder (Sacks, 2008; 
Zimmerman, Sheeran, Chelminski, & Young, 2004). The negative predictive accura-
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cy or value is the proportion or percentage of cases screening negative that are truly 
negative for mental disorder (Sacks, 2008; Zimmerman et al., 2004). If in the above 
example the measure actually screened 120 participants as positive for the condition 
(including the 80 who actually were), its positive predictive value would be 80/120 
(66%). That same example would see the measure having screened 80 participants as 
negative (including 70 who were truly negative), giving it a negative predictive value 
of 70/80 (87.5%). Predictive accuracies or values are said to be clinically useful but 
like sensitivity, specificity and likelihood ratios they vary with the underlying preva-
lence rate of the population in which they are ascertained (Brenner & Gefeller, 1997; 
Schmitz et al., 1999). As the prevalence of a disorder in a population decreases, the 
sensitivity and positive predictive accuracy of the test also decrease while the speci-
ficity and negative predictive accuracy increase (Brenner & Gefeller, 1997). With 
higher population prevalences, the opposite occurs (Brenner & Gefeller, 1997). Thus 
where underlying population prevalence is high, statistically sensitivity and positive 
predictive accuracy are most important. Where underlying prevalence is low, statisti-
cally negative predictive accuracy and specificity are most important.  
Positive and negative likelihood or odds ratios are an indication of the change 
in odds for a person having or not having a mental disorder given a positive or nega-
tive screen at a certain cut off score. Expressed another way, the positive odds ratio 
(sensitivity/1-specificity) and the negative odds ratio (1-sensitivity/specificity) ex-
press the odds that a person with and without a disorder respectively will score above 
the given cut off score on the measure in question (Neovius, Linne, Barkeling, & 
Rossner, 2004). 
The receiver operating characteristic area under the curve score (ROC-AUC) 
is a measure of an instrument’s overall performance across all possible cut off scores 
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(Swets, 1988). A graphical curve is constructed where at each cut off score the meas-
ure’s true-positive rate (sensitivity) is plotted on the y-axis and its false-positive rate 
(1 – specificity) is plotted on the x-axis. Each point thus plotted for each cut off score 
is then joined to form a curve and the area under the curve is the measure’s overall 
performance at correctly differentiating between a random participant with and with-
out the given condition being screened for across all cut off scores. The closer to the 
upper left-hand corner of the graph the curve approaches, the better the performance 
of the measure (or the more true-positive cases it detects whilst producing less false-
positive results). ROC-AUC results usually vary between 0.50 and 1.0. A ROC-AUC 
score of 0.50 represents a diagonal line with a slope of 1 and indicates a complete lack 
of predictive ability, (it is the equivalent of chance, a 50/50 result) (Bisoffi, Mazzi, & 
Dunn, 2000). A score of 1.0 would represent perfect prediction. Results between 0.70 
and 0.80 represent good accuracy (Cacciola et al., 2008). Results greater than 0.80 
represent reasonable to excellent accuracy and results above 0.90 excellent to out-
standing accuracy (Cacciola et al., 2008; J. A. Swartz, 2007).  
The ROC curve analysis technique and the analyses it afforded represented a 
significant improvement in screening instrument validation. What a ROC curve anal-
ysis still did not provide was an indication of how best to use a test in a given context 
or which cut off score was best for making a diagnosis (Hsiao et al., 1989). The pit-
falls of blindly reporting a ROC curve analysis without considering the context of 
screening and the implications of choosing different cut off scores are discussed be-
low. 
Validation+Studies+That+Use+A+ROC+Curve+Analysis+
Subsequent to ROC curve analysis adoption as a statistical technique, for some years 
validation studies continued to be largely incomparable due to other variations in ex-
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perimental methodology such as the criterion measure used. Comparative perfor-
mance of German language versions of the Symptom Checklist 90 Revised (SCL-90-
R,  Derogatis et al., 1981) and the General Health Questionnaire 12 (GHQ-12, 
Goldberg et al., 1997) was conducted on 572 adult German primary care outpatients 
in 1999 (Schmitz et al.). Participants were administered these two screening measures 
which were validated against German language versions of the Structured Clinical 
Interview for the Diagnostic Manual of Mental Disorders – Third Edition Revised 
(SCID-III-R) (past 30-days) and the Impairment Score measure of psychological im-
pairment (score 5+ = disordered). The SCID-III-R and the Impairment Score measure 
represented movement to a different (as well as) joint criteria for caseness (Schmitz et 
al., 1999). A ROC curve analysis revealed that at each instrument’s best cut off score 
the SCL-90-R was slightly more sensitive to the detection of mental disorder (64% vs. 
60% for the GHQ-12), both measures had the same specificity (74%) and therefore 
the SCL-90-R was slightly more accurate at the screening task (75% vs. 73% for the 
GHQ-12). The positive predictive values were .58 for the SCL-90-R and .57 for the 
GHQ-12 meaning both measures were only right about a positive screen about half 
the time. Negative predictive values were .77 and .76 respectively (Schmitz et al., 
1999). The Area Under the Curve (AUC) scores were also slightly in favour of the 
SCL-90-R (.75 vs. .73), a small difference that was not statistically significant 
(Schmitz et al., 1999). This research was conducted in a primary care population 
where the SCID-III-R put the prevalence of mental disorder at 37% of those tested 
(Schmitz et al., 1999). 
In 2001 Franken and Hendriks validated the SCL-90 and the Addiction Severi-
ty Index Psychiatric Status Composite Score (ASI-PSYCS) against CIDI (DSM-III-R) 
anxiety and affective disorder diagnoses only (Franken & Hendriks, 2001). Partici-
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pants were 116 consecutively admitted substance abuse treatment inpatients in the 
Netherlands (Franken & Hendriks, 2001). Three ROC analyses were undertaken: 
SCL-90 and ASI-PSYCS administration prior to detoxification and SCL-90 admin-
istration post detoxification (an average of 19 days later when the CIDI was also ad-
ministered) (Franken & Hendriks, 2001). The study did not report whether these in-
struments were compared to current or lifetime CIDI prevalence. Lifetime CIDI prev-
alence of anxiety or affective disorders (only) was 69.8%. Current CIDI prevalence of 
anxiety or affective disorders (only) was 46.6% (Franken & Hendriks, 2001). Cut off 
scores were chosen that reported at least 90% sensitivity, suggesting that the authors 
appreciated the importance of detecting COD in this population.  The results were as 
follows in Table 10. 
Table 10. ROC Analyses for SCL-90 and ASI-PSYCS (Franken & Hendriks, 2001).  
Measure      Sensitivity (%)      Specificity (%)     Accuracy (%)      AUC Score 
ASI-PSYCS (pre-detox)    91.3       24.1        57.7       .52 
SCL-90 (pre-detox)    92.7       19.7        56.2       .64 
SLC-90 (post-detox)    90.9       49.2        70.1       .75 
ASI-PSYCS (pre-detox) = the Addiction Severity Index Psychiatric Status Composite Score administered pre-detoxification, 
SCL-90 (pre-detox) = the Symptom Checklist 90 administered pre-detoxification, SCL-90 (post-detox) = the Symptom Checklist 
90 administered post detoxification, AUC Score = Area under the curve score. 
+
The authors rightly concluded that only the post-detoxification SCL-90 could be rec-
ommended as a screen for anxiety and affect disorder psychiatric comorbidity among 
inpatient substance abuse treatment participants (Franken & Hendriks, 2001). This 
study highlighted the importance of the time between admission of screening instru-
ments and the criterion they are to be judged against. The pre-detoxification SCL-90 
and the pre-detoxification ASI-PSYCS, barely performed at a level better than 
chance, but this may have been largely due to the measures being administered on av-
erage nearly 20-days prior to the CIDI criterion they were measured against. The 
amount of time between administrations made the results effectively incomparable. 
In 2004 Calsyn and others validated the Addiction Severity Index Psychiatric 
Status Domain Composite Score (ASI-PSYCS) against a veterans’ version of the 
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Medical Outcomes Study Short Form- 36 (SF-36V). The Medical Outcomes Study 
Short Form – 36 (SF-36, Ware & Sherbourne, 1992), of which the veterans version is 
a minor modification, is a frequently used assessment of health-related quality of life 
in medical conditions. It is a self-report instrument that measures eight constructs over 
a 4-week period: physical functioning, physical role limitations, bodily pain, social 
functioning, emotional role limitations, general mental health, vitality and general 
health perceptions (Calsyn et al., 2004). When assessing mental health the latter four 
components are aggregated and labeled the Mental Component Summary (MCS). The 
former four components are aggregated to constitute the Physical Component Sum-
mary (PCS) – a measure of physical health (Calsyn et al., 2004). The Mental Compo-
nent Summary was used as the criterion measure to assess the validity of the ASI-
PSYCS with participants categorised as impaired if they scored below the 25th percen-
tile of US population norms on the SF-36 MCS (Calsyn et al., 2004). This study was 
conducted among 674 veterans entering various substance abuse treatment modalities 
in Washington (detox unit, outpatient with beds provided for the homeless and inten-
sive outpatient) (Calsyn et al., 2004). Five hundred and twenty-six of these partici-
pants (78% of the sample) fell within the impaired category (Calsyn et al., 2004). A 
mean of 20-days after admission to treatment participants were administered the ASI-
PSYSCS and the SF-36V (Calsyn et al., 2004). Correlations and ROC analyses were 
undertaken. The ASI-PSYCS correlated highly significantly not only with the SF-36V 
Mental Component Summary aggregate and each of its individual components, but 
also with all of the components of the Physical Component Summary as well (p < 
.001) (Calsyn et al., 2004). These results provided evidence of concurrent but not dis-
criminant validity for the ASI-PSYCS when compared with the SF-36V (Calsyn et 
al., 2004). The ROC-AUC score for the ASI-PSYCS was .90 (Calsyn et al., 2004). At 
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a cut off score of .22 the ASI-PSYCS demonstrated 90% sensitivity, 71% specificity 
and 80.5% accuracy (Calsyn et al., 2004). The construct validity of the criterion 
measure itself (the SF-36V) is another question, an issue that came to the fore in a 
study by Degenhardt and others (2005) examined below. Certainly there is a strong 
relationship and concurrent validity between the ASI-PSYCS and the SF-36V Mental 
Component Summary, the latter representing yet another measure used as a criterion 
in this line of research. 
The potentially confounding effect of using different “gold standard” criterion 
measures was emphasized in a validation study on a brief 7-item Psychosis Screener 
(PS) (Degenhardt et al., 2005). The study was conducted in two samples, the first 
consisted of 87 inpatient participants whose Psychosis Screener responses were com-
pared to International Classification of Diseases version 9 (ICD-9) diagnoses obtained 
from hospital discharge records. Sample 2 consisted of 259 persons whose responses 
to the seven screener items were compared to International Classification of Diseases 
version 10 (ICD-10) and DSM-III-R diagnoses derived using the Diagnostic Inter-
view for Psychosis (DIP). According to the criterion measures used, sample 1 had 
51.3% ICD-9 affective psychosis, 16% schizophrenia and 31.3% some other (non-
psychotic) disorder (Degenhardt et al., 2005). Sample 2 consisted of just under half 
(47.1% and 46.4%) schizophrenia according to DSM-III-R and ICD-10 criterion 
measures respectively, almost 10% schizoaffective disorder (9.3% and 9.8% DSM-
III-R and ICD-10 respectively), around one-quarter affective psychosis (DSM-III-R 
23.9%, ICD-10 25.5%), and the remaining fifth either a different diagnosis (DSM-III-
R 15.8%, ICD-10 13.7%) or no diagnosis (DSM-III-R 3.9%, ICD-10 5.0%) 
(Degenhardt et al., 2005). The authors concentrated upon psychotic disorders because 
even though lower in prevalence than other mental disorders, psychotic disorders ‘uti-
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lise a disproportionately high segment of health services … [and] … impose a consid-
erable public health burden because of their impact on sufferers and their families [ci-
tation omitted]’ (Degenhardt et al., 2005, p. v). Narrow and broad definitions of psy-
chosis were used for the analysis; the narrow definition was limited to diagnoses of 
either schizophrenia or schizoaffective disorder. The broad definition also included 
diagnoses of affective psychosis. The very high population prevalences of the disor-
ders in question meant that sensitivity, positive predictive values and likelihood ratios 
should be influenced by this underlying population prevalence to be high (Brenner & 
Gefeller, 1997). Even so, the ROC analysis of sample 1 (testing the PS against ICD-9 
diagnoses of psychosis that included affective psychoses) produced an area under the 
curve score barely better than chance (.55) (Degenhardt et al., 2005). See Table 11 
below for full results: 
Table 11. ROC Analysis for Broad and Narrow Definition of Psychosis (Degenhardt 
et al., 2005)+
Sample    Criterion Cut Sens Spec PPV NPV   AUC 
Sample 1 Broad (N=87)  ICD-9  3 25.4 85.7 68.4 82.4 .55 
Sample 2 Broad (N=259)  ICD-10  1 98.1 39.6 87.7 82.6 .79 
Sample 2 Broad (N=259)  DSM-III-R 1 97.6 35.3 86.0 78.3 .77 
Sample 1 Narrow (N=87)  ICD-9  3 57.1 84.9 42.1 91.2 .78 
Sample 2 Narrow (N=259) ICD-10  3 82.1 57.0 70.8 71.4 .73 
Sample 2 Narrow (N=259) DSM-III-R 3 81.5 56.6 70.8 70.3 .74 
Sens = Sensitivity, Spec = Specificity, PPV = Positive Predictive Value, NPV = Negative Predictive Value, AUC = Area Under 
the Curve Score, ICD-9 = International Classification of Diseases – 9, ICD-10 = International Classification of Diseases – 10, 
DSM-III-R = Diagnostic and Statistical Manual for Mental Disorders III – Revised. 
+
The authors hypothesized the barely better than chance result with sample 1 was pos-
sibly due to a discrepancy in the “gold standard” used to categorize these patients. In 
the words of the authors the poor results may have been ‘due to discrepancies be-
tween ICD-9 and ICD-9-CM codes, particularly for affective psychoses’ (Degenhardt 
et al., 2005, p. 13). Degenhardt and others thought this possibility was supported by 
the fact the PS was able to discriminate between cases and non-cases using the two 
other diagnostic systems as “gold standards” (ICD-10 and DSM-III-R) (Degenhardt et 
al., 2005). Even in the same sample and being interviewed with the same Diagnostic 
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Interview for Psychosis (DIP), however, results for sample 2 still differed slightly de-
pending upon whether ICD-10 or DSM-III-R classification systems were used 
(Degenhardt et al., 2005). The different operationalisation of disorders used by the 
three different “gold standard” criterion measures in the study caused the authors to 
note: 
This highlights another issue in the use of “gold standards”: they are assumed to be 
valid and accurate. Any limitations in the ability of these diagnostic systems to dis-
criminate between actual cases and non-cases necessarily attenuates the distinction 
between true cases and non-cases used in ROC analyses, and hence reduces the abil-
ity of the analysis to estimate the true discriminant power of the screener [citation 
omitted] (Degenhardt et al., 2005, p. 14). 
Recent studies have increased the methodological standardization of this area of 
research by settling upon the Structured Clinical Interview for DSM disorders and/or 
the Composite International Neuropsychiatric Interview as the criterion measures 
against which screening instruments should be validated. Other methodological prob-
lems have remained, however, such as using aggregated populations drawn from mul-
tiple different settings and failing to report all the statistics necessary to understand 
instrument performance. In 2007 more than 150 screening measures then available 
were comprehensively reviewed with regard to cost (public domain), brevity (less 
than 20 minutes), ease of administration (no specific mental health training needed) 
and existing psychometric validation work (Sacks, Melnick, Coen, Banks, Friedmann, 
Grella, & Knight, 2007; Sacks, Melnick, Coen, Banks, Friedmann, Grella, Knight, et 
al., 2007). Three measures were chosen by an expert panel to be validated against the 
Structured Clinical Interview for DSM-IV in a prison substance abuse population; the 
Global Appraisal of Individual Needs Short Screener version 1.0 (GSS, Dennis, Chan, 
& Funk, 2006), the Mental Health Screening Form (MHSF, Carroll & McGinley, 
2000) and the Mini-International Neuropsychiatric Interview - Modified (MINI-M, 
Sheehan et al., 1998). A pilot study was conducted among 100 participants with an 
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actual rate of mental disorders of 60%. The authors reported in this population the lat-
ter two measures, the MHSF and the MINI-M, performed the best when these three 
measures were run head-to-head against one another. The MHSF had the highest sen-
sitivity (90%) and the highest overall accuracy score (73%) at a cut-off score of three. 
The MINI-M produced the highest specificity score (52.5%) or was the best at identi-
fying cases that did not have a co-occurring mental disorder at a cut-off score of five 
(Sacks, Melnick, Coen, Banks, Friedmann, Grella, & Knight, 2007). ROC curve area 
under the curve scores for correctly determining whether any co-occurring mental 
disorder was present or not across all cut off scores also favoured the MHSF and 
MINI-M as outperforming the GSS (.805, .741 and .731 for the MHSF, the MINI-M 
and the GSS respectively) (Sacks, Melnick, Coen, Banks, Friedmann, Grella, & 
Knight, 2007). ROC curve areas for determining the presence of any “severe” mental 
disorder, (defined as major depression, schizophrenia and bipolar disorders), were al-
so calculated and ranked the instruments the same way (.659, .642 and .639 for the 
MHSF, the MINI-M and the GSS respectively) (Sacks, Melnick, Coen, Banks, 
Friedmann, Grella, & Knight, 2007). Finally in the pilot study a correlation then re-
gression analysis was performed to determine which items from each screener corre-
lated with and explained the variance in positive SCID diagnoses of mental disorder 
and severe mental disorder respectively. For mental disorders the authors found that 
six items were highly correlated with/explained the variance in SCID diagnoses: four 
items from the MHSF, one item from the MINI-M and one item from the GSS. For 
severe mental disorder, (major depression, schizophrenia and bipolar disorders), three 
items were identified, two from the MHSF and one from the MINI-M (Sacks, 
Melnick, Coen, Banks, Friedmann, Grella, & Knight, 2007). 
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A subsequent validation study was conducted among 180 participants again 
drawn from prison substance abuse settings, this time with an actual rate of mental 
disorder of 78.3% (Sacks, Melnick, Coen, Banks, Friedmann, Grella, Knight, et al., 
2007). Table 12 notes the results of this study for determining the presence or absence 
of any disorder weighted for gender along with the test-retest reliability of each meas-
ure. 
Table 12. Sensitivity, Specificity, Accuracy and Test-Retest Reliability of Three 
Measures Detecting Any Mental Disorder Weighted for Gender (Sacks, Melnick, 
Coen, Banks, Friedmann, Grella, Knight, et al., 2007) 
Measure  Cutoff  Sensitivity Specificity Accuracy Test/Re-test 
GSS  2  81.6%  47.1%  72.6%  Κ = 0.381 
MHSF  3  80.9%  47.5%  72.1%  Κ = 0.625 
MINI-M  5  71.3%  60.7%  68.5%  Κ = 0.618 
Note. MHSF = Mental Health Screening Form, GSS = Global Appraisal of Individual Needs Short Screener, MINI-M = Mini-
International Neuropsychiatric Interview – Modified. 
+
It should be noted the GSS performed better than in the pilot study as the most accu-
rate instrument, but also returned a much lower test-retest reliability score on the im-
portant task of consistently indicating the same respondents as needing further as-
sessment for any disorder (Sacks, Melnick, Coen, Banks, Friedmann, Grella, Knight, 
et al., 2007). Expressed as a percentage of the time each measure agreed with itself 
about the need to refer a participant for further assessment, the scores were: MHSF 
(85.0%), MINI-M (81.7%) and GSS (76.7%). Otherwise the scores were quite similar 
and the importance of sensitivity given the high prevalence of disorder can be noted 
by observing the MINI-M result. Regrettably positive and negative predictive values 
and odds ratios were not reported so only a partial picture of instrument performance 
could be gained. For detecting severe mental disorders the results are reported in Ta-
ble 13 below. 
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Table 13. Sensitivity, Specificity, Accuracy and Test-Retest Reliability of Three 
Measures Detecting Severe Mental Disorders Weighted for Gender (Sacks, Melnick, 
Coen, Banks, Friedmann, Grella, Knight, et al., 2007) 
Measure  Cutoff  Sensitivity Specificity Accuracy Test/Re-test 
GSS-IDS 5  37.5%  95.9%  76.7%  Κ = 0.487 
MHSF  11  35.4%  93.3%  74.5%  Κ = 0.761 
MINI-M  10  41.8%  60.7%  68.5%  Κ = 0.682 
Note. MHSF = Mental Health Screening Form, GSS-IDS = Global Appraisal of Individual Needs Short Screener – Internal Dis-
order Screener, MINI-M = Mini-International Neuropsychiatric Interview – Modified. 
+
The GSS again performed the most accurately in detecting severe mental disorder, but 
again did so less reliably/consistently than the other measures. Expressed as a per-
centage of the time each measure agreed with itself about the need to refer a partici-
pant with severe mental disorder for further assessment, the scores were: MHSF 
(91.7%), MINI-M (88.3%) and GSS (83.3%) (Sacks, Melnick, Coen, Banks, 
Friedmann, Grella, Knight, et al., 2007). The other notable aspect of the above results 
was the very low sensitivity demonstrated by all the measures at their statistically 
most accurate cut off scores. The cut off scores reported may have been the statistical-
ly most accurate, but measures failing to detect far more than half of the cases of seri-
ous mental disorder present in a population obviates the purpose of screening. The 
important context of screening, a desire to practically identify a maximum number of 
clients with mental disorder comorbidity, reveals these statistically generated cut off 
scores as clinically inappropriate. The importance of considering the context of 
screening is highlighted and in this instance would have led to lower cut off scores 
being recommended despite a slight reduction in accuracy so that cases of comorbidi-
ty did not slip through the net of screening. At the conclusion of this otherwise excel-
lent comparison study, Sacks and others rightly warned that the instruments con-
cerned could be expected to perform differently in different populations and that the 
results reported should not be generalised beyond the prison populations in which 
they were found (Sacks, Melnick, Coen, Banks, Friedmann, Grella, Knight, et al., 
2007). 
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In 2008 Cacciola, Pecoraro and Alterman conducted an archive analysis to 
validate the many indices of the Addiction Severity Index Psychiatric Status domain 
(Cacciola et al., 2008). The Addiction Severity Index is mandated for use in licensed 
substance abuse treatment programs in a majority of states in the United States of 
America (Cacciola et al., 2008). Some of the psychiatric summary scores produced by 
the ASI had been validated using straight correlations with pen and paper measures, 
but a ROC curve analysis validating the measure against a full structured clinical in-
terview had not been previously undertaken (Cacciola et al., 2008). In a mixed inpa-
tient, residential and outpatient sample of 672 respondents all four ASI Psychiatric 
summary scores were included in the analysis (Interviewer Severity Rating, ISR; 
Composite Score, CS; Clinical Factor, CF; and Evaluation Indices, EI). Results of the 
ROC curve analysis against the SCID-III-R are in Table 14 below. 
Table 14. ROC curve analysis of four ASI Psychiatric scales (Cacciola et al., 2008) 
ASI Scale AUC Cut off  Sensitivity Specificity Accuracy 
ISR  .73      3  81.19%  52.89%  67.04% 
CS  .76    .22  80.07%  60.11%  70.09% 
CF  .78     53  84.98%  54.93%  69.96% 
EI  .75     52  79.73%  59.66%  69.70% 
ASI Scale = Addiction Severity Index Psychiatric Status scale, AUC = Area Under the Curve score, ISR = Interviewer Severity 
Rating, CS = Composite Score, CF = Clinical Factor, EI = Evaluation Indices. 
+
In the same year Alexander and others (2008) validated a version of the Mini 
International Neuropsychiatric Interview - Modified, called the Modified Mini Screen 
(MMS, Brandau et al., 2005). The study was conducted in a mixed population of 476 
individuals in chemical dependency treatment across 23 different settings in jails, 
shelters and street community outreach programs (Alexander et al., 2008). Forty-six 
percent of this population met criteria for anxiety, mood or psychotic disorders ac-
cording to the Structured Clinical Interview for DSM-IV (Alexander et al., 2008). 
Eighty percent of the interviews were conducted by telephone and SCID interviews 
took place within 2 weeks of the screening interview (Alexander et al., 2008). Three 
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indices of reliability were reported, internal consistency (Chronbach’s Alpha = 0.92), 
inter-rater reliability (92%), and test-retest reliability (based upon 42 screens = 79%) 
(Alexander et al., 2008). A full ROC curve analysis was undertaken and importantly, 
these authors reported not only the usual sensitivity, specificity and overall accuracy 
values, but also positive and negative predictive values, the proportion of participants 
that were indicated as needing further assessment at each cut off score and the number 
of true cases that were missed at that cut off score. These last two figures, (number of 
cases indicated as needing further assessment and number of true cases missed at a 
given cut off score), are particularly helpful for understanding the practical implica-
tions of using a screen at a given cut off score and should always be reported by vali-
dation studies. Table 15 contains these results. The overall area under the curve score 
was 0.81, indicating a high probability the MMS would correctly differentiate a ran-
dom disordered participant from a random not disordered participant across all cut off 
scores (Alexander et al., 2008). 
Table 15. Modified Mini Screen (MMS) Validation Results (Alexander et al., 2008) 
Cut Off     Sensitivity       Specificity       Positive      Negative       Overall        % Sent      % of True 
Score               Predictive   Predictive     Accuracy     Further Cases 
             Value          Value              Assess.t Missed  
6     81.9  61.4          61.4 81.9        70.2             57.1 18.1 
7     75.0  69.5          64.8 78.8        71.8             49.6 25.0 
8     69.6  78.3          70.7 77.5        74.6             42.2 30.4 
9     62.8  82.7          73.1 74.8        74.2             36.8 37.2 
Based on a SCID-interview prevalence of 42.9% for current anxiety, mood or psychotic disorder. 
+
These authors attempted to compare the MMS results they obtained with results other 
authors had obtained using other screening measures in other populations published in 
other studies. Attempting such a cross study comparison is of questionable value be-
cause the studies were completed in different populations with different underlying 
prevalences of disorder using different methodologies, criterion measures, etc. Differ-
ent underlying population prevalences, among other things, effect sensitivity, speci-
ficity, positive and negative predictive values and positive and negative odds ratios 
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(Brenner & Gefeller, 1997). Cut off scores are unlikely to be the same and instrument 
performance will not be as reported in one population or setting when used in another 
(Brenner & Gefeller, 1997; Castel et al., 2008). Irrespective in the population in ques-
tion the MMS performed equally well across gender and ethnic groups. It should be 
noted, however, that even when the most sensitive cut off score of 6 on the MMS was 
used a full 18% of disordered cases in this study were missed. This is an undesirable 
result where the aim of screening is not to let anyone with COD slip through the 
screening net. This result again highlights the importance of using a cut off score that 
affords high sensitivity to the detection of COD. 
 Two-years after the study conducted by Alexander and others (Alexander et 
al., 2008), two measures were validated for possible use in the Psycheck screening 
package. Unfortunately 117 individuals were sourced from mixed treatment modali-
ties for this validation study, a recurrent methodological limitation in the recent litera-
ture to be dealt with below (Lee & Jenner, 2010). An amended version of the Self Re-
porting Questionnaire 20, the Self Reporting Questionnaire 20 – Revised (SRQ-20R) 
and the General Health Questionnaire 28 (GHQ-28) were validated against the mental 
health module of the Composite International Diagnostic Interview – Auto, a comput-
erized 1997 version of the CIDI that applied DSM-III-R and ICD-10 diagnostic crite-
ria (Lee & Jenner, 2010). The General Health Questionnaire 28 data was collected 
using the usual Likert scoring system and this data was then converted to dichoto-
mous score data (GHQ-R; symptoms vs. no symptoms) to facilitate comparison with 
the dichotomous SRQ-20R. The Self Reporting Questionnaire was first designed by 
the World Health Organisation to screen for psychiatric disturbance in primary health 
care settings, especially in developing countries (Beusenberg & Orley, 1994). Origi-
nally, the Self Reporting Questionnaire contained 25 questions, 20 related to neurotic 
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symptoms, four concerning psychotic symptoms and one question asking about epi-
leptic-type fits or convulsions (Beusenberg & Orley, 1994). This measure is known as 
the Self Reporting Questionnaire 25. Lee and Jenner’s (2010) adaptation of this 
measure used only the 20 questions related to neurotic symptoms. These questions 
were adapted to the AOD treatment environment by the addition of an extra column 
that asked respondents to indicate whether the problem they had reported had also oc-
curred at a time when they were not using drugs or alcohol. The resultant measure 
was called the Self Reporting Questionnaire 20 – Revised (SRQ-20R). Participants 
were recruited from four outpatient counselling clinics, an acute assessment clinic, 
ambulatory detoxification services and two pharmacotherapy clinics. Some had al-
ready been in treatment for up to three-months at the time of recruitment. This is a 
long time frame for the validation of a measure presumably intended to be adminis-
tered shortly after admission. Clients with a serious medical illness, active suicidal 
ideation, acute psychosis, and those in acute drug withdrawal were not eligible to par-
ticipate (Lee & Jenner, 2010). In what the authors describe as the first validation 
study of the Self Reporting Questionnaire 20 in a clinical drug treatment setting, the 
following results were reported, see Table 16: 
Table 16. Self Reporting Questionnaire Amended and Normal Versions Validation 
Results (Lee & Jenner, 2010). 
Measure  Cut Off  Sensitivity Specificity 
SRQ-20R 3.5  0.897  0.755 
  4.5  0.809  0.837 
  5.5  0.765  0.918 
 
SRQ-20  7.5  0.838  0.653 
  8.5  0.765  0.735 
  9.5  0.706  0.796 
SRQ-20R = the amended version of the Self Reporting Questionnaire 20, SRQ-20 = the Self Reporting Questionnaire 20. 
+
Sensitivity and specificity scores for the General Health Questionnaire 28 were not 
reported, making comparison of the two measures at specific cut off scores impossi-
ble. Area under the curve scores were reported as follows: SQR-20R (0.895), SRQ-20 
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(0.839), GHQ-28 (0.797) and GHQ-R (0.780) (Lee & Jenner, 2010). The authors con-
cluded the SRQ-20R was most successful at identifying non-psychotic mental health 
disorders and incorporated it into the Psycheck screening toolkit at a recommended 
cut off score of 5 (Lee & Jenner, 2010). 
Rush and others (2013) published a promising validation study that compared 
four screening measures against the Structured Clinical Interview for DSM-IV-TR 
Axis I Disorders – Research Version (First, Spitzer, et al., 2002). Unfortunately there 
were some methodological issues with this study. Firstly, the study was conducted 
across a mixed modality population and only reported results aggregated across all the 
modalities. In this regard Rush and others (2013) stated their sites were intentionally 
chosen to include a heterogenous mix of services and clients, but by treating these 
heterogenous groups as a monolith for the purposes of screening instrument validation 
these authors produced results that would not generalize to any specific treatment 
modality individually. As far back as 1982 Hanley and McNeil noted that, ‘ROC 
curves have been plotted and evaluated qualitatively with relatively little attention 
paid to their statistical characteristics’ (p. 29). Castel, Rush and Scalco (2008) explain 
that: 
Validity has been referred to as a property of the screening test but is better conceptu-
alized as a property of a procedure, i.e., the use of a screening test, in a given context, 
for a specific purpose (Streiner and Norman 2006). Thus, on screening for mental 
disorders among clients in treatment for substance use disorders, the question is to 
find screening tools that have been validated with samples drawn from the target 
population, within the treatment context (p. 65).  
If a measure is validated across two or more different settings with different popula-
tions in each, (for e.g., an outpatient setting and a residential setting), the different set-
tings will likely have different prevalences and types of comorbidity at different lev-
els of severity (Ries, 2008). For example, a very large study (N = 1,814,830) conduct-
ed by Lai and Sitharthan (2012), found different hospital settings had different rates 
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of comorbidity. If sensitivity, specificity and AUC scores are calculated from both 
settings combined, the measure is unlikely to perform as reported in either of those 
settings individually (Brenner & Gefeller, 1997). The question asked by studies that 
aggregate different treatment populations in this way might not be specific enough 
(for e.g.,  “Is this screening test valid among clients in treatment for substance use 
disorder?” or “Is this screening test valid?”). It is preferable to ask, “Is this screening 
test valid among clients in this treatment modality?” Ideally, measures should be vali-
dated in the population or setting in which they will be used because ‘validity is not a 
property of a screening instrument that remains stable across different populations’ 
(Castel et al., 2008, p. 70). Sensitivity, specificity, ROC-AUC scores, positive and 
negative predictive values and odds ratios all vary with the underlying prevalence and 
taxonomy of disorders in the population in which they are used (Brenner & Gefeller, 
1997). Research suggests the populations and the prevalence of COD varies across 
different treatment modalities (Carra & Johnson, 2009; Craddock et al., 1997; 
Gerstein & Harwood, 1990; J. Ross et al., 2005). These differences preclude across-
modality aggregation or comparisons (Craddock et al., 1997). Screening measure per-
formance including appropriate cut off scores will not be the same in different popula-
tions. ‘Thus, the validity of a screening instrument has to be reassessed in accordance 
with the intended use in studies that will also inform the choice of cutoff scores’ 
(Castel et al., 2008, p. 70). As advised by Brenner and Gefeller: 
The validity of diagnostic tests can typically be quantified only in relation to a de-
fined distribution of the underlying traits. As a consequence, estimates of sensitivity 
and specificity of various diagnostic tests cannot be compared, unless they are de-
rived from populations in which this distribution is comparable. … These findings … 
require careful consideration by public health professionals in the design of screening 
programs … [which] may be considerably improved by taking the variability of per-
formance of diagnostic tests between patient subgroups into account (1997, p. 989). 
Another limitation of Rush and other’s (2013) study was its relevance to an 
AOD treatment industry in need of screening instruments that have no costs associat-
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ed with their use. Two of the four screening measures validated in the study have 
costs associated with either their purchase and/or administration, making them less 
viable as screening options for much of the addiction treatment industry. Rush and 
others administered the GAIN Short Screener – Internalizing Disorder Screener 
(GSS-IDS, Dennis et al., 2006 a user license costs $100 per site) and the Psychiatric 
Diagnostic Screening Questionnaire (PDSQ, Zimmerman & Mattia, 2001, the test 
manual costs US$55 + on average US$2.10 per administration for summary scoring 
sheets and test booklets). These two measures along with the Psychiatric subscale of 
the Addiction Severity Index (McLellan et al., 1992) and the K6 (Kessler et al., 2002) 
were administered to 544 clients across three treatment centers, (a teaching hospital, a 
normal hospital and a community agency), involved in the provision of a number of 
treatment modalities (specialized assessment, withdrawal management, residential 
and non-residential services) (Rush et al., 2013). The overall prevalence of Axis I dis-
orders across all these modalities taken as a whole was 69.9% (Rush et al., 2013). The 
performance of the four screening measures in this mixed population is summarized 
below in Table 17. Note: for reporting purposes the highest aggregate of sensitivity 
and specificity for each measure was chosen as the cut off score reported and then the 
positive and negative predictive values at that cut off score are also reported. 
Table 17. AUC, Sensitivity, Specificity, Positive Predictive Value and Negative Pre-
dictive Value of Four Screening Measures (Rush et al., 2013) 
Measure  AUC Cut Off  Sensitivity Specificity PPV NPV 
GSS-IDS .78 3  71  72  81 62   
K6  .78 9  76  70  86 56 
ASI(5)  .77 61-70  51  86  90 43 
PDSQ  .82 35-39  74  74  87 55 
AUC = Area Under the Curve score, PPV = Positive Predictive Value, NPV = Negative Predictive Value, GAIN-SS-IDScr = 
GAIN Short Screener - Internalizing Disorder Screener, ASI (5) = Addiction Severity Index 5th Edition Psychiatric Status Do-
main, PDSQ = Psychiatric Diagnostic Screening Questionnaire. 
+
A thorough literature review of the validation studies completed to date re-
veals the lack of research to compare popular, freely available, easily administrable 
screening measures in a residential AOD treatment population. The available 
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measures have not been validated and compared in this population. Study 2 of this 
thesis addresses this gap in the literature and aims to provide evidence upon which 
residential AOD treatment services can base and improve their practices. There is a 
need to conduct validation studies that provide comparative data amongst screening 
measures to help identify those that might perform best for particular treatment set-
tings.  If treatment services are to improve the identification and (thereafter) treatment 
of clients with co-occurring disorders, an evidence-base must be provided to inform 
these services which screening instrument(s) to use and at what cut-off score(s). Study 
2 validates and compares five commonly used screening measures against a Struc-
tured Clinical Interview as a criterion for caseness. Research questions answered by 
Study 2 will include: 
1.! What is the rate and taxonomy of mental disorder comorbidity in residential 
AOD treatment services as determined by a standardized semi-structured clin-
ical interview? 
2.! How do commonly used screening measures compare in detecting comorbid 
mental disorders? 
3.! What are the optimal cut-off scores to be used in this population? 
!
!
+
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Chapter+2+Study+11+
1."Introduction"
Currently, internationally and in Australia, there are limited data regarding the extent 
of mental disorder comorbidity in AOD residential treatment services. Little is known 
about contemporary residential AOD treatment populations specifically. This is likely 
to hamper the appropriate development of treatments and services to address comor-
bidity. This study aims to fill this gap by using standardized, widely used screening 
measures to estimate the prevalence of co-occurring Axis I mental disorders in Aus-
tralian AOD residential treatment services. 
!
2."Materials"and"methods"
2.1.+Participants+
The study was conducted across eight of The Salvation Army's AOD recovery service 
centers located throughout New South Wales, the Australian Capital Territory and 
Queensland during 2008-2009. The Salvation Army residential recovery services pro-
vide up to 10-months of residential alcohol and other drug treatment. Participants 
were 278 AOD residential recovery service clients. The Salvation Army Bridge Pro-
gram uses the 12-Step recovery model based upon a disease perspective of addiction 
and aims for abstinence. University of Wollongong Human Research and Ethics 
Committee approval was gained for the study and all participation followed an in-
formed consent process with participants. There were 233 (84%) males and 44 (16%) 
females (one participant failed to enter their gender). Ages ranged from 18 to 68-
years, averaging 37-years old (SD = 10.90). Participants had been in the programs for 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1 This chapter is based on Mortlock, K. S., Deane, F. P., & Crowe, T. P. (2011). Screening for mental 
disorder comorbidity in Australian alcohol and other drug residential treatment settings. Journal of 
Substance Abuse Treatment, 40(4), 397-404. doi: 10.1016/j.jsat.2011.01.002 
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an average of 16-weeks (SD = 17.05) and indicated they had alcohol or other drug 
problems for an average of 17-years (SD  = 9.59). Alcohol was the primary drug of 
concern for 155 participants (55.8%), followed by amphetamines for 41 participants 
(14.8%), cannabis for 29 participants (10.4%) and heroin for 16 participants (5.8%). 
Most participants (63%) had sought drug or alcohol treatment previously and almost 
half (48%) indicated they had sought treatment for a mental disorder previously. Fif-
ty-seven percent of clients reported at least one historical mental disorder diagnosis. 
Sixty-eight participants (24%) were resident in a recovery service that included an 
identified dual disorder program for some (less than 50%) of its clients. However, the 
overall rate of mental disorder at this service was actually lower than the rate of men-
tal disorder in the rest of the sample so this did not positively skew the estimates. 
!
2.2.+Materials+
The rate of CODs in The Salvation Army AOD recovery service centers was estimat-
ed by administering two widely used mental disorder screening instruments as part of 
a larger cross-sectional study: 
Addiction Severity Index—Self-Report Psychiatric Status Domain 
The Addiction Severity Index (ASI; McLellan et al., 1992; McLellan et al., 1980) is 
the most used measure in research of substance abuse outcomes (Doub, 2001). It has 
been extensively validated, including within COD populations (Hodgins & El-
Guebaly, 1992). The full ASI is a structured clinical interview that usually takes ap-
proximately 40 minutes to complete. It covers seven domains: medical condition, em-
ployment, drug use, alcohol use, legal status, family/social relations and psychiatric 
condition (McLellan et al., 1992). ASI composite scores in each domain are arithmet-
ically derived indices based upon items that examine problem severity over the last 30 
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days. Scores range from 0 (no significant problem) to 1 (extreme problem) (Clark & 
Young, 2009).  
In this study, a self-report version of the ASI Psychiatric Status domain was 
used (ASI-SR; Rosen, Henson, Finney, & Moos, 2000). Cacciola, Pecoraro, and Al-
terman (2008) reported that at a cutoff score of 0.22 the ASI Psychiatric Status Com-
posite Score had a sensitivity of 80.07% and a specificity of 60.11%, giving the in-
strument an overall accuracy of about 70% in their sample where it predicted 58% of 
the sample was positive for mental disorder and the actual overall prevalence as 
measured by a SCID-III-R diagnostic interview was 45.3%. 
Rosen et al. (2000) compared the full interview version with the self-
administered version of the ASI and concluded the two formats had similar internal 
consistency and were strongly correlated in the Psychiatric scale (0.67). The mean 
endorsement of psychiatric symptoms was significantly higher on the self-
administered version (0.36) than in the interview (0.27), p <  .01, in line with a gen-
eral tendency to endorse more problems on the pencil-and-paper questionnaire (Rosen 
et al., 2000). The authors speculated this difference may reflect social desirability 
concerns with respondents more willing to endorse psychiatric symptoms on a pencil-
and-paper measure than when face to face with an interviewer (Rosen et al., 2000). 
Given the negative consequences associated with unidentified comorbidity, the ten-
dency of the ASI Self-Report Psychiatric Status Domain (ASI-SR) to act in a more 
sensitive manner was viewed as desirable in our population. 
The ASI is considered adequate as a screening instrument for CODs, but the 
individual ASI domains examined singly have been criticized for not providing 
enough descriptive detail and depth of coverage (Doub, 2001). It has been recom-
mended that the Psychiatric Status section of the ASI be supplemented with more de-
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tailed, domain-specific measures and that validity with respect to DSM-IV diagnostic 
criteria could be ‘improved through the addition of expanded descriptors of clinical 
symptomatology [sic]’ (Doub, 2001, p. 104). We followed this recommendation in 
this study by adding an additional measure detailed below: 
Mental Health Screening Form III 
The Mental Health Screening Form III (MHSF-III; Carroll & McGinley, 2001) is a 
screening instrument designed to detect mental disorder comorbidity in drug and al-
cohol taking populations. The first four questions on the MHSF-III are not unique to 
any particular mental disorder diagnosis. Questions 5 through 17 reflect symptoms 
associated with specific diagnoses/diagnostic categories (for example, Q5, schizo-
phrenia; see Table 19 for others). Each MHSF-III question is answered with either 
“yes” or “no.”  All questions reflect the respondent's life history; therefore, all ques-
tions begin with the phrase “Have you ever…”. A total score is calculated by adding 
the total number of “yes” responses. The maximum possible score on the MHSF-III is 
18 (question 6 has two parts). 
The MHSF-III was first validated within a long-term, residential, therapeutic, 
AOD treatment community in the Bronx, New York (r  = .74 for test– retest; 
Cronbach's α = .83 and .89 at Time 1 and Time 2, respectively; 87% of participants 
marked items “ yes” that corresponded with their primary mental health diagnosis; 
Carroll & McGinley, 2001). The original recommendation made by the creators of the 
MHSF-III was that specialist consultation should be arranged if any of Items 5 
through 17 were endorsed with a “yes” response (Carroll & McGinley, 2000). In a 
subsequent review of more than 150 screening measures, the MHSF-III was identified 
as one of the three best-performing measures when the MHSF-III total score was used 
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as an indication of overall need for follow-up (Sacks, Melnick, Coen, Banks, 
Friedmann, Grella, & Knight, 2007).!
!
2.3.+Procedure+
Questionnaires were handed out to participants in large group meetings at each of The 
Salvation Army recovery service centers. Participation was voluntary, and those who 
chose not to participate could return incomplete measures in an envelope without be-
ing identified. Participants were given as much time as they required to complete the 
questionnaires. Literacy problems were overcome by reading questions to participants 
where necessary, although this was rarely required. The data were entered into SPSS 
v. 21 for analysis.  
!
3."Results"
Almost half (47.6%) of the respondents reported seeking psychological treatment pre-
viously and 56.8% self-reported being diagnosed with a mental disorder previously. 
Table 18 displays the breakdown of these historical self-reported diagnoses. A histor-
ical affect disorder diagnosis was self-reported by 48% of participants, followed by 
14% reporting some form of anxiety disorder. Nine percent of self-reported historical 
mental disorder diagnoses were schizophrenia or psychosis-related disorders. 
Table 18. Percentage of Self-Reported Previous Mental Disorder Diagnoses 
Historical Mental Disorder Diagnosis  Proportion of Historical Diagnoses 
Depression      35% 
Bipolar Disorder      13% 
Anxiety         9% 
Post Traumatic Stress Disorder      5% 
Schizophrenia       5% 
Psychosis     4% 
Borderline Personality Disorder      3% 
!
On the MHSF-III (N = 259) using the first cutoff score of 3, 253 of the 259 
(97.68%) participants in our residential AOD treatment sample screened positive for 
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mental disorder. Using psychometric validation figures from previous research 
(Sacks, Melnick, Coen, Banks, Friedmann, Grella, & Knight, 2007), it is suggested 
that if semi-structured clinical interviews were conducted upon the sample it would be 
found that the MHSF-III accurately identified 73% of these 253 respondents who 
screened positive, meaning the best estimate is that 185 of the 259 (71.31%) respond-
ents who completed the full measure actually have a fully diagnosable mental disor-
der. 
On the MHSF-III (N = 259) using the cutoff score of 6, 229 of the 259 
(88.4%) participants screened positive for mental disorder. Again, previous psycho-
metric validation research using semi-structured clinical interviews as the criterion 
suggests at this cutoff score, it would be found that the MHSF-III accurately identi-
fied 72% of these 229 respondents who screened positive. This returns the estimate 
that 165 of 259 (63.66%) respondents actually have a diagnosable mental disorder.  
Lastly, on the MHSF-III (N = 259) at the cutoff score of 11 previously rec-
ommended for detecting severe mental disorder only (major depression, bipolar dis-
order and schizophrenia), 137 of the 259 (52.90%) participants screened positive, and 
using previous research that reports 76% accuracy, 104 of the 259 (40.20%) clients in 
our sample are estimated to have a severe mental disorder. 
The mean MHSF-III total score (N = 259) in our sample was 10.60 (SD = 
4.07), which indicated clients reported an average of 10.60 symptoms of mental dis-
order. The breakdown of these positive responses to the different symptom questions 
contained within the MHSF-III was as follows in Table 19.  
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Table 19. MHSF-III Symptom-Question Response Prevalence 
Question Number/Disorder Symptom Queried            Frequency     Percentage 
Q5 Schizophrenia symptom      97/272  35.7% 
Q6a Depressive disorder symptom   215/271  79.3% 
Q6b Depressive suicide attempt symptom  120/262  45.8% 
Q7 Post traumatic stress disorder symptom  160/272  58.8% 
Q8 Phobias symptom    201/272  73.9% 
Q9 Intermittent explosive disorder symptom  174/270  64.4% 
Q10 Delusional disorder symptom   191/271  70.5% 
Q11 Sexual & gender identity disorder symptom  136/270  50.4% 
Q12 Eating disorders symptom        93/270  34.4% 
Q13 Manic episode symptom    169/269  62.8% 
Q14 Panic disorder symptom    209/276  75.7% 
Q15 Obsessive compulsive disorder symptom  143/276  51.8% 
Q16 Pathological gambling symptom   138/275  50.2% 
Q17 Learning disorder & mental retardation    64/275  23.3% 
Q6a & Q13 Bipolar disorder symptoms  143/269  53.1% 
!
On the ASI-SR (n  = 164) using a cutoff composite score of .22, 107 of the 
164 (65.2%) participants who validly completed the measure in our sample screened 
positive for mental disorder. Using previous psychometric validation figures derived 
from comparing the ASI Psychiatric Status score to a SCID-III-R interview (Cacciola 
et al., 2008), it is suggested the ASI-SR accurately identified 70% of these 107 re-
spondents who screened positive, with the result that the ASI-SR estimate is that 75 of 
the 164 (45.67%) respondents who completed the full ASI-SR measure have a diag-
nosable mental disorder. The mean ASI-SR Psychiatric Composite score (n  = 164) 
was .41 (SD  = .38). For the reasons to be discussed below, these ASI-SR results 
should be considered preliminary. 
!
3.1+Comparison+of+MHSFJIII+and+ASIJSR+estimates+
Of those who did screen positive for mental disorder on the ASI-SR, 92.52% (99/107) 
validly completed the MHSFIII. At a cutoff score of 3 on the MHSF-III, all of those 
99 (100%) who screened positive for current mental disorder when asked about the 
last 30 days on the ASI-SR also screened positive for current mental disorder when 
asked about their entire lifetime on the MHSF-III (as would be expected). At a cutoff 
score of 6 on the MHSF-III, 95.96% (95/99) of those who screened positive for men-
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tal disorder when asked about the last 30 days on the ASI-SR also screened positive 
on the MHSF-III. This means four participants who screened positive for mental dis-
order in the last 30 days on the ASI-SR did not also screen positive for mental disor-
der when asked about their lifetime experience on the MHSF-III at this higher cutoff 
score of 6. At a cutoff score of 11 on the MHSF-III, 69.70% (69/99) of those who 
screened positive for mental disorder when asked about the last 30 days on the ASI-
SR also screened positive for severe mental disorder on the MHSF-III. Of those who 
screened negative for mental disorder on the ASI-SR, 96.49% (55/57) validly re-
sponded to the MHSF-III. At a cutoff score of 3 on the MHSF-III, 98.18% (54/55) of 
those who screened negative for mental disorder on the ASI-SR screened positive on 
the MHSF-III. At a cutoff score of 6 on the MHSF-III, 83.64% (46/55) of those who 
screened negative for mental disorder on the ASI-SR screened positive on the MHSF-
III. Even at a cutoff score of 11 on the MHSF-III, 38.18% (21/55) of those who 
screened negative for mental disorder on the ASI-SR screened positive for severe 
mental disorder on the MHSF-III.  
Of the significant number of participants who failed to validly complete the 
ASI-SR, 91% managed to validly complete the MHSF-III. Using a cutoff score of 3 
on the MHSF-III, 95% of participants who failed to validly complete the ASI-SR 
screened positive for mental disorder on the MHSF-III. Using a cutoff score of 6, it 
was 84%, and with a cutoff score of 11, 44% of those who failed to validly complete 
the ASI-SR screened positive for severe mental disorder on the MHSF-III. 
!
4."Discussion"
My results suggest there are very high levels of mental disorder comorbidity in Aus-
tralian AOD residential treatment services. Sixty-five percent to 98% of participants 
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screened positive to the presence of mental disorder using two screening instruments. 
Before discussing these results in greater detail it should be noted a problem emerged 
with using the ASI-SR in this population. The scoring methodology used with the 
ASI-SR requires all items on the form to be completed for a composite score to be 
generated. One missing item means the score cannot be generated. In our sample, on-
ly 164 of 278 (59%) respondents managed to complete every part of the ASI-SR to 
enable a score to be generated. This compares to the MHSF-III, where 259 of 278 
(93.2%) respondents successfully completed the MHSF-III measure. The relatively 
high frequency of missing data on the ASI-SR measure combined with the limitation 
of any missing data to generating a score emerged as a major constraint with using a 
self-report version of the ASI with COD populations in my study. As a consequence 
of this limitation and the smaller sample size using the ASI-SR measure as a result, 
the mental disorder estimates from the ASI-SR should be viewed as preliminary only, 
and the mental disorder estimates from the MHSF-III are to be preferred. It is recom-
mended that the ASI should be administered in its interview format to this population 
in the future. 
Estimates based upon previous psychometric validation research conducted 
upon the MHSF-III suggest that diagnosable general Axis I mental disorder comor-
bidity exists in between 64% and 71% of clients in residential AOD services run by 
the Salvation Army in Australia. Severe mental disorder is estimated to be present in 
40% of residential clients. These estimates represent a significant increase in psycho-
logical comorbidity compared with the figure (45%) reported 30-years ago in a Unit-
ed States of America therapeutic community population (Jainchill, 1994). 
Previous research on the MHSF-III reported three different cutoff scores at 
which general and severe mental disorder may be indicated (Sacks, Melnick, Coen, 
! 89!
Banks, Friedmann, Grella, & Knight, 2007). AOD treatment services must weigh up 
the relative costs and benefits related to correctly identifying the maximum number of 
clients with mental disorder comorbidity with the increased costs from initiating fur-
ther assessment of the false positives that a more sensitive cutoff score also returns. 
This issue is discussed in greater detail later in this thesis, but if the overall true preva-
lence of mental disorder in a sample is high, then a low cutoff score that provides the 
highest sensitivity (for example, at a cutoff score of 3, 90%) will provide the most ac-
curate estimate of mental disorder (71% in our study; Gordis, 2004). Accordingly, my 
results suggest a cutoff score of 3 on the MHSF-III is most appropriate for AOD ser-
vices unwilling to allow clients with current COD to fall through the cracks of screen-
ing given the serious consequences that correlate with untreated COD. This is because 
previous psychometric validation research indicates a cutoff score of 3 affords maxi-
mum (90%) sensitivity and is most unlikely to miss mentally disordered cases. If true 
prevalence is not that high and/or services wish to limit false positives for cost or oth-
er reasons such as limited access to further mental disorder assessment and follow-up, 
then a cutoff score of 6 may be preferred with its increased ability to rule out false 
positives (with a higher specificity of 67.5%) at the expense of lesser sensitivity 
(75%). In our sample, this cutoff score provided an estimate that 64% of participants 
had a COD. The higher cutoff score used to generate this estimate is likely to result in 
fewer false positives but lower overall accuracy due to a lower sensitivity that could 
see disordered cases missed. At the other end of the scale is the cutoff score of 11 
recommended as indicating severe mental disorder, such as major depression, bipolar 
disorder and schizophrenia. Services that are interested in identifying the most severe 
mental disorder may choose this cutoff score. In our sample, this reduced the number 
of participants identified to 40%.  
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A significant number of participants screened negative for mental disorder on 
the ASI-SR but screened positive on the MHSF-III: 95%, 84%, and 44% respectively 
at cutoff scores of 3, 6, and 11 on the MHSF-III. These results could be interpreted in 
two ways. The difference in estimated prevalence based upon lifetime (MHSF-III) 
and 30-day (ASI-SR) information may reflect the fact that some individuals made a 
recovery from mental disorder. Alternatively, the discrepancy may suggest that the 
ASI-SR with its truncated taxonomy of mental disorder symptoms lacks sensitivity to 
detect a broad spectrum of mental disorders in this population, as suggested by previ-
ous research (Doub, 2001). A further complication was the low valid response rate 
returned on the ASI-SR. It appears that the self-report format of the ASI-SR may be a 
limitation that could see significant comorbidity missed in this population. Unlike the 
MHSF-III, which is consistent in its simple “Yes/No” format throughout its (effec-
tively) 18 questions, the ASI-SR varies the format of answers it requires. Some ques-
tions ask how many days in the past 30-days the respondent has experienced psycho-
logical or emotional problems (requiring a numerical 0-30 response). Other questions 
are in a “Yes/No” format. And still other questions ask for a check-box rating accord-
ing to a rating scale with the following options: not at all, slightly, moderately, con-
siderably, extremely. It is possible this variation in the format of required answers is a 
problem for the self-report version of this measure. The interview version of the ASI 
needs to be tested in conjunction with the MHSF-III to confirm whether it is the self-
report version or something inherent in the items that raises the risk of missing 
comorbidity. 
Another notable finding was the high frequency of symptom endorsement. 
Participants across the entire valid sample of MHSF-III responses (N = 259) reported 
experiencing more than 10 symptoms of mental disorder on average. This high fre-
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quency of symptoms represents a significant departure from previous research using 
this measure. The original validation study conducted upon the MHSF-III in a long-
term residential therapeutic community program for substance abuse in New York 
reported a mean MHSF-III total score of just 5.1 (SD  = 4.0; Carroll & McGinley, 
2001). More recently, in a prison substance abuse setting, the average MHSF-III total 
symptom endorsement score was again only 4.2 (SD  = 4.3; Ruiz, Peters, Sanchez, & 
Bates, 2009). Our mean MHSF-III total symptom endorsement score (10.60) is dou-
ble these previously reported figures. This result suggests clients in residential AOD 
treatment services in Australia may be presenting with much higher rates of psycho-
logical comorbidity than clients in other settings. It could also represent a continua-
tion of the trend towards worsening comorbidity reported in therapeutic communities 
in the United States of America by Jainchill over the ten-year period from the 1974 to 
1984 (Jainchill, 1994). The clients in this study definitely endorsed a higher number 
of psychological symptoms when queried with a short survey. Whether this high 
symptom endorsement represents high rates of full-blown mental disorder presenting 
to Australian residential alcohol and other drug treatment can only be investigated by 
administering a full diagnostic interview that enquires into all the criteria of each dis-
order. 
The breakdown of symptoms experienced by clients in Australian residential 
AOD treatment services was very different from epidemiological surveys in the gen-
eral population. Lending weight to Grella and Stein’s (2006) findings that 36% of res-
idential substance abuse treatment clients with identified comorbidity had a psychotic 
disorder, in the present study more than 35% of participants indicated that they had 
heard voices no one else could hear or had seen objects or things that others could not 
see. Seventy percent of participants endorsed the delusional disorder symptom ques-
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tion, indicating they had felt that people may have something against them without 
them necessarily saying so or that some person or group may be influencing their 
thoughts or behavior. It is unclear whether these are positive symptoms associated 
with a psychotic disorder or secondary to drug use. A semi-structured clinical inter-
view would be needed to clarify this issue further, but the potential that psychotic dis-
orders are much more prevalent than previously thought in this population is clearly 
indicated. Many screening measures fail to screen for “lower prevalence” disorders 
and may fail to identify these clients in need of further assessment (for e.g., the GAIN 
Short Screener, Dennis et al., 2006; the General Health Questionnaire, Goldberg et 
al., 1997; the K6 or K10, Kessler et al., 2002; or the Self Reporting Questionnaire 20, 
Lee et al., 2007).  
When high-prevalence affect and anxiety disorders are considered, they too 
may be much more prevalent in my Australian residential AOD treatment sample than 
in the general population (Slade et al., 2009). Almost 80% of participants indicated 
they had major symptoms of depression, and almost half (45.8%) of the participants 
indicated they had attempted to commit suicide previously. Symptoms of a manic epi-
sode had been experienced by 62.8% of participants, and when combined with posi-
tive responses to the depressive disorders symptom question, 53.1% or more than half 
of participants screened positive for possible bipolar disorder. Three quarters (75.5%) 
of Australian AOD residential treatment clients endorsed experiencing symptoms of 
panic disorder. All of these results represent a significant potential increase in psychi-
atric comorbidity when compared with the United States of America therapeutic 
community studies of the 1970s and 1980s reported on by Nancy Jainchill (1994). 
It has previously been noted that chemically dependent persons present with a 
variety of disorders across a wide spectrum of diagnoses (Carroll & McGinley, 1998). 
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Ross and others (2005) found that those with heroin substance use disorder in residen-
tial treatment represented a hard core with significantly greater levels of psychiatric 
comorbidity even when compared with heroin users in other treatment modalities. My 
results accord with this previous research and suggest the same may well be true for a 
broader range of substance-disordered clients in residential treatment. Clearly, more 
research using semi-structured clinical interviews is needed in this area to definitively 
identify the needs of this population. 
!
5."Conclusions"
Axis I mental disorder comorbidity is estimated to exist at high rates (64%-71%) in 
the Salvation Army Australian residential AOD treatment populations. Much higher 
than the rate reported in the United States of America 30-years ago (45%; Jainchill, 
1994). The Salvation Army Australian residential AOD treatment populations endorse 
a large number of mental disorder symptoms from a wide spectrum of mental disor-
ders when surveyed with short screening instruments. Psychotic disorders may be 
present in this population at a much higher rate than reported previously in either 
treatment or non-treatment populations (Jainchill, 1994; Morgan et al., 2011). Com-
prehensive mental disorder assessment with semi-structured clinical interviews is 
necessary to accurately ascertain the identity and needs of this population. 
+
+
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Chapter+3+Study+2+
1."Introduction"
Study 2 is predominantly a psychometric validation study. It is aimed at validating 
and comparing the ability of five commonly used screening instruments to detect co-
occurring mental disorders in residential alcohol and other drug program participants. 
This will provide much-needed evidence for residential alcohol and other drug treat-
ment services to base their screening practices, assisting with both instrument selec-
tion and cut off score decisions. Several of the results from Study 1, however, war-
ranted follow up and thus there is also an additional prevalence/taxonomy aspect to 
Study 2 that was aimed at clarifying the results of Study 1.  
In residential alcohol and other drug treatment the prevalence of mental disor-
der comorbidity was until recently unknown. Study 1 suggested comorbidity might be 
present at rates even higher than that found across treatment modalities taken together 
(64-71%) (Mortlock, Deane, & Crowe, 2011; J. Ross et al., 2005). If accurate, the es-
timates from Study 1 represent a significant increase in comorbid psychopathology 
since studies conducted into the residential AOD treatment population nearly forty-
years ago (when the rate was 45% in an American therapeutic community population, 
Jainchill, 1994). In Study 1 participants in residential AOD treatment in Australia en-
dorsed experiencing on average more than 10 symptoms of mental disorder when ad-
ministered a short survey (Mortlock et al., 2011). This is double the rate of symptom 
endorsement found in either an American therapeutic community setting (5.1) or an 
American prison setting (4.2) using the same measure. It is also possible that psychot-
ic disorders exist in this subpopulation at rates many times those found in the general 
population (up to 35%) (Grella & Stein, 2006; Mortlock et al., 2011).  
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If found to be accurate, the prevalence and taxonomy of mental disorder 
comorbidity estimated in Study 1 would have marked implications for services. It is 
possible that the 35% of clients in Study 1 who reported “seeing things no one else 
could see and/or hearing things no one else could hear” could be reporting these 
symptoms as secondary to substance use disorders. However, even if half of these re-
ports were due to primary psychosis that would still represent 17.5% of residential 
AOD clients suffering a current comorbid psychotic disorder. It has been thought pre-
viously that clients with such severe mental disorders only presented to – and certain-
ly should only be treated by – specialist mental health services, not AOD services 
(see, for e.g., the four quadrants of care conceptualisation that classifies clients of the 
AOD and mental health systems into four categories based upon symptom severity in 
Center for Substance Abuse Treatment, 2005). If clients with psychosis are frequently 
presenting to residential AOD treatment services serious thought needs to be given to 
the training needs of the workers in those services and additionally the need to im-
prove and standardize service access to specialist psychiatric consultants.  
The figures in Study 1, however, are only estimates based upon short screen-
ing measures. Short screening measures lack the ability, for example, to tease out and 
discriminate between symptoms representative of primary psychoses and those sec-
ondary to substance use disorders. They also don’t determine whether all criteria for a 
disorder are met, or make an assessment of functional impairment to determine how 
relevant to treatment the comorbidity is. In order to clarify the prevalence and taxon-
omy of comorbidity in residential treatment services – and the identity and needs of 
the population within these services – a study that utilizes a full diagnostic interview 
is necessary.  
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It has been known for some time that successful early identification of mental 
disorder comorbidity is the first step in achieving better outcomes for the co-occurring 
disorder population (Croton, 2005b; Ziedonis et al., 2005). This has led to govern-
ment funding and guidelines aimed at improving the identification of those with both 
a mental disorder and a substance use disorder in treatment settings. Resources have 
been published that review the screening measures currently available to detect co-
occurring mental disorders (Center for Substance Abuse Treatment, 2005; Croton, 
2007; Dawe et al., 2002). Guidelines have been published both nationally and interna-
tionally that advocate routine screening for mental disorder comorbidity. (Center for 
Substance Abuse Treatment, 2005; Dawe et al., 2002; Gordon, 2008; Hawkings & 
Gilburt, 2004; Health Canada, 2002; Institute of Medicine, 2006; Mills et al., 2010; 
NSW Health, 2000; Substance Abuse and Mental Health Services Administration, 
2002). Yet despite the guidelines, reviews, and increasing awareness of the preva-
lence and harms associated with undetected COD, the ongoing failure of substance 
misuse treatment systems to recognize co-occurring mental disorders is well docu-
mented (Croton, 2007; Donald et al., 2005; Hu et al., 2006; Lubman et al., 2008). 
Various reasons have been proposed why substance misuse treatment systems are 
continuing to fail to recognize co-occurring mental disorders. One major barrier to 
improving the identification of clients with co-occurring disorders in these systems to 
date has been a lack of appropriate research aimed at validating and comparing the 
various screening instruments available to detect co-occurring disorders. A review of 
the validation research conducted to date revealed a dearth of applicable research and 
significant methodological issues and inconsistencies among the studies that have 
been conducted. Comparative studies that compare multiple measures’ performance 
against a recognized criterion measure are rare and they have not been conducted 
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within residential alcohol and other drug services. The studies that have been con-
ducted at best reported a truncated set of statistical analyses inadequate to properly 
ascertain screening instrument performance, and at worst utilised methodologies that 
invalidated their results and revealed a significant lack of understanding of the under-
lying statistical analyses involved. 
As noted previously, it is highly preferable that screening measures are vali-
dated within the treatment modality in which they will be used (Castel et al., 2008). 
Measures validated in a different treatment modality or in several different treatment 
modalities aggregated as a whole simply will not perform as indicated and cannot be 
generalized beyond the study conducted. The underlying prevalence and taxonomy of 
disorder in a population affects the performance of screening measures, including the 
sensitivity, specificity, positive and negative predictive values and odds ratios and the 
area under the curve score. Cut off scores may not be the same in different popula-
tions. Therefore validation results produced by jumbling settings/populations together 
will not apply accurately to any one setting/population disaggregated from such a 
mistakenly homogenized whole (Brenner & Gefeller, 1997). As a result, there is a 
need for studies that validate and compare commonly available screening measures in 
each of the various treatment modalities that exist within substance misuse treatment 
systems. 
In the current study the treatment modality is residential alcohol and other 
drug treatment. A detailed description of the sample demographic information allows 
further clarity about the context in which these results can be applied.  
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The study was conducted across four of The Salvation Army’s alcohol and other drug 
recovery service centers located in New South Wales and the Australian Capital Ter-
ritory, Australia during 2010-2011. Participants were randomly selected from among 
all AOD service clients within four weeks of their admission date using a random 
number generator (http://www.random.org). All participants had already gone through 
withdrawal management previous to admission to the program. The only inclusion 
criterion was that potential participants were within four weeks of admission and all 
had an equal chance of being included in the study. Sample size and power calcula-
tion were determined in accordance with the procedure described by Hajian-Tilaki 
(2011) under the “Sample size in estimating the proportion of binary outcome – de-
scriptive study” subheading. Using an estimated prevalence of 70% (based upon study 
1 results), 90% power may be achieved with 95% confidence with a minimum sample 
size of 80.67 (to two decimal places). One-hundred and twenty-four participants 
agreed to participate in the study out of 144 clients approached, easily meeting this 
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requirement and giving a participation rate of 86%. Of the 124 alcohol and other drug, 
residential, recovery service clients who agreed to participate, 121 participants com-
pleted four screening instruments, 120 participants completed SCID-I/P interviews 
and 117 participants completed both the four screening instruments and a SCID-I/P 
interview. Of the four participants who did not complete a SCID-I/P interview, two 
participants stopped participating due to emotional difficulties experienced during the 
interview or active psychosis, one participant had to be sedated by the service at the 
time the interview was to be conducted and one participant went to the gym. One 
screening measure, the Addiction Severity Index Psychiatric Status Domain, was col-
lected by caseworkers at the services and unfortunately valid data was only available 
for 65 of the above participants on this measure, of which 63 had also completed a 
SCID-I/P interview. This was due mainly to staff failing to enter data into the data 
management system or failing to administer the measure. University of Wollongong 
Human Research and Ethics Committee approval was gained for the study and all par-
ticipation followed an informed consent process with participants. 
The 124 participants who took part in the study were 84% male and 16% fe-
male. Ages ranged from 18.25 to 63.75 years, averaging 36.56 years old (SD = 
10.03). Alcohol was the primary drug of concern for 77 participants (62%), followed 
by amphetamines for 18 participants (14.5%), cannabis for 6 participants (5%) and 
heroin/methadone/other opiates for 7 participants (5.6%). 
+
2.2+Materials+
The following interview and self-report mental disorder screening instruments were 
administered: 
Structured Clinical Interview for DSM-IV-TR Axis I Disorders - Research Ver-
sion, Patient Edition (SCID-I/P) 
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The SCID-I/P was used as a criterion measure to establish the rate and taxonomy of 
co-occurring Axis I mental disorders (SCID-I/P, 1/2007 Revision, First, Spitzer, et al., 
2002). The SCID-I/P is considered the gold standard in diagnosing mental disorders, a 
large number of studies testify to its reliability and validity (First, Gibbon, Spitzer, & 
Williams, 2002). Structured clinical interviews such as the SCID-I/P have been re-
ported to be more sensitive to the presence of comorbid mental disorders than un-
structured clinical interviews (Grove & Meehl, 1996; Zimmerman & Mattia, 1999). 
The SCID-I/P (First, Spitzer, et al., 2002) was administered and rated by a doctoral 
psychology student who had received intensive training in conducting SCID-I/P in-
terviews. 
Addiction Severity Index – Psychiatric Status Domain (ASI).  
The Addiction Severity Index is a semi-structured interview and was administered by 
trained caseworkers at the recovery services within 1-2 weeks of participant admis-
sion to treatment as part of a routine intake assessment.  As mentioned previously the 
Addiction Severity Index (McLellan et al., 1992; McLellan et al., 1980) is the most 
used measure in research into substance abuse outcomes (Doub, 2001). It has been 
extensively validated, including within COD populations generally (Hodgins & El-
Guebaly, 1992). In the present study only the Psychiatric Status domain of the inter-
view version of the fifth edition of the Addiction Severity Index is reported.  
Mental Health Screening Form III (MHSF-III).  
The MHSF-III (Carroll & McGinley, 2001) is the same instrument as was used in 
Study 1. 
Self Reporting Questionnaire 20 Revised (SRQ-20R) and the                             
Self Reporting Questionnaire 25 Revised (SRQ-25R). 
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The Self Reporting Questionnaire was designed by the World Health Organisation to 
screen for psychiatric disturbance in primary health care settings, especially in devel-
oping countries (Beusenberg & Orley, 1994). As mentioned previously, originally, the 
Self Reporting Questionnaire contained 25 questions, 20 related to neurotic symp-
toms, four concerning psychotic symptoms and one question asking about epileptic-
type fits or convulsions (Beusenberg & Orley, 1994). This measure is known as the 
Self Reporting Questionnaire 25 (SRQ-25). An adaptation of the SRQ-25 that used 
only the 20 questions related to neurotic symptoms was used by Lee et al., (2007) as 
part of the Psycheck mental disorder screening package. In this version, known as the 
Self Reporting Questionnaire 20 – Revised (SRQ-20R), questions were adapted to the 
AOD treatment environment by the addition of an extra column that asks respondents 
to indicate whether the problem they have reported has also occurred at a time when 
they were not using drugs or alcohol. In the present study, the SRQ-20R and the five 
additional questions covering psychosis and epilepsy that together constitute the 
SRQ-25 and modified in the same way were administered separately to facilitate a 
comparison of the performance of the SRQ-20R and what effectively became the Self 
Reporting Questionnaire 25 – Revised (SRQ-25R) measures in the population of in-
terest. 
Modified Mini-Screen (MMS). 
The Modified Mini Screen (MMS) was created by the New York State Office of 
Mental Health and the New York State Office of Alcohol and Substance Abuse Ser-
vices, (with expert consultation), to remedy the lack of validated measures available 
to base a systemic decision rule to refer people with substance use problems in public 
sector settings for further mental health assessment (Alexander et al., 2008). The 
MMS is a combination of gateway questions taken from the Diagnostic and Statistical 
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Manual for Mental Disorders–IV–TR (American Psychiatric Association, 2000), the 
Structured Clinical Interview for DSM–III–R Non-Patient Edition (Spitzer et al., 
1988), and the Mini International Neuropsychiatric Interview (Sheehan et al., 1998). 
There are 22 self-report items designed to identify persons in need of further assess-
ment for mood, anxiety and/or psychotic disorders in a variety of settings including 
research studies (Brandau et al., 2005; Connecticut Department of Mental Health and 
Addiction Services, 2007). The MMS has been validated in a combined addiction, 
social services and corrections population and demonstrated good internal consistency 
(Cronbach’s alpha 0.92), inter-rater agreement (92%) and one-week, test-retest relia-
bility (79%) (Alexander et al., 2008).  
2.3+Procedure+
Participants were administered the ASI within 1-2 weeks of admission to treatment as 
part of a routine intake assessment. Within four-weeks of admission to treatment di-
agnostic and self-report data were collected as part of a larger study assessing the 
psychometric validity of measures of mental disorder and mental health in a residen-
tial AOD treatment population. Randomly selected participants participated in two 
research sessions two-days apart. In a diagnostic interview session participants were 
administered the SCID-I/P (First, Spitzer, et al., 2002). In the other session partici-
pants were administered the MHSF-III (Carroll & McGinley, 2001), the MMS 
(Brandau et al., 2005), the Psycheck version of the SRQ-20R (Lee et al., 2007) and 
the five additional questions that with the SRQ-20R combine to form the SRQ-25R 
(Beusenberg & Orley, 1994).  Information from one session was not consulted when 
conducting the other session. The data was entered into SPSS v. 21 for analysis.  
+
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2.4+Data+Analysis+
A Receiver Operating Characteristic (ROC) curve analysis was conducted on all of 
the short screening instruments to determine their diagnostic validity using the SCID-
I/P as a criterion measure for caseness. Sensitivity, specificity, accuracy, positive and 
negative predictive values and positive and negative odds ratios were calculated for 
each measure across a range of different cut off scores along with an area under the 
curve (AUC) score that goes across all cut off scores. The number of clients indicated 
for further assessment and the number of disordered cases correctly identified by each 
measure at each cut off score is also noted to facilitate a proper analysis of the real 
world results of screening with each measure at each cut off score. 
ROC-AUC results usually vary between 0.50 and 1.0. A ROC-AUC score of 
0.50 represents a line with a slope of 1 and indicates a complete lack of predictive 
ability, (it is the equivalent of chance, a 50/50 result) (Bisoffi et al., 2000). Results 
between 0.70 and 0.80 represent good accuracy (Cacciola et al., 2008). Greater than 
0.80 represent reasonable to excellent accuracy and results above .90 excellent to out-
standing accuracy (Cacciola et al., 2008; J. A. Swartz, 2007). 
Inter-rater reliability was established by an independent clinical and research 
psychologist reviewing audiotape recordings of ten randomly selected SCID-I/P in-
terviews. Ten was a modest sample but the overall rate of agreement on whether a 
current diagnosis was present was substantial at 90%, Kappa = 0.78 (p = .011). The 
rates for specific categories of disorder were, affective disorder 90%, Kappa = 0.80 (p 
= .01); anxiety disorder 80%, Kappa = 0.615 (p = .035); and a current psychotic dis-
order 100%, Kappa = 1.00 (p = .002) (all within past 30 days).  
!
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3."Results"
According to the Structured Clinical Interview for DSM-IV-TR Axis I Disorders - 
Research Version, Patient Edition (First, Spitzer, et al., 2002), 105 of the 120 partici-
pants (87.5%) who answered the SCID/IP had a lifetime comorbid Axis I mental dis-
order. Eighty-eight of 120 participants (73.33%) had a current (30-day prevalent) 
comorbid Axis I mental disorder. Among the 73.3% of participants who had a current 
comorbid disorder, 1.67 comorbid mental disorders were present for each participant 
on average (in addition to their substance use disorder(s)). The taxonomy of these 30-
day prevalent comorbid Axis I mental disorders is listed in Table 20 below: 
Table 20. Comorbid Axis I Mental Disorder Prevalence. 
Disorder    Valid N   Percentage 
Major Depressive Disorder  38/120   31.67% 
Dysthymic Disorder   18/120   15.00% 
Bipolar I Disorder   10/120   8.33% 
Other Bipolar Disorders   10/120   8.33% 
Other Mood Disorders   2/120   1.67% 
ANY MOOD DISORDER  67/120   55.83% 
Generalized Anxiety Disorder  28/120   23.33% 
Posttraumatic Stress Disorder  21/120   17.50% 
Panic Disorder    12/120   10.00% 
Agoraphobia w/o History Panic  4/120   3.33% 
Social Phobia    12/120   10.00% 
Specific Phobia    10/120   8.33% 
Obsessive Compulsive Disorder  4/120   3.33% 
Other Anxiety Disorder   4/120   3.33% 
ANY ANXIETY DISORDER  55/120   45.83% 
Schizoaffective Disorder   10/120   8.33% 
Schizophrenia     7/120   5.83% 
Other Psychotic Disorder    6/120   5.00% 
ANY PSYCHOTIC DISORDER  23/120   19.17% 
Binge Eating Disorder    2/120   1.67% 
Anorexia Nervosa    2/120   1.67% 
Hyperchondriasis     1/120   0.83% 
ANY OTHER DISORDER  5/120   4.17% 
+
The mean total scores, minimum scores, maximum scores and standard deviations for 
the five screening instruments validated in this study are listed in Table 21 below: 
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Table 21. Mean Total Scores, Range and Standard Deviations for Five Screening In-
struments. 
Measure    N   Min.       Max. Mean  SD 
Mental Health Screening Form III  121     0         17  9.14  3.65 
Modified Mini Screen   121     0         20  8.74  5.16 
Self Reporting Questionnaire 20 Revised 121     0         20  7.15  5.05 
Self Reporting Questionnaire 25 Revised 121     0         21  8.05  5.47 
Addiction Severity Index   65     0        .88  0.41  0.22 
Note. N = number of participants who validly completed the measure, Min = minimum score, Max = maximum score, SD = 
Standard deviation. 
+
The performance of the five short screening measures with reference to a 
SCID-I/P diagnosis as the criterion for caseness is reported in Table 22 below. The 
measure, sample and cut off score used are listed, followed by the sensitivity, speci-
ficity, accuracy, positive and negative predictive values, positive and negative odds 
ratios, the number of participants the measure indicated required further assessment 
and how many of the truly disordered cases the measure correctly identified at each 
cut off score. The rows with bold font indicate each measure’s most accurate cut off 
score or the highest aggregate of sensitivity and specificity scores. As will be dis-
cussed, although this accuracy statistic is traditionally relied upon, it does not neces-
sarily indicate the best cut off score to use with a measure, or which is the best meas-
ure to use, as it is merely a statistic that fails to consider the context of screening or 
the real world results of each measure at each cut off score. 
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Table 22. Performance of Five Short Screening Measures with Reference to SCID-I/P. 
Measure/Cut Score Sensitivity Specificity  Accuracy  PPV.  NPV.   P.ODD  N.ODD  Ind.  Corr.ID 
MHSFIII (N=117)       
Cut Off 3 100.0  16.1  58.1  76.8  100.0  1.19  0.00  112/117  86/86 
Cut Off 6 96.5   38.7   67.6        81.4       80.0  1.57  0.09  102/117  83/86 
Cut Off 9 61.6   71.0   66.3  85.5  40.0  2.12  0.54  62/117   53/86 
 Cut Off 11 41.9  87.1   64.5  90.0  35.1  3.25  0.67  40/117   36/86 
 Cut Off 12 34.9   93.5   64.2  93.8  34.1  5.37  0.70  32/117  30/86 
 
MMS (N=117)         
 Cut off 3 97.7  38.7  68.2  82.4  85.7  1.59  0.06  102/117  84/86 
Cut Off 5 93.0   61.3   77.15  86.95  76.0  2.40  0.11  92/117  80/86 
 Cut Off 6 84.9   61.3   73.1  85.9  59.4  2.19  0.25  85/117  73/86 
 Cut Off 7 77.9  71.0   74.45  88.2  53.7  2.69  0.31  76/117  67/86 
Cut Off 8 72.1   74.2   73.15  88.6  48.9  2.79  0.38  70/117  62/86 
Cut Off 9 61.6   83.9  72.75  91.4  44.1  3.83  0.46  58/117  53/86 
Cut Off 10 53.5   90.3  71.9  93.9  41.2  5.52  0.51  49/117  46/86 
 
SRQ20-R (N=117)         
 Cut Off 2 90.7   41.9   66.3  81.3  61.9  1.56  0.22  96/117  78/86 
Cut Off 3 87.2   54.8  71.0  84.3  60.7  1.93  0.23  89/117  75/86 
Cut Off 4 82.6   64.5   73.55  86.6  57.1  2.33  0.27  82/117  71/86 
Cut Off 5 77.9   77.4   77.65  90.5  55.8  3.45  0.29  74/117   67/86 
 Cut Off 6 73.3   83.9  78.6  92.6  53.1  4.55  0.32  68/117  63/86 
Cut Off 7 67.4   87.1   77.25  93.5  49.1  5.22  0.37  62/117   58/86 
Cut Off 9 50.0   90.3   70.15  93.5  39.4  5.15  0.55  46/117  43/86 
 
SRQ25-R (N=117)        
 Cut off 2 90.7   29.0   59.85     78.0  52.9  1.28  0.32  100/117  78/86 
Cut Off 3 89.5   38.7   64.1  80.2  57.1  1.46  0.27  96/117  77/86 
Cut Off 4 86.0   54.8   70.4  84.1  58.6  1.90  0.26  88/117   74/86 
Cut Off 5 80.2   71.0   75.6  88.5  56.4  2.77  0.28  78/117   69/86 
 Cut Off 6 76.7   83.9   80.3          92.95  56.5  4.76  0.28  71/117  66/86 
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Table 22 Con’d. Performance of Five Short Screening Measures with Reference to SCID-I/P. 
Measure/Cut Score Sensitivity Specificity  Accuracy  PPV.  NPV.   P.ODD  N.ODD  Ind.  Corr.ID 
Cut Off 7 73.3   83.9  78.6  92.6  53.1  4.55  0.32  68/117  63/86 
Cut Off 9 55.8   90.3   73.05  94.1  42.4  5.75  0.49  51/117   48/86 
ASI (N=62)       
Cut Off .1636 91.3   29.4   60.35  77.8   55.6  1.29  0.29  53/62  41/45 
Cut Off .2371 89.1   52.9   66.43  83.7   64.3  1.89  0.21  48/62  40/45 
Cut Off .3477 67.4   64.7   66.05  83.8   42.3  1.91  0.50  36/62  30/45 
Cut Off .3788 63.0   76.5  69.75  87.9   43.3  2.68  0.48  32/62  28/45 
Cut Off .4008 60.9   82.4   71.65  90.3  43.75  3.46  0.47  30/62  27/45 
Cut Off .6348 23.9   94.1   59.0  91.7   31.4  4.05  0.81  11/62  10/45 
Note. PPV. = Positive Predictive Value, NPV. = Negative Predictive Value, P.ODD. = Positive Odds Ratio, N.ODD. = Negative Odds Ratio, Ind. = number of participants who screened positive as requiring further 
assessment, Corr.ID = number of clients with COD correctly identified, MHSF-III = Mental Health Screening Form III, MMS = Modified Mini Screen, SRQ-20R = Self-Reporting Questionnaire 20 Revised, SRQ-25R 
= Self-Reporting Questionnaire 25 Revised, ASI = Addiction Severity Index Psychiatric Status Domain Composite Score, The most accurate cut off score for each instrument is highlighted in bold font. 
! !
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The receiver operating characteristic curve comparing four of the five measures is below in 
Figure 2, (this excludes the ASI Psychiatric Status Domain because it had a significantly 
smaller valid N).  
 
 
!
Figure 2. Receiver operating characteristic curves for four screening measures directly compared in the same 
residential alcohol and other drug service population. 
!
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The Receiver Operating Characteristic Area Under the Curve (ROC-AUC) scores for those 
four measures are in Table 23. 
Table 23. Directly Compared Area Under the Curve Scores for Four Screening Instruments. 
Measure  AUC (N=117) 
MHSF-III  .754 
MMS   .837 
SRQ-20R  .814 
SRQ-25R  .815 
AUC = Area Under the Curve Score, MHSF-III = Mental Health Screening Form III, MMS = Modified Mini Screen, SRQ-20R = Self 
Reporting Questionnaire 20 Revised, SRQ-25R = Self Reporting Questionnaire 25 Revised. 
!
!
4.!Discussion!
There are very high levels of psychiatric comorbidity and psychiatric severity in the Salva-
tion Army Australian, AOD residential treatment services. Eighty-seven point five percent of 
participants received a lifetime comorbid Axis I mental disorder diagnosis on the SCID-I/P 
and 73.3% met criteria for the current (30-day) period.  Current mood disorders were most 
prevalent (56%) followed by current anxiety disorders (46%) and current psychotic disorders 
(19%). The prevalence and taxonomy of comorbid mental disorders discovered in this resi-
dential treatment population with a semi-structured clinical interview confirms earlier re-
search into this population utilizing short screening measures (see Study 1, and Mortlock et 
al., 2011). Mental disorder comorbidity appears worse in Australian, the Salvation Army res-
idential alcohol and other drug treatment centres when compared with the last prevalence 
studies conducted in therapeutic communities in the United States of America during the 
1970s and 1980s (Jainchill, 1994). Current psychotic disorders are also present in a signifi-
cantly higher proportion of the population in this residential treatment modality (19%) than 
was previously reported to be the case elsewhere (2.51%, Jainchill, 1994). Psychotic disor-
ders constituted more than one-in-four disorders detected (26.14%), a startling result similar 
to that reported by Grella and Stein (36%) (2006). Whether this increase in the reported 
prevalence of psychotic disorders in residential alcohol and other drug treatment services is 
!
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due to the emergence of pseudoephedrine-based amphetamines and the drug ice, as well as 
cannabis of far greater potency, is a question of aetiology. As already noted in the aetiology 
section above, methodologically sound evidence of a causal relationship between substance 
abuse and mental disorders does not exist at the current time.   
When compared with previous research, the current study’s population endorsed a 
notably higher mean total number of psychiatric symptoms on several of the short screening 
measures. Previous validation research on the Modified Mini Screen across a spectrum of 
settings returned a mean total score of 7.48 (SD=5.77) (Alexander et al., 2008). The mean 
total MMS score in the current study was 8.74 (SD=5.16). Previous research using the Men-
tal Health Screening Form-III reported mean total scores of 5.1 (SD=4.0) (Carroll & 
McGinley, 2001) and 4.2 (SD=4.3) (Ruiz et al., 2009) in therapeutic community and prison 
substance abuse populations respectively. The mean total MHSF-III score in the current 
study was 9.14 (SD=3.65), roughly double those previously reported rates and close to re-
sults reported in Study 1 (10.60, SD=4.07,  Mortlock et al., 2011). The Salvation Army re-
covery services in Australia have an open door policy for individuals with comorbidity and 
do not attempt to exclude people unless they are too disruptive or unwell to be satisfactorily 
treated in their centers. In addition there is evidence that the Salvation Army residential re-
covery services have individuals with more severe levels of need for treatment across the 
range of domains measured by the Addiction Severity Index compared to participants in oth-
er residential services who completed the standardized ASI (Deane, Kelly, Crowe, Coulson, 
& Lyons, 2013). Results of the present study, however, are similar to those that have focused 
on heroin users (J. Ross et al., 2005), and suggest that in residential AOD treatment there is 
significantly higher rates of mental disorder comorbidity and severity than in other treatment 
modalities. To some extent this is a positive since it indicates that those with the highest need 
are accessing more intensive treatment. The ability of residential alcohol and other drug ser-
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vices to adequately treat a population with the needs indicated by the prevalence and taxon-
omy of mental disorder comorbidity reported above is another question, to be discussed be-
low.  
There was sufficient variation in the performance of the five screening measures to 
suggest some might be more effective in residential treatment settings than others depending 
upon the goals of screening. Accuracy across the measures varied by more than 12% at each 
measure’s statistically most accurate cut off score and ranged from 67.6% to 80.3%. Area 
under the receiver operating characteristic curve scores ranged from .73 to .84. Importantly, 
in real world terms the number of clients with current co-occurring mental disorders missed 
by each screening measure at its most accurate cut off score varied widely from just three 
missed cases of comorbidity to 23 missed cases. This latter figure not only represented a 
failure to detect 26.74% of comorbid clients, but one that occurred at the measure in ques-
tion’s statistically most accurate cut off score, the score usually reported and relied upon un-
critically by validation studies. 
The need to consider all of the indicators of instrument performance provided by the 
analysis in the context of screening is highlighted by this study’s findings. Too much screen-
ing instrument validation research simply reports the sensitivity, specificity and overall accu-
racy figures without adequate analysis, and without reporting and analyzing the additional 
statistics that reveal how the screening instrument achieved this performance. Typically nor 
do screening instrument validation studies examine how these statistics translate into real 
world performance via the screening task in question. Such a truncated analysis, decontextu-
alized from the screening task, in the current study would suggest the Self Reporting Ques-
tionnaire 20 Revised and Self Reporting Questionnaire 25 Revised had the highest accuracy 
figures (78.6% & 80.3%) and therefore must be the best measures for the task at hand. How-
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ever, it was these two measures that failed to detect the most cases of comorbidity in the 
study, failing to identify 26.74% and 23.27% of cases respectively.  
A cursory analysis of only the usual statistics divorced from the context of the screen-
ing task at hand could conclude the Self Reporting Questionnaire measures were good at rul-
ing out cases that did not have COD, (that these measures achieved their accuracy through 
high specificity), and that they were optimal. However, when the aim of the actual task of 
screening for co-occurring mental disorders is brought into view, (detecting as many clients 
with COD as is reasonably practiceable), it should immediately be noted these measures 
were not sensitive to detecting clients that did have COD at their statistically most accurate 
cut off scores, (scores that delivered sensitivity of only 73.3% & 76.7% respectively). Com-
mentators have rightly opined that the most important characteristics of a mental disorder 
screening measure are sensitivity and negative predictive value, (the latter often not even re-
ported by validation studies, its crucial importance to not missing clients with comorbidity 
apparently not being understood). The value of sensitivity (detecting true cases) over speci-
ficity in the context of screening for co-occurring mental disorders has been recognized for 
many years. In 1979 Rounsaville and others wrote (p. 226):!
The purpose of screening instruments is to detect those clients… [who warrant] further exten-
sive clinical evaluation… Sensitivity is vital to insure [sic] that clients who have depression 
are adequately treated while specificity is less crucial, being important mainly to reduce the 
number of unnecessary evaluations that will be performed on clients without the disorder. 
Sensitivity should always be preferred over specificity when analyzing screening instrument 
performance when the task is detecting cases of mental disorder comorbidity. If a screening 
instrument achieves its statistical maximum accuracy at a low sensitivity score, this figure 
should be disregarded and the instrument’s accuracy at an acceptable (90%+) sensitivity be 
examined.  
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The negative predictive value is the proportion of cases indicated by a measure as neg-
ative for mental disorder that actually are truly negative for mental disorder. Zimmerman and 
others (2004) explain with regard to negative predictive value that: 
From a clinical perspective it is most important that the diagnostic aid have good sensitivity, 
and corresponding high negative predictive value. With high negative predictive value, the 
clinician can be confident that when the test indicates that the disorder is not present there is 
little need to inquire about that disorder’s symptoms (p. 185). 
In addition to lacking sensitivity for detecting those with a COD, a close analysis of the neg-
ative predictive value scores for the SRQ-20R and SRQ-25R revealed that despite high spec-
ificity scores, these measures actually were not very efficient at identifying those without a 
comorbid mental disorder either, they just (over) identified so many respondents as being 
negative that they also managed to pick up a lot who were truly negative. The SRQ-20R was 
only correct about a client’s negative status 61.9% of the time and the SRQ-25R was only 
correct 52.9% of the time. This means these measures falsely screened a client as negative 
for comorbid mental disorder and not needing any further investigation when that client was 
actually positive for comorbid mental disorder nearly 40% and 50% of the time respectively. 
What the above results demonstrate for research studies validating screening instru-
ments is the importance of reporting more than just the sensitivity, the specificity, the accu-
racy (aggregate) and area under the curve score. Unless the additional indicators of instru-
ment performance such as negative predictive values are also reported, a proper picture of 
how an instrument has performed the way it has cannot be gained.  
In this study a similarly cautionary tale is told against taking an under-analyzed, trun-
cated set of statistics at face value by two additional pieces of information that are critical to 
report when undertaking a screening instrument validation. These two additional scores are 
the proportion of clients indicated for further assessment by a measure at a given cut off 
score and the number of true cases actually detected (and missed) at that cut off score. These 
real world results of how the screening instruments in question actually performed at the task 
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at hand are critical to report because they reveal how the statistics translate to real world clin-
ical utility. They are an aid to not being deceived by statistical performance that does not 
translate to real world clinical utility. An aid that is important in this study. 
An analysis of the performance of the Modified Mini Screen (MMS) and the Mental 
Health Screening Form III (MHSF-III) measures as compared to the two Self Reporting 
Questionnaire (SRQ-20R & SRQ-25R) measures is illustrative. At face value, the MMS and 
the MHSF-III were statistically less accurate than the two Self Reporting Questionnaire 
measures. Yet when the real world results are examined, the Modified Mini Screen only 
missed six cases out of 86 present (a 6.98% failure rate). The Mental Health Screening Form 
III only missed three cases out of 86 present (a 3.49% failure rate). This is possible because 
the MMS, whilst only returning the third highest accuracy figure of the measures behind the 
two Self Reporting Questionnaire measures (77.15%), did so with the second highest sensi-
tivity to the detection of COD (93.0%) and the second highest negative predictive value of 
any of the measures (76%). The MHSF-III returned the smallest “accuracy” statistic 
(67.6%), but it did so whilst displaying the highest sensitivity (96.5%), the highest negative 
predictive value (80%), the highest negative odds ratio (0.09) and thereby it correctly identi-
fied the highest number of true cases (83/86). In contrast to the Self Reporting Questionnaire 
measures that achieved their statistical accuracy through over-identifying clients as negative 
for disorder (which afforded high specificity at the expense of many false negatives and low 
sensitivity), the MMS and MHSF-III achieved their greatest accuracy through high sensitivi-
ty and high negative predictive value. This means the MMS and MHSF-III were accurate 
because they were sensitive enough to identify most cases of comorbidity and when they ac-
tually indicated a client as negative for disorder, they were right more than three-quarters of 
the time. In this study’s sample, the above figures and the importance of sensitivity and 
negative predictive value translated to real world performance where the SRQ-25R actually 
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missed 20 disordered cases out of 86 present, (a 23.26% failure rate) whilst being statistically 
the “most accurate” measure. The SRQ-20R failed to detect 23 of 86 disordered cases pre-
sent, (a 26.74% failure rate) whilst statistically being the second “most accurate”.  
The question of whether the MMS or the MHSF-III is a better measure becomes a 
question of resource allocation. The MHSF-III did perform more sensitively at each meas-
ure’s most accurate cut off score, but at the expense of referring nearly every client for fur-
ther assessment (102 of 117). The MMS achieved its performance while only referring 92 of 
117 clients for further assessment. When compared with the MHSF-III it also had a higher 
positive odds ratio (2.40 vs. 1.57) and higher ROC-AUC score (.837 vs. .754). As noted by 
Castel and others (2008):!
… a screening instrument is needed to help to select those clients who would benefit from a 
comprehensive psychiatric assessment and those for which it is not needed. Logically, the fi-
nal decision should be based not only on the results of a screening instrument, but also on the 
available resources for subsequent assessment for diagnostic verification (p. 65). 
Previous research on the MMS recommended a cut off score of six and suggested that 
when a score equal to or less than five was obtained, no further action or assessment is need-
ed (Frieden, Plapinger, Tom, & King, 2007). This paper validates the MMS as best able to 
detect the need for further assessment in residential alcohol and other drug treatment popula-
tions using a cut off score of five or more, a reduction in the cut off score of one point that 
increases sensitivity and accuracy. The MHSF-III performed best at a cut off score of six in 
the current study. It has been recommended at this cut off score and a cut off score of three 
previously (Sacks, Melnick, Coen, Banks, Friedmann, Grella, & Knight, 2007; Sacks, 
Melnick, Coen, Banks, Friedmann, Grella, Knight, et al., 2007). 
If sheer sensitivity was the most important requirement, reducing the cut off score on 
the MMS from five to three would see the MMS correctly identify one more case than the 
MHSF-III whilst referring the same number of clients for further assessment (102 of 117). In 
fact, lowering the cut off score on the MMS from five to three would see the MMS out-
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perform the MHSF-III on every statistic except specificity where they would be tied (at 
38.7%). However, that would be at the expense of referring nearly every client for assess-
ment. In a substance treatment screening context where access to follow up psychiatric ser-
vices and funding can be difficult and limited, the MMS seems the more preferable measure 
at a cut off score of five due to its greater efficiency at this cut off score. Either of these high-
ly sensitive measures, however, could be used. 
These results provide a cautionary tale to those conducting and interpreting psychomet-
ric validation study results. In this instance a cursory view of only the usual statistics would 
completely mislead the reader to believe that the SRQ-20R and SRQ-25R are the more accu-
rate measures. A full analysis of all the indicators of instrument performance and their real 
world clinical utility, however, tells a very different story. The Self Reporting Questionnaire 
measures missed around one-in-four disordered cases because they lacked sensitivity and 
negative predictive value. They were clearly outperformed at the task of screening by the 
more sensitive measures. This highlights the importance of reporting all of the available pa-
rameters and carefully considering the statistics with regard to the real world clinical utility 
and performance of the measures. 
Given the high rate of current (30-day) psychotic disorders found in this population 
(>19%), it came as no surprise the SRQ-25R performed better than the SRQ-20R. The rein-
statement of the five questions aimed at detecting psychoticism and epilepsy in the SRQ-25R 
increased the sensitivity of this measure without detracting from its specificity compared to 
the SRQ-20R. The SRQ-20R and SRQ-25R performed exactly the same in detecting single 
affective disorders and single anxiety disorders. Where the two measures differed was in de-
tecting those with multiple affect and anxiety disorders, (where the SRQ-25R picked up one 
additional case missed by the SRQ-20R), and in detecting those with psychotic disorders 
(where the SRQ-25R picked up twice as many true cases as the SRQ-20R). Generally it 
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should be noted that the two Self Reporting Questionnaire measures were the only measures 
that failed to detect a psychotic disorder in the study and they were also the only two 
measures that failed to detect a client with multiple comorbid axis I disorders (with the SRQ-
20R failing to detect up to four disorders in a single case). The failure of the Self Reporting 
Questionnaire measures to detect psychotic disorders cannot be attributed to the SRQ-20R’s 
lack of items designed to probe this type of psychopathology alone.  This is because the 
SRQ-25R also missed two psychotic disorder cases despite having four questions specifical-
ly aimed at detecting them. This lack of sensitivity to psychotic disorders combined with the-
se measures’ failure to detect multiple, multiply-disordered comorbid cases indicates some-
thing additional may be contributing to their poorer performance. It is possible that the 
method, which requires clients to first indicate whether they have experienced a particular 
problem and then additionally to go back over their answers once they have gotten to the end 
of the measure to further indicate if they have experienced that problem at time when they 
were not using alcohol or other drugs, might be problematic. Whilst the aim of differentiat-
ing between symptoms that are primary in nature or secondary and due to alcohol and/or 
drug use is clear in theory, in practice it confused a lot of clients and required frequent ex-
planation, sometimes multiple times. As a result, whilst clearly there is a problem with the 
SRQ-20R lacking any items that probe for psychotic disorders, there may also be an addi-
tional problem with the clinical utility of both the SRQ-20R and the SRQ-25R measures as 
they appear difficult for clients to understand. Given the very serious nature and consequenc-
es of failing to detect either a co-occurring psychotic disorder or clients with multiple disor-
ders of several different types, the SRQ-20R, the SRQ-25R and other screening measures 
that do not screen for psychotic disorders, or that lack sensitivity, cannot be recommended 
for use in residential alcohol and other drug treatment settings. 
! 118!
Unfortunately after Study 1 where a self-report version of the Addiction Severity Index 
Psychiatric Status domain suffered from a poor completion rate, (raising doubts about the 
utility of this measure in this population), we again had trouble with the interview version of 
this measure in Study 2. This time the nature of the measure itself cannot be blamed. Recov-
ery service staff was expected to complete full Addiction Severity Index interviews with all 
incoming clients as part of the service’s routine intake procedures. However, in the current 
sample they failed to complete this task about 50% of the time. Anecdotal reports indicated 
that this was occasionally due to some interviews occurring outside of the time frame for the 
research (i.e., too late). As a result, it is still unknown whether there is a problem with the 
nature of the ASI measure or other organizational issues.  Consequently, the validation re-
sults we have for the ASI come from a much smaller sample. The smaller sample is effec-
tively different to the sample used to validate the other four screening measures and so the 
figures reported for the ASI are preliminary and although similar, they are not directly com-
parable. 
4.1$Limitations$
There were several limitations to Study 2. Firstly, diagnostic interviews were conducted by a 
single interviewer. Despite excellent inter-rater reliability when validated, the single inter-
viewer design may subtly effect the reliability and validity of the results (Horowitz, 
Siegelman, & Inouye, 1979). Secondly, only Axis I disorders were assessed. None of the 
self-report questionnaires are designed to detect personality disorders. As a result Axis II 
comorbidity is unknown. Thirdly, the study was conducted in four residential alcohol and 
other drug treatment services in New South Wales and the Australian Capital Territory. Alt-
hough participants were selected randomly the sample may not generalize to all residential 
alcohol and other drug treatment participants nationally or internationally. Lastly, there was a 
relatively small sample size in both the not mentally disordered group and in groups with 
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specific diagnoses. A larger study would strengthen the results, particularly on a disorder-by-
disorder basis. 
!
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Implications$&$Future$Directions$ $
Comorbid mental disorders are highly prevalent in residential alcohol and other drug treat-
ment services. More than seven-in-ten clients (73.33%) entering residential alcohol and other 
drug treatment had a current comorbid axis I mental disorder. Many of the remaining one-in-
four clients who did not meet all criteria for a current disorder satisfied criteria for a past dis-
order and/or had a current subclinical disorder that was clinically relevant and justified 
treatment intervention (Haver, 1997). Psychotic disorders were currently present in more 
than 19% of participants according to a semi-structured clinical interview where all criteria 
were met and time was taken to carefully tease out and exclude cases that could be drug-
related or that were in remission. Nineteen percent was a conservative estimate for current 
comorbid psychotic disorders and that is almost one-in-five clients presenting to residential 
recovery services for treatment.  
Both the prevalence and taxonomy of comorbid mental disorders revealed in this thesis 
have a number of implications for residential alcohol and other drug treatment services and 
for future co-occurring disorder research. It has previously been noted by researchers that 
chemically dependent persons present with a variety of disorders across a wide spectrum of 
diagnoses (Carroll & McGinley, 1998). In the 2007 guidelines for the Victorian Dual Diag-
nosis Initiative it was argued that a criteria of screening instrument selection is that the in-
strument must screen for the gamut of possible disorders and it was also noted that many 
screening instruments fail to screen for psychotic disorders (Croton, 2007). The prevalence 
and taxonomy of co-occurring mental disorders reported in this thesis strongly demonstrate 
the need to use screening measures that screen for “lower prevalence” disorders, such as 
psychotic disorders in this population. These disorders may be low prevalence in the general 
population at large, (0.45%, Morgan et al., 2011), but the results in this thesis support earlier 
research (Grella & Stein, 2006; Mortlock et al., 2011) and demonstrate psychotic disorders 
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are highly prevalent in the residential alcohol and other drugs treatment population (>19%). 
As noted by Degenhardt and others (2005): 
Psychotic disorders have a lower prevalence than other forms of mental illness such as de-
pression and anxiety disorders, yet they impose a considerable public health burden because 
of their impact on sufferers and their families (Keith, Regier, & Rae, 1991). Persons with psy-
chotic disorders also utilise a disproportionately high segment of health services (p. v). 
Screening instruments that fail to screen for psychotic disorders cannot be recommended for 
use to detect co-occurring mental disorders in residential alcohol and other drug program 
participants. 
A connected implication flowing from the results reported in this thesis is that the ac-
curacy of conceptualisations, such as the four quadrants of care model, is in question (Center 
for Substance Abuse Treatment, 2005; Ries, 2008). The four quadrants of care model pro-
poses clients with more severe psychopathology (should) only present to and are treated by 
specialist mental health services whereas alcohol and other drug services (should) only re-
ceive clients with “high prevalence” disorders such as depression and anxiety. In Study 1 
more than 35% and 70% of 278 residential substance abuse treatment clients endorsed ques-
tions indicating they had suffered hallucinations and delusions respectively. Nine percent of 
those participants in Study 1 also indicated they had previously been diagnosed with schizo-
phrenia or psychosis. In Study 2 19.33% of 120 different clients met all criteria for diagnosis 
of a current psychotic disorder according to a standardized, semi-structured clinical inter-
view.  These studies and earlier research, such as that conducted by Grella and Stein (2006) 
and Ross and others (J. Ross et al., 2005), are evidence that clients with severe psycho-
pathology are presenting to residential AOD services in significant numbers. Prevalence and 
taxonomy studies need to be conducted in other treatment modalities to ascertain whether 
this is the case across the substance misuse treatment system or is particular to the residential 
alcohol and other drug treatment modality, (as current evidence suggests it may be). The 
findings in Study 1 and Study 2, taken together with previous research, suggest that tradi-
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tional thinking about what sort of clients present to which parts of the mental health and sub-
stance misuse treatment systems may be erroneous. If found to be the case, this has signifi-
cant implications for the alcohol and other drug treatment industry. The need for a significant 
increase in access to specialist mental disorder service providers, a significant increase in 
mental disorder qualifications and greater mental disorder training among alcohol and other 
drug treatment workers may be warranted. 
In a review of a number of studies that surveyed current access to specialised psychiat-
ric staff in the substance misuse treatment services in America, Flynn and Brown (2008) 
conclude that although evidence exists for an association between on site psychiatric staff 
and better treatment outcomes, such as retention and reduced substance use, the utility of 
such staff is moot because of their limited availability to public treatment programs. The re-
search relied upon by these authors included research that reported a current dearth of post-
graduate specialist mental health staff in the industry, a level of staff turnover so high that it 
jeopardized treatment program stability, and an inability to fill existing positions with staff 
competent to fill them due to an inability to offer appropriate remuneration. These authors 
reported results indicating that substance misuse treatment services do not have adequate ac-
cess to specialised mental health services (Flynn & Brown, 2008). Flynn and Brown con-
clude: 
In brief, there is the suggestion that the level of staff, often seen as the most critical resource 
needed for the implementation of intensive and complex interventions for clients manifesting 
COD, is in short supply in substance abuse treatment programs. Moreover, there appears little 
reason for optimism that this situation will change any time soon (Flynn & Brown, 2008, p. 
41). 
Thankfully, direct employment of specialised psychiatric staff by substance misuse 
treatment providers is not the only means of securing access to specialised psychiatric ser-
vices. Edward and others (2012) showed the importance of networking between the AOD 
and mental health treatment systems as a means of providing integrated treatment for co-
occurring disorders in Australia. These authors advocated collaboration and clear channels of 
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communication between alcohol and other drug treatment services and mental disorder 
treatment services so that opportunities for secondary consultation are taken advantage of 
and “dual diagnosis capability” becomes part of the core business of both services. Whilst 
reporting some success in this endeavour, these authors noted that: 
as illustrated by the case studies presented here, it appears that the structure and constraints of 
current mental health service provision mean that it is not always possible for mental health 
services to respond to invitations of shared care of dually diagnosed clients. Additionally, 
AOD services face similar barriers to integrated care. This requires something of a cultural 
shift on the part of AOD and mental health clinicians. This cultural shift needs to be articulat-
ed in organisational policy directions and funding agreements that support the shift from seg-
regated, stand-alone services to fully integrated dual diagnosis care for clients, families and 
carers (Edward et al., 2012, p. 21). 
An inability to attract and retain access to appropriately qualified and specialised psy-
chiatric staff is a major concern for substance misuse treatment services. The results of this 
thesis demonstrate there is also a need for greater AOD treatment staff training in mental 
disorders to maximize the utility of existing staff. In one study of 3,972 clients entering out-
patient substance misuse treatment, counselors under-rated the need for mental health ser-
vices in 32% of clients who reported psychiatric problems (Mericle et al., 2012). Thirty-six 
percent of these (essentially) unidentified co-occurring disorder clients had also indicated the 
importance of obtaining treatment for their mental health problems (Mericle et al., 2012). 
The authors hypothesized that the failure to recognize client concerns as symptoms of 
comorbid mental disorders may have been due to the lack of personnel with clinical back-
grounds and advanced degrees in substance abuse treatment settings (Mericle et al., 2012). 
The speculative association by these authors of staff qualification/training levels with the 
problem of under-identification of comorbidity warrants future research. The need to upskill 
existing staff with higher qualifications and training in the area of mental disorder in the 
AOD treatment system is apparent, but the real question is, “How much more training?” Is it 
enough to upskill existing staff with diploma-level qualifications or are degree-qualified staff 
needed in much greater numbers than industry funding currently supports? To answer this 
important question first research needs to determine what the current qualification levels are 
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in the substance abuse treatment industry in Australia. Then the existence of any demonstra-
ble link between these levels of staff qualification/training and the identification and treat-
ment of comorbidity should be investigated. There are already studies that suggest increasing 
the qualification levels and training of staff may increase the efficacy of treatment (Alterman 
et al., 2001; Grella & Stein, 2006).  
Significant mental disorder demands are being placed upon residential alcohol and oth-
er drug treatment services. The studies in this thesis provide data to indicate the importance 
of screening as a necessary efficient means of allocating scarce mental disorder resources in 
this context. Several studies have demonstrated individuals manifesting low to moderate lev-
els of mental disorder comorbidity appear to respond positively to the nonspecialized treat-
ment provided by AOD services (Flynn & Brown, 2008). The same studies, however, show 
that those with moderate to severe mental disorder comorbidity do not respond positively 
and require specialized treatment (Flynn & Brown, 2008). One of the tasks of screening is to 
differentiate between these two groups so that treatment services can identify the COD cli-
ents who require specialized treatment resources. These resources are scarce at the current 
time and screening is therefore ‘a single, critical step in the provision of quality care for co-
occurring mental health and substance use disorders, and must be integrated into treatment 
settings with an eye to the constraints and pressures on clients, staff and agencies’ 
(Alexander et al., 2008, p. 115).  
From a statistical/methodological standpoint, nearly 25-years ago Hsiao and others 
wrote that (1989, p. 667):!
Receiver operating characteristic methods are descriptive graphic tools that provide a way to 
assess and compare the performances of different diagnostic techniques. They are, if appro-
priately used, a potentially powerful tool for examining how biological and psychological 
measures relate to diagnosis. These methods can never be better than the data to which they 
are applied, and they can be of no use at all if those data are not available. In the future, if 
ROC is to fulfill its promise, researchers will have to present the full range of their data rather 
than just means, SDs, and sensitivity and specificity at a single cutoff point. Presentation of an 
ROC curve, assessment of sensitivity and specificity at multiple cutoff points, or, better yet, 
the actual data themselves, will be essential. 
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Twenty-five years later studies are still reporting a truncated array of statistics on screening 
measure performance. There is a need for psychometric validation studies to be conducted in 
different treatment modalities to compare the popular and freely available screening 
measures in different substance using populations. But these validation studies must report a 
full array of statistics about each measure and they must include a report of the real world 
performance, the actual clinical utility of each measure. It is only when treatment services 
are possessed of all this information that they will be able to make a properly informed deci-
sion about which screening measure is the best for them and at what cut off score. 
In summary, future research must concentrate upon improving the evidence-base for 
alcohol and other drug treatment services so they have proper research evidence upon which 
to base their screening and treating practices. Future research should survey the prevalence 
and taxonomy of co-occurring disorders in different treatment modalities. Future research 
should assess the performance of popular and freely available screening instruments in dif-
ferent treatment modalities. The current availability of specialised mental disorder services 
must be ascertained and when known, the potential efficacy of improved access to such ser-
vices, along with different levels of improved mental disorder qualifications and training for 
existing AOD treatment staff, should all be tested. Lastly, future research must evaluate the 
effects of better identifying and meeting the mental disorder needs of those seeking treatment 
for alcohol and other drugs. 
! !
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Table 24. Nomenclature changes in DSM-5 (Peele et al., 2013) 
DSM-IV-TR     DSM-5 
Dementia     Neurocognitive disorder 
Alcohol-induced persistent amnestic disorder Alcohol-induced major cognitive disorder, 
      amnestic confabulatory type 
“Mood” in the title of many disorders  “Depressive” or “Bipolar” 
Nicotine      Tobacco 
General medical condition    Another medical condition 
(Does not have the word “Probably” in the  “Probably” added to the name of some neuro- 
name of any Disorders)    cognitive disorders 
(Does not have the word “Possible” in the name “Possible” added to the name of some neuro- 
of any Disorder     cognitive disorders 
Autistic disorder     Autism spectrum disorder 
Dissociative fugue    Dissociative amnesia with dissociative fugue 
Social phobia     Social anxiety disorder 
Dysthymia     Persistent depressive disorder 
Hypochondriasis     Illness anxiety disorder 
Pedophilia     Pedophilic disorder 
Transvestic fetishism    Transvestic disorder 
Exhibitionism     Exhibitionistic disorder 
Female sexual arousal disorder   Female sexual interest/arousal disorder 
Male orgasmic disorder    Delayed ejaculation 
Dyspareunia     Genito-pelvic pain/penetration disorder 
Frotteurism     Frotteuristic disorder 
Stuttering     Fluency disorder 
Transient tic disorder    Provisional tic disorder 
Chronic motor or vocal tic disorder   Persistent motor or tic disorder 
Sleep terror disorder    Non-rapid eye movement sleep arousal dis- 
      order, sleep terror type 
Sleepwalking disorder    Non-rapid eye movement sleep arousal dis- 
      order, sleepwalking type 
Feeding disorder of infancy or early childhood Avoidant/restrictive food intake disorder 
Reading disorder     Specific learning disorder, with impairment in 
      reading 
Mathematics disorder    Specific learning disorder, with impairment in 
      mathematics 
Disorder of written expression   Specific learning disorder, with impairment in 
      written expression 
Phonology disorder    Speech sound disorder 
Narcolepsy     Five types: autosomal dominant cerebellar 
      ataxia and narcolepsy; autosomal dominant 
      narcolepsy, obesity, and type 2 diabetes; 
      narcolepsy without cataplexy but with hypo- 
      cretin deficiency; narcolepsy with cataplexy 
      but without hypocretin deficiency; narcolepsy 
      secondary to another medical condition 
Breathing-related sleep disorder   Central sleep apnea 
 
DSM-IV-TR = Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (American Psychiatric Association, 
2000), DSM-5 = Diagnostic and Statistical Manual of Mental Disorders, fifth edition (American Psychiatric Association, 2013). 
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Table 25. New Disorders in DSM-5 (Peele et al., 2013) 
New Disorder 
Social communication 
Disruptive mood dysregulation 
Premenstrual dysphoric 
Hoarding 
Excoriation 
Disinhibited social engagement 
Binge eating 
Central sleep apnea 
Sleep-related hypoventilation 
Rapid eye movement sleep behaviour 
Restless legs 
Caffeine withdrawal 
Cannabis withdrawal 
Neurocognitive disorder with Lewy body disease, major and mild 
Ten “mild” neurocognitive disorders 
Thirty-eight “other disorders”a 
Thirty “unspecified disorders”a 
a “Other disorder” and “unspecified disorder” in DSM-5 replace “Not Otherwise Specified” in DSM-IV-TR. 
!
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CINAHL Plus with Full Text 
(screen* + psychology 1957-2014: 126, screen* + alcohol and other drug 1957-2014: 82; 
screen* + substance use 1957-2014: 588; prevalence + psychology 1957-2014: 111; preva-
lence + alcohol and other drug 1957-2014: 126; prevalence + substance use 1957-2014: 853; 
co-occurring disorders 1957-2014: 366; dual diagnosis 1957-2014: 483; alcohol and other 
drug 1957-2014: 282; substance use + psychology 1957-2014: 98; mental health + substance 
use 1957-2014: 1103; comorbidity + psychology 1957-2014: 14; comorbidity + alcohol and 
other drug 1957-2014: 31; comorbidity + substance use 1957-2014: 292; psychometric + 
psychology 1957-2014: 127; psychometric + alcohol and other drug 1957-2014: 14; psy-
chometric + substance use 1957-2014: 85; receiver 1957-2014: 199; roc 1957-2014: 174; cut 
off 1957-2014: 291).  
 
PsycINFO 
(screen* + psychology 1860-2014: 301; screen* + alcohol and other drug 1860-2014: 63; 
screen* + substance 1860-2014: 694; prevalence + psychology 1860-2014: 173; prevalence 
+ alcohol and other drug 1860-2014: 43; prevalence + substance 1860-2014: 1006; co-
occurring disorders 1860-2014: 802; dual diagnosis 1860-2014: 2737; alcohol and other drug 
1860-2014: 2528; substance + psychology 1860-2014: 3135; mental health + substance 
1860-2014: 9753; comorbidity + psychology 1860-2014: 624; comorbidity + alcohol and 
other drug 1860-2014: 171; comorbidity + substance 1860-2014: 5783; psychometric + psy-
chology 1860-2014: 2444; psychometric + alcohol and other drug 1860-2014: 37; psycho-
metric + substance 1860-2014: 703; receiver 1860-2014: 292; roc 1860-2014: 145; cut off 
1860-2014: 113). 
 
PsycARTICLES 
(screen* + psychology 1860-2014: 175; screen* + alcohol and other drug 1860-2014: 36; 
screen* + substance 1860-2014: 87; prevalence + psychology 1860-2014: 125; prevalence + 
alcohol and other drug 1860-2014: 65; prevalence + substance 1860-2014: 80; co-occurring 
disorders 1860-2014: 183; dual diagnosis 1860-2014: 274; alcohol and other drug 1860-
2014: 7965; substance + psychology 1860-2014: 340; mental health + substance 1860-2014: 
479; comorbidity + psychology 1860-2014: 43; comorbidity + alcohol and other drug 1860-
2014: 41; comorbidity + substance 1860-2014: 60; psychometric + psychology 1860-2014: 
319; psychometric + alcohol and other drug 1860-2014: 47; psychometric + substance 1860-
2014: 94; receiver 1860-2014: 20; roc 1860-2014: 9; cut off 1860-2014: 2). 
 
MEDLINE with Full Text 
(screen* + psychology 1946-2014: 7768; screen* + alcohol and other drug 1946-2014: 185; 
screen* + substance 1946-2014: 2052; prevalence + psychology 1946-2014: 6595; preva-
lence + alcohol and other drug 1946-2014: 325; prevalence + substance 1946-2014: 2639; 
co-occurring disorders 1946-2014: 378; dual diagnosis 1946-2014: 643; alcohol and other 
drug 1946-2014: 388; substance + psychology 1946-2014: 6854; mental health + substance 
1946-2014: 2395; comorbidity + psychology 1946-2014: 1835; comorbidity + alcohol and 
other drug 1946-2014: 96; comorbidity + substance 1946-2014: 896; psychometric + psy-
chology 1946-2014: 4151; psychometric + alcohol and other drug 1946-2014: 20; psycho-
metric + substance 1946-2014: 215; receiver 1946-2014: 1417; roc 1946-2014: 994; cut off 
1946-2014: 1091). 
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ScienceDirect 
(screen* + psychology 1822-2014: 946; screen* + alcohol and other drug 1822-2014: 1460; 
screen* + substance 1822-2014: 3935; prevalence + psychology 1822-2014: 785; prevalence 
+ alcohol and other drug 1822-2014: 1647; prevalence + substance 1822-2014: 1869; co-
occurring disorders 1822-2014: 133; dual diagnosis 1822-2014: 216; alcohol and other drug 
1822-2014: 130; substance + psychology 1822-2014: 1372; mental health + substance 1822-
2014: 1784; comorbidity + psychology 1822-2014: 337; comorbidity + alcohol and other 
drug 1822-2014: 571; comorbidity + substance 1822-2014: 839; psychometric + psychology 
1822-2014: 933; psychometric + alcohol and other drug 1822-2014: 210; psychometric + 
substance 1822-2014: 324; receiver 1822-2014: 1800; roc 1822-2014: 454; cut off 1822-
2014: 1486). 
 
Web of Science 
(screen* + psychology 1965-2014: 142; screen* + alcohol and other drug 1965-2014: 210; 
screen* + substance 1965-2014: 2143; prevalence + psychology 1965-2014: 94; prevalence 
+ alcohol and other drug 1965-2014: 382; prevalence + substance 1965-2014: 1630; co-
occurring disorders 1965-2014: 608; dual diagnosis 1965-2014: 1007; alcohol and other drug 
1965-2014: 869; substance + psychology 1965-2014: 131; mental health + substance 1965-
2014: 2003; comorbidity + psychology 1965-2014: 19; comorbidity + alcohol and other drug 
1965-2014: 150; comorbidity + substance 1965-2014: 1073; psychometric + psychology 
1965-2014: 241; psychometric + alcohol and other drug 1965-2014: 31; psychometric + sub-
stance 1965-2014: 181; receiver 1965-2014: 25,681; roc 1965-2014: 2062; cut off 1965-
2014: 2859). 
 
Scopus 
(screen* + psychology 1960-2014: 1625; screen* + alcohol and other drug 1960-2014: 376; 
screen* + substance 1960-2014: 3821; prevalence + psychology 1960-2014: 1322; preva-
lence + alcohol and other drug 1960-2014: 549; prevalence + substance 1960-2014: 3240; 
co-occurring disorders 1960-2014: 640; dual diagnosis 1960-2014: 1173; alcohol and other 
drug 1960-2014: 970; substance + psychology 1960-2014: 1867; mental health + substance 
1960-2014: 3199; comorbidity + psychology 1960-2014: 312; comorbidity + alcohol and 
other drug 1960-2014: 176; comorbidity + substance 1960-2014: 1188; psychometric + psy-
chology 1960-2014: 1190; psychometric + alcohol and other drug 1960-2014: 32; psycho-
metric + substance 1960-2014: 265; receiver 1960-2014: 34,178; roc 1960-2014: 1872; cut 
off 1960-2014: 3212). 
 
Many individual searches were also done in various databases including on individual 
screening instruments, major prevalence studies such as the ECA, NCS and Australian 
MHWB 1& 2. Additionally “seminal” sources were often forwards searched as well with all 
sources that had cited such works also researched. 
! $
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Research Office use only 
          HE 08/297  
 
UNIVERSITY OF WOLLONGONG/ILLAWARRA AREA HEALTH SERVICE 
 
Human Research Ethics Committee 
 
 
INITIAL APPLICATION FOR APPROVAL TO UNDERTAKE 
RESEARCH INVOLVING HUMAN PARTICIPANTS 
(A separate application is required for each project) 
Please answer questions in terms understandable to the layperson. 
 
1. Descriptive Title of Project:  
Mental health screening within residential drug and alcohol rehabilitation. 
 
2. 7 line summary of project aims: 
This project will examine the relationship between a series of screening measures used within 
residential drug and alcohol treatment. It will include screens for mental health, Alexithymia, 
emotional control and wellness. The relationship between the screening measures and individ-
ual reactions to music will also be examined. Results will be used to inform assessment, treat-
ment planning and treatment services (e.g. cue exposure) within substance abuse treatment fa-
cilities. 
   
 
 
3. Name  Position/Appointment Institution Qualifications 
 Chief Investigator(s)    (Academic or Professional) 
  
Dr Peter Kelly (PhD Clin. Psych, BSc) 
Research Assistant 
Illawarra Institute for Mental Health 
University of Wollongong 
 
Prof Frank Deane (PhD, Dip. Clin. Psych) 
Director 
Illawarra Institute for Mental Health 
School of Psychology 
University of Wollongong 
 
Kane Mortlock (BA, LLB, BPsyc) 
PhD candidate  
 Illawarra Institute for Mental Health 
School of Psychology 
University of Wollongong 
 
Address for Correspondence (1st named investigator): 
 
Illawarra Institute for Mental Health 
Building 22  
University of Wollongong 
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Wollongong, NSW 2522 
 
Contact Phone Number: 0403 541 306    Fax: (02) 4221 5585    Email: pkelly@uow.edu.au 
 
4.  Where will potential participants be approached by the researchers to seek their partici-
pation in the research and where will research activities involving participants be con-
ducted: 
 
 Caseworkers of the Salvation Army Bridge program will be informed of the proposed study by 
the researchers via a presentation at their team meetings. Clients will be informed of the study 
in their house meeting where the study will be conducted. A participant information sheet (Ap-
pendix A) will be provided along with contact details so that the clients can contact the re-
searcher if there are any further questions.  Researchers will be on site at the time of distrib-
uting the questionnaires and they will be the only other people present in the room at the time 
of the questionnaires’ completion.  This allows the opportunity for the client to refuse to partic-
ipate outside of direct contact with his/her caseworker. The Salvation Army will not provide 
the researcher with any confidential information regarding the potential participant.  The re-
search team will distribute the survey on site.  Once the survey is completed, all clients will be 
instructed to put it into a sealed envelope. That way, clients can either refuse to participate or 
put the incomplete survey in the envelope. 
 
Purpose and Funding of Project 
5.a Is this: Yes   Staff Research  (University of Wollongong) 
   ______Staff Research  (Illawarra Area Health Service) 
  Yes    Student Research (Post grad. degree or subject) 
  Course undertaken PhD (Psychology) 
  Unit/ Faculty/Department  School of Psychology HBS 
  Supervisor Prof Frank Deane & Dr. Trevor Crowe 
  ______Other (Please specify e.g. for external people who want to research Uni   
  students or IAHS clients) 
 
5.b What is the source and amount of funding from all sources for this research? 
  
Source (Name of Organisation / Funding Scheme) Amount  
The Salvation Army $397,000 
  
  
 
5.c Is there any affiliation or financial interest between the sponsor/funding body and the 
researcher(s) or supervisor associated with this research?  If Yes, Please declare. 
 No 
 
5.d Are there any conditions placed on this research by the funding body? (please provide 
details)  
 No 
 
5.e Is a copy of the HREC approval to be forwarded to the Granting Body? Yes  
 
 
If YES, please advise of any deadlines: 
No deadline, but provided to the funding body before the research is commenced. 
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6. Has this research project been reviewed by any other Institutional Ethics Committee? 
(for example multi-centre research)        
  
 No 
 
 If YES, include a copy of any correspondence the sponsor or researcher has entered into 
with the other Ethics Committee(s) to this point. 
  
7. Research Categories 
 
 Please mark the research categories relevant to this research proposal. See guidelines for 
descriptions of the categories. At least one category should be marked for each grouping. 
For "Other", please specify. 
 
 If your research only involves participants and research procedures from a-d under  
 A Participants and B Research Procedures Used, it may be open to expedited review by 
the Chair of the HREC. In that case, submit only one copy of your application (please see 
guidelines regarding expedited review). 
  
A Participants  
 
a. Healthy members of the community 
b. University students   
c. Employees of a specific company/organisation 
d. Members of a specific community group, club or association  
e. Clients of a service provider  
f. Health Service clients (e.g. users/clients of a health service) 
g. School children  
h. Hospital in-patients  
i. Clinical clients (e.g. patients)   
j. Aboriginal/Torres Strait Islander people  
k. Members of socially disadvantaged groups 
l. Cadavers/ cadaveric organs 
m. Other:            
 
Expected age(s) of participants – please circle one or more  
  
Children (under 14) Young people (14-18)  Adults (> 18) YES 
 
B Research procedures used 
  
a. Anonymous questionnaires/ surveys 
b. Coded (potentially identifiable) questionnaires/ surveys 
c. Identifiable questionnaires/ surveys  
d. Examination of student work, journals etc 
e. Examination of medical, educational, personnel or other confidential records  
f. Observation (overt) 
g. Observation (covert) 
h. Interviews (structured or unstructured)  
i. Telephone interviews  
j. Procedures involving physical experiments (e.g. exercise, reacting to computer im-
ages) 
k. Procedures involving administration of substances (e.g. drugs, alcohol, food) 
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l. Physical examination of participants (including eg. blood glucose, blood pressure 
and temperature monitoring) 
m. Collection of body tissues or fluid samples 
n. Surgical procedures 
 
o. Other:           
 
C Research areas 
 
a. Qualitative research  
b. Social Science research  
c. Humanities research  
d. Educational research 
 
e. Health research  
f. Psychological research  
g. Comparison or evaluation of drugs or surgical or other therapeutic devices  
h. Comparison or evaluation of clinical procedures 
i. Comparison or evaluation of counselling or training methods  
j. Investigation of the effects of an agent (drug or other substance) 
k. Investigation of bio-mechanical processes 
l. Biomedical research 
m.! Epidemiology 
n.! Genetic research 
 
o. Other:           
 
 
 
8.a Does the project involve the use of drugs?     
 
 NO 
 
 If YES give details:  
 
 Is the research clarified as a:           
 CTN Trial                 CTX Trial               Other (Please detail)   
 
8.b Does the project involve the use of a surgical or other therapeutic device? (please detail)
  
 NO 
 
8.c If you answered YES to 8a. or 8b., is there any business or similar association between 
the researcher and the supplier of a drug or surgical or other therapeutic device to be 
used in the trial? (please detail). 
 
 NA 
 If you answered YES to 8a. or 8b., please include the budget for this trial including in-
formation about capitation fees, payments to researchers, institutions or organisations 
involved in the research, current and consequential costs and costs which may be in-
curred by participants. 
 
 Please include evidence of arrangements to ensure adequate compensation to participants 
for any injury suffered as a result of participation in the trial. (Indemnification forms 
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and, if the research is being undertaken in a private practice, evidence of adequate and 
appropriate insurance coverage) 
 
 NA 
 
 
9. Justify the design of your proposed research and describe what you want participants to 
do.   
 Please provide an explanation, in terms understandable by a non-expert reader.  For stu-
dent researchers, please provide (in no more than 2 pages) the background to this project 
(Attach extra sheets if necessary) 
 
Background 
 
The current research is in two parts.  
 
Mental health screening 
 
The Illawarra Institute for Mental Health (iiMH) has been contracted by The Salvation Army to de-
velop, trial and integrate mental health screening tools across their residential sites. The Salvation 
Army provides a range of long-term, residential treatment services for people with substance abuse 
problems. Although recommended as best practice, The Salvation Army does not currently use men-
tal health screening procedures within their organisation.  
 
35% to 89% of individuals seeking treatment from alcohol and other drug (AOD) services also have a 
co-occurring mental health disorder (Hides, et al., 2007). Problems facing people with comorbidity 
include: poorer treatment response (Grella & Stein, 2006), higher rates of relapse, more hospital vis-
its, increased involvement in violence, family difficulties, homelessness (Brunette, et al., 2004) and 
HIV (Adams, 2008). It has also been acknowledged that clients with comorbidity have received poor 
care due to gaps in service provision (Adams, 2008). Accurate and effective identification of mental 
illness comorbidity is the first step to a comprehensive needs assessment that can be readily trans-
ferred into effective, individualised and collaborative care planning to better meet the needs of this 
population. Recent research conducted by Corey Keyes, (see 2002, 2005, 2006, 2008), however, has 
empirically disproven the notion that the absence of mental illness can be equated with the presence 
of mental health in epidemiological, youth and cross-cultural populations. Keyes’ research has 
demonstrated that mental illness and mental health are distinct, only moderately correlated construct 
domains in these populations. Keyes’ empirical revelation indicates systematic procedures to screen 
AOD clients for mental illness comorbidity and the treatment protocols used to treat them are in need 
of comprehensive review in terms of scope, aims and purpose.  It may no longer be enough to identi-
fy which clients have co-occurring mental illness. Clients’ mental health may also need to be as-
sessed and the information fed into the treatment planning process.  
 
The Addiction Severity Index (ASI; McLellan, 1980) is the most widely used structured interview 
within substance abuse treatment settings. This scale includes several items that screen for possible 
co-morbid mental illness problems. A previous evaluation indicates that these items provide good 
sensitivity (Cacciola, Peceoraro & Alterman, 2008). Another screening scale, The Mental Health 
Screening Form – III (MHSF–III; Carroll & McGinley, 2000), has also been widely used within both 
treatment and research settings. The current study aims to examine if the sensitivity of these measures 
can be improved if they are administered concurrently. This study also aims to compare instruments 
that screen for mental illness with Keyes’ measure of mental health to determine whether the absence 
of mental illness may be equated with the presence of mental health or a two factor model is to be 
preferred. Keyes’ measure of mental health, The Mental Health Continuum – Short Form (MHC–SF; 
Keyes, 2006), has not been used in an AOD residential treatment or co-occurring disorder popula-
tions. 
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Emotional control and cue exposure 
 
Effective drug and alcohol treatment should focus on the prevention of further relapse. This typically 
involves identifying the person’s high-risk situations / triggers and preparing the person to manage 
these events. Cue exposure has consistently been recommended as an important treatment approach 
within the substance abuse field (Otto, Powers & Fischmann, 2005). It involves directly exposing the 
patient to situations that the person would normally associate with their substance of abuse (e.g., drug 
using equipment, emotions associated with drug use). The goal of exposure is to break the patient’s 
bond between these events / emotions and their drug use. Whilst laboratory studies have consistently 
demonstrated that cue exposure is an important component of relapse prevention training (Siegel & 
Ramos, 2002), this has typically not translated into routine practice. This is likely to be associated 
with ethical issues associated with cue exposure (i.e. using illicit substances, bringing substances of 
abuse into drug free environments) and practical difficulties (i.e. difficulties accessing the person’s 
local pub).  
 
Poor emotion regulation is generally associated with poorer outcomes for individuals with substance 
misuse problems (e.g. Bonn-Miller, Vujanovic & Zvolensky, 2008; Fox, Axelrod, Paliwal & Sinha, 
2007; Fox & Sinha, 2008). For example, approximately 50% of substance abuse patients returning to 
residential treatment report their previous relapse was the direct result of trying to cope with negative 
emotions (Fernandez-Montalvo, et al., 2007). Similarly, individuals scoring highly on Alexithymia 
scales are at higher risk of relapse following substance abuse treatment (Loas, et al., 1997). It is im-
portant that cue exposure activities address negative emotions. The use of music for cue exposure in 
residential treatment settings is likely to be extremely beneficial for this purpose. Music has been 
successfully used in laboratory-based studies to induce both positive and negative mood states (Mar-
tin, 1990). Its effects occur quite quickly (within 10 minutes) and 75% of participants report changes 
in mood in clinical studies (see Martin, 1990). Additionally, most patients have access to music, and 
cue exposure homework activities could be developed with relative ease. Whilst music has been 
promoted for use in substance abuse treatment settings (Dingle, Gleadhill & Baker, 2008), very lim-
ited research has been conducted to examine the relationship between mood and substance abuse 
treatment. 
 
The study is exploratory in nature and seeks to examine the degree to which substance abuse patients 
report that music influences their mood. It will also compare differences in individuals’ reactions to 
music with patients’ self-rated emotional control ratings. 
 
 
Research plan 
 
 
a)! Research design 
A cross-sectional design will be used. Participants will be at different stages of their 10-month 
treatment program.  All measures will be quantitative self-report questionnaires. 
 
b)! Participants 
The sample will consist of individuals attending the Salvation Army Bridge residential rehabili-
tation program located in, Townsville (n = 32), Brisbane (n = 90), Gold Coast (n = 55), Lake 
Macquarie (n = 104), Sydney (n = 110), Blue Mountains (n = 17), Central Coast (n = 40) and 
Canberra (n = 40). We anticipate at least 70% of these residents to participate.  All individuals 
will be diagnosed with an alcohol and/or substance misuse problem. Participants may also be 
diagnosed with a co-occurring mental illness problem (e.g. depression, anxiety, psychotic dis-
order). 
 
c)! Treatment Condition 
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Clients will be attending the Salvation Army Bridge program. The program is 10 months in 
length, with participants completing a 6-stage, group-based treatment process. The treatment 
programs provide a combination of skills training, psycho-education, 12-step based interven-
tions and individual counseling.  
 
d) Measures 
The measures outlined in the section below have all been combined into one questionnaire, the ‘Men%
tal!Health!Screening!and!Emotional!Control’. The questionnaire takes approximately 60 minutes 
and contains 188 items. 
 
 
Background Information and drug and alcohol use 
Basic demographic information will be collected. This will include age, weeks in the program, gen-
der and The Salvation Army centre they are attending. We will also collect information on the per-
son’s drug and alcohol history. This will include the length of time the person has had a substance 
misuse problem, the types of drugs the person has used in the previous 12-months, the substance the 
person considers their primary drug of choice, frequency of drug use and if they have ever received 
treatment before. We will ask clients to specify any previous mental illness diagnoses, how well their 
current service is meeting their mental health needs and if they have suffered any of the poorer treat-
ment responses and outcomes traditionally associated with co-occurring AOD and mental illness dis-
orders previously. 
 
Desires for Alcohol Questionnaire – Strong Desire Subscale (DAQ; Clark, 1994).  This is a self-
report questionnaire that measures an individual’s current desire for alcohol.  The questionnaire con-
sists of three subscales (negative reinforcement, strong desire, mild desire). This scale was modified 
for this study in order to assess drug and alcohol desires.  An example is the statement ‘My desire to 
drink now seems overwhelming’ was adjusted to ‘My desire to drink and/or use drugs now seems 
overwhelming’. 
 
Mental Health Screening 
 
Mental Health Screening Form – III (MHSF-III; Carroll & McGinley, 2000) - The Mental Health 
Screening Form – III is designed as a mental illness screening device for clients seeking admission to 
substance abuse treatment programs. Each MHSF-III question is answered either “yes” or “no.” All 
questions reflect the respondent’s entire life history; therefore all questions begin with the phrase 
“Have you ever...”. The MHSF-III features a “Total Score” line to reflect the total number of “yes” 
responses. The maximum score on the MHSF-III is 18 (question 6 has two parts). This feature per-
mits programs to do research and program evaluation on the mental illness-chemical dependence in-
terface for their clients. The first four questions on the MHSF-III are not unique to any particular 
mental illness diagnosis; however, questions 5 through 17 reflect symptoms associated with the fol-
lowing diagnoses/diagnostic categories: Q5, Schizophrenia; Q6, Depressive Disorders; Q7, Posttrau-
matic Stress Disorder; Q8, Phobias; Q9, Intermittent Explosive Disorder; Q10, Delusional Disorder; 
Q11, Sexual and Gender Identity Disorders; Q12, Eating Disorders (Anorexia, Bulimia); Q13, Manic 
Episode; Q14, Panic Disorder; Q15, Obsessive-Compulsive Disorder; Q16, Pathological Gambling; 
and Q17, Learning Disorder and Mental Retardation. 
 
 
Mental Health Continuum – Short Form (MHC – SF; Keyes, 2006) - The Mental Health Continuum 
– Short Form is a measure of mental health that consists of 14 items. It measures the degree of (1) 
Emotional Well Being (items 1–3) as defined in terms of positive affect/satisfaction with life; (2) So-
cial Well Being (items 4–8) as described in Keyes’s (1998) model of Social Well Being (one item on 
each of the dimensions of social acceptance, social actualization, social contribution, social coher-
ence and social integration); and (3) Psychological Well Being (items 9–14) as described in Ryff’s 
(1989) model (including one item on each of the dimensions of autonomy, environmental mastery, 
personal growth, positive relations with others, purpose in life and self-acceptance). The MHC–SF 
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allows a diagnosis to be made of the level of mental health an individual enjoys from languishing 
mental health to flourishing mental health. 
 
Addiction)Severity)Index)–)Self)Report!(ASI–SRr!Rosen,!Henson,!et!al.,!2000)!–!The!Addiction!SeverA
ity!Index!(ASIr!McLellan,!et!al.,!1980)!is!the!most!widely!published!substance!abuse!assessment.!For!
the!purposes!of!this!study!we!will!be!using!the!‘Your!Health’!section!of!the!self!report!version.!PreviA
ous!research! indicates! that! the!ASI!provides!good!sensitivity!and!specificity! to! identify!coAoccurring!
mental!illness!problems!(Cacciola,!Pecoraro,!&!Aterman,!2008).!
 
 
Alexithymia and Emotional Regulation 
 
The Toronto Alexithymia Scale (TAS-20; Bagby, et al., 1992) is a widely used self-report measure of 
Alexithymia. The scale is 20-items in length and provides independent measures of (1) Difficulties in 
Identifying Feelings; (2) Difficulties in Describing Feelings; and (3) Externally Orientated Thinking. 
 
Difficulties in Emotion Regulation Scale (DERS; Gratz & Roemer, 2004) – this is a 36-item self-
report measure that provides a total score of emotional regulation and 6-subscale scores (Nonac-
ceptance of Emotional Response; Difficulties Engaging in Goal Directed Behaviour; Impulse Control 
Difficulties; Lack of Emotional Awareness; Limited Access to Emotion Regulation Strategies; and 
Lack of Emotional Clarity). The scale has previously been used with substance abuse populations 
(e.g. Bonn-Miller, Vujanovic, & Zvolensky, 2008; Fox, Paliwal & Sinha, 2007).  
 
A 53-item scale was developed for the purposes of this study to examine the relationship between 
emotions and (a) using drugs and/or alcohol; and (b) listening to music. The emotions used in the 
scale were selected from a previous survey examining emotions and music (Juslin & Laukka, 2004). 
  
Music 
 
Music Experience Questionnaire (MEQ; Werner, Swope & Heide, 2006). The MEQ is a 53-item self 
report measure of individual differences in reaction to music. It is comprised of 6 independent sub-
scale scores (Commitment to Music; Innovative Musical Aptitude; Social Uplift; Affective Reac-
tions; Positive Psychotropic Effects; and Reactive Musical Behaviour). 
 
 
See Appendix B for copies of the measures.  
 
e)    Procedures 
 
Assessment protocol 
 
The process will first involve informing staff members of the study through a presentation in 
their weekly staff meetings.  Following this staff will then inform the clients of the study in the 
clients ‘house meeting’.  Questionnaires will then be distributed and completed by the clients 
who are willing to participate. All clients will be provided with a participant information sheet. 
Researchers will be on site at the time when clients are completing the questionnaires.  
 
10.  Please provide a brief statement of the ethical considerations relevant to the proposed 
research; specifically in relation to the participants’ welfare, rights, beliefs, perceptions, 
customs and cultural heritage both individual and collective. (Attach an extra sheet if 
necessary) 
 
Informed consent – It is important that clients are aware of their freedom of choice to partici-
pate or refuse participation in this study.  For this to be made certain clients will be approached 
about this study through the Salvation Army staff so clients do not feel pressured by the re-
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searchers to participate.  Salvation Army staff will be instructed to reinforce to the clients that 
participation is voluntary and there will be no negative repercussions for refusing to participate.  
Also clients will also be given the option of refusing participation through the researchers be-
ing the ones to hand out the questionnaires and be present while they are completed, in the in-
stance they don’t want to refuse through Salvation Army staff.  A third option for clients to re-
fuse participation is by not completing the survey and placing it in an anonymous envelope.  
This will allow clients to refuse participation without informing Salvation Army staff or the re-
searchers.  Clients will be made aware of this before they receive their survey and envelope. 
We have used the same research protocol previously and clients did return blank surveys indi-
cating that they felt comfortable to refuse participation. 
 
  
Confidentiality – To ensure confidentiality consent forms will not be used. Rather the 
following statement will be included on the participant information sheet “In order to 
protect your privacy we will not request your written consent to participate in this study, 
instead by completing and returning this questionnaire you will be providing your con-
sent to participate in this study. If you do not wish to participate in this study you can 
either: (1) Discuss this with the Salvation Army staff; (2) Discuss this with one of the 
researchers; and/or (3) Return the incomplete questionnaire in the envelope provided.” 
 
The surveys will be collected directly by researchers from the University of Wollongong and 
no individual data will be given to the case managers or the service.  The researchers will be on 
site to collect the data and clients will also be given the option of posting their survey directly 
to the researchers at the University of Wollongong with their provided reply-paid envelope.  
All information will be stored securely at the University of Wollongong. 
 
 
11. Referring to the categories of participants to be involved in this project identified in ques-
tion 7, above, What is the rationale for selecting participants from this/these group/s?  
 
We are interested in identifying co-occurring mental illness problems within residential drug 
and alcohol rehabilitation programs. The study will use clients who are currently attending the-
se programs. 
 
 
12. How will potential participants be approached initially and informed about the project? 
Please explain in detail and include copies of any letters, advertisements or other re-
cruitment information. (e.g. direct approach to people on the street, mail-out to potential 
participants through an organisation, posters or newspaper advertisements, etc) 
 
Salvation Army staff will be informed of the proposed study by one of the researchers via a 
presentation at a team meeting. 
 
Clients will initially be informed of the study by Salvation Army staff. A participant infor-
mation sheet (Appendix A) will be provided with contact details so if a client has further ques-
tions they can contact the researcher. This allows the opportunity for the client to refuse to par-
ticipate outside of direct contact with Salvation Army staff. 
 
We believe the safest approach to clients will be through Salvation Army staff.  The staff will 
be instructed to reinforce to the clients that participation is voluntary and there will be no nega-
tive repercussions for refusing to participate.  Also clients will be given the option of refusing 
participation through the researchers, in the instance they don’t want to refuse through their 
caseworker.  Clients will first be asked to put their survey in a provided envelope on comple-
tion.  This allows a third option for clients to refuse participation by not completing the survey 
and placing it in an anonymous reply-paid envelope.  This means that clients have the option to 
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refuse participation without contacting their caseworker or the researchers.  Clients will be 
made aware of this option by Salvation Army staff before they receive their survey and enve-
lope. 
 
 
13. How many participants in total do you anticipate will be involved in the project? If the 
research has several stages involving different participants, please provide the total num-
ber of participants expected as well as the number of participants involved in each stage. 
 
 There are at total of 488 beds in the rehabilitation centres throughout NSW, QLD and the ACT, 
however not all of these beds are always occupied.  Therefore with an estimated 70% participa-
tion rate it is expected there will be around 340 clients involved in the study.  
 
Participant Consent  
Attach copies of any letters of invitation, information packages, consent forms, 
proxy/substitute consent forms, debriefing information, identification cards, contact de-
tail cards, etc. 
  
14 a. Is it anticipated that all participants will have the capacity to consent to their participa-
tion in the research?          
           
 
 Yes 
 
 
 If NO, please explain why (e.g. children, incompetent participants, etc.) and explain how 
proxy or substitute consent will be obtained from the person with legal authority to con-
sent on behalf of the participant (see Guidelines).  
 
14 b. For participants who have the capacity to consent, how does the process ensure that in-
formed consent is freely obtained from the participant? 
 
To enter the Bridge program clients will have undergone a supervised detoxification pro-
gramme prior and will have already been assessed as having appropriate psychological stabil-
ity. As previously noted, the consent process allows clients to refuse consent through discuss-
ing participation with Salvation Army staff or via a third party (the researchers). Also if partic-
ipants do not wish to participate they are given the option of placing the incomplete survey in a 
blank reply-paid envelope which will be kept separate from the consent form which will be re-
turned before the survey is completed.  This means there will be no way of identifying those 
who chose not to participate because no name will be identified on the survey.  This also gives 
clients the option of posting the envelope, allowing them to time to decide whether they wish 
to participate and complete the survey.   
 
 
14 c. Will written consent from participants be obtained?      
 
 No 
 
 If NO, please explain why it would be inappropriate or unethical to seek written evidence 
of consent to this project. 
  
 By not obtaining written consent we eliminate any possible method of identifying any particu-
lar individual with their time in a residential drug and alcohol rehabilitation program. Also as 
the study does not require identifying information collection of such information would be 
both redundant and an unnecessary risk to the participant’s privacy. 
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15. Are any participants in a dependent relationship with the researcher, the institution or 
the funding body (for example the researcher’s clinical clients or students; employees of 
the institution; recipients of services provided by the funding body)? If so, what steps will 
be taken to ensure that participants are free to participate or refuse to participate in the 
research? 
 
The clients will be in a clinical relationship with the Salvation Army staff who will inform 
them of the study. As noted it will be clearly emphasised that participation is voluntary. In ad-
dition, the client will be provided with an option of contacting (or asking to be contacted by) 
the researchers so they have the opportunity to refuse to participate without having to do so di-
rectly with the caseworker.   
 
 
16. How does the project address the participants’ freedom to discontinue participation? 
Will there be any adverse effects on participants if they withdraw their consent and will 
they be able to withdraw data concerning themselves if they withdraw their consent?  
 
Once participants have completed their questionnaire and passed it on to researchers there will 
be no option to withdraw their data (as we do not have identifying information). Clients will be 
informed of this in their participant information sheet before completing the survey. Also cli-
ents will be made aware of their options to refuse participation before completing and returning 
the questionnaire. 
 
17.! Does the project involve withholding relevant information from participants or deceiving 
them about some aspect of the research?       
 
No 
 
If YES, what is the justification for this withholding or deception and what steps will be 
taken to protect the participants’ interest in having full information about their partici-
pation? 
 
 
18. Will participants be paid or offered any form of reward or benefit (monetary or other-
wise) for participation in the research?  If so, please detail and provide a justification for 
the payment, reward or benefit.  
 
No 
 
 
19. Confidentiality: 
 What measures will be taken to protect the privacy of individual subjects in terms of the 
test results and other confidential data obtained (both in recording the data and in its 
publication)?  
 
 As consent forms will not be collected there will be no means by which the data collected can 
be attributed to an individual. Therefore data that is recorded and published will have no link to 
individual participants. 
 
20. Will information collected from data or interview be published?   
  
 Yes 
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 If YES, please indicate what form this will take (Please note that any further use of in-
formation which may identify a participant is conditional upon the participant’s permis-
sion for such use):  
 
No individual identifying data will appear in any reports from the study. Data will be published 
in group form only. The data will be used for the purposes of research student theses and po-
tentially publication in scholarly journals and conference presentations. A report will also be 
written for the Salvation Army. 
 
 
21. Will any part of the research activities be placed on an audiotape, film, photograph or 
video-tape?  
 
 No 
 
 To what purpose will the audiotape, film, photograph or video-tape be used?    
    
      
 For what audience(s) will the audiotape, film, photograph or video-tape be exhibited?  
   
22.  How will the data (including questionnaires, surveys, computer data, tapes, transcripts 
and specimens) be held securely, during and on completion of the project?  
 
 Confidential data will be stored securely at the Illawarra Institute for Mental Health, it will be 
stored in locked filing cabinets and at the completion of the project will be held in a locked 
storage room. 
 
 Please confirm that original data will be held securely for a minimum of 5 years (15 years 
for clinical research).   
 
 Clinical research data will be securely stored for 15 years.  
 
 If NO, please give reasons why it would be unethical to store the data for this period. 
 
 
23. Does the project involve the use of invasive procedures (e.g. blood sampling) or the risk of 
physical harm or emotional distress?  
 
 Yes 
 
 If YES, give details:  
 
  
Explain how the risks of harm or distress will be minimised. In the case of risks of emo-
tional distress, what provisions have been made for an exit interview or the necessity of 
counselling? 
   
Clients may experience mild distress from answering questions about cravings for drugs or al-
cohol, or by questions about past situations in which another individual has offended them.  In 
the unlikely event that emotional distress occurs in response to some of the study questions 
there will be provision for participants to meet with one of the counselling staff who are avail-
able at the treatment centre. 
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24. Does this project involve obtaining information (e.g. data) of a private nature from any 
Commonwealth/State/Local Government Department or any other Agency, including 
health records from Area Health Services.   
 
 No 
 
 If YES, which Department (s)/Agency?  
 
 Please include copies of any correspondence regarding permission to access this infor-
mation from a responsible officer of the Agency and complete a Privacy Guideline Form 
(available from Ethics Officer). 
 
25. Does the research intend to determine whether illegal activity has occurred or anticipate 
that participants may reveal information about criminal activity?  
 
 Yes 
 
 If YES, how do you propose to respond to the legal issues raised?  
   
 There are questions in the survey that relate to clients’ past drug use which may involve clients 
providing responses on past illegal substance use. Clients will be informed through their partic-
ipant information sheet that any reports of current or past drug use will not be reported to the 
authorities or the Salvation Staff.  Also clients’ names will not be associated with their data 
from their questionnaire so no data can be traced to an individual client. 
! !
As!this!research!is!concerned!with!substance!use!the!researchers!will!not!report!
any!illegal!drug!use.!
 
   
26. Period of Research Clearance Requested (Please specify as near as possible 'start' and 
'finish' dates for the conduct of research):      
   
 FROM:  15/11/08 TO:  15/11/09. 
 
27. Any research project that involves the collection of data should be designed so that it is 
capable of providing information that can be analysed to achieve the aims of the project. 
Usually, although not always, this will involve various important statistical issues. It is 
important that the design and analysis be properly planned in the early stages of the pro-
ject. You should seek statistical advice. The University of Wollongong has a Statistical 
Consulting Service that provides such advice to research students and staff undertaking 
research. 
 
 Are statistical issues relevant to this project?        Yes 
 If so, have you discussed this project with the Statistical Consulting Service?  No    
  
Statistical staff from the School of Psychology, will be consulted regarding the design of this 
study if required. 
 
28. Does this project involve the collection or use of personal health information or infor-
mation relating to the provision of a health service to an individual? This includes gen-
eral information such as a gymnasium would collect as well as information collected for a 
medical purpose.  
 If so, you need to complete the Initial Application Form Part 2 – Privacy Addition for 
Health Information. For additional information regarding this please read the document 
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‘Health Records and Privacy Act’ and the NSW Privacy Commissioners’ Statutory 
guidelines on research. Both documents are available from the HREC webpage.  
   
Yes 
 
 
 
 
NSW HEALTH 
HEALTH ETHICS BRANCH 
PRIVACY ADDITION TO HREC APPLICATION FORM 
 
 
The Health Records and Information Privacy Act 2002 commences on 1 September 2004.  
The Act creates a scheme to regulate the collection, use and disclosure of personal health in-
formation.  It requires personal health information to be handled in accordance with 15 
Health Privacy Principles (HPPs) set out in the Act.  It is necessary for you to complete this 
part of the application form in order to ensure: 
 
•! You and the [name of institution] comply with the Act; 
•! This HREC can properly assess your research under the Act; 
•! This HREC can meet its statutory obligations to report to the Privacy Commissioner on its activities 
under the Act. 
 
Please read the Statutory Guidelines made under the Act entitled Health Records and Information Privacy Act 
2002 (NSW): Statutory Guidelines on Research which can be found on the website of Privacy NSW. This web-
site can be accessed through www.lawlink.nsw.gov.au.  Reading these documents will assist you in completing 
this section of the application form. 
 
Q1. Does this project involve the collection, use, or disclosure of personal health infor-
mation which is identified, or from which the identity of the person can be reasonably 
ascertained? 
 
Yes!–!you!must!complete!this!section!of!the!application!form.!Go!to!question!2.!
! No – you do not need to complete this section of the application form. Go to [insert next 
section of your standard HREC application form] 
 
29.  Comments. If you would like to make any comment about the application or the applica-
tion process please do so. 
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DECLARATION BY CHIEF INVESTIGATOR 
 
 I, the undersigned, have read the current National Statement on Ethical Conduct in Re-
search Involving Humans: 
  http://www.health.gov.au/nhmrc/publications/synopses/e35syn.htm 
and accept responsibility for the conduct of the research activities detailed in this appli-
cation in accordance with the principles contained in the National Statement and any 
other conditions laid down by the University of Wollongong's Human Research Ethics 
Committee. 
 Chief Investigator's signature/s: 
  Date:   
  
 If the Chief Investigator is a student include: 
 Supervisor's signature: 
 
  Date:   
 
Signature/s of other researcher/s: (The first named researcher will assume responsibility 
for the project in the absence of the Chief Investigator) 
 
  Date:   
 
DECLARATION BY HEAD OF UNIT 
 
As Head of Unit I have responsibility for ensuring that Occupational Health and Safety 
(OHS) issues surrounding research in the Unit are addressed.  
 
(please tick all relevant boxes) 
 
___ I am satisfied that a general risk assessment for the research project addressed in this 
application has been completed adequately 
___ I will ensure that a risk assessment specific to this application will be completed prior to 
commencing the activities described in this application 
___  I will ensure that there exist appropriate mechanisms to address potential OHS issues 
that may arise and I have responsibility for implementing those mechanisms 
___ I will ensure that mechanisms exist for ongoing assessment of the OHS issues related to 
this research 
___ This research involves use of radiation, chemicals or biohazards. A Risk Assessment has 
been conducted and is attached to this application 
 
 Head of Unit’s Signature.................................................Date........................ 
  
NOTE:  RESEARCH MUST NOT COMMENCE UNTIL APPLICATION HAS BEEN 
FULLY APPROVED. 
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CHECKLIST  
Applications should be sent to the Ethics Officer, Human Research Ethics Committee, Office of 
Research, University of Wollongong, Northfields Ave, Wollongong  NSW  2522 
 
 
 Original Ethics Application plus appropriate number of copies (See Guidelines) 
 
 Consent Form(s)  
 
 Participant Information Sheet/Package 
 
 Copies of Questionnaire(s)/Survey(s) or Interview Questions 
 
 Copies of all documents and other material used to inform potential participants  
 about the research including advertisements and letters of invitation. 
 
 Evidence of permission to conduct research in locations not associated with the  
 University of Wollongong 
 
 Evidence of approval/rejection by other HREC(s), including comments and re-
quested alternations to the protocol  
 
 Any form requiring signature by the HREC (one copy) 
 
 For Clinical Trials : Application Form (original +14 copies),  Patient  
 Information Package (14 copies), Consent Forms (14 copies), Indemnity Form (14  
copies), Protocols (14 copies),  Advertisement (14 copies), Summary Sheet (14 cop-
ies), Budget (14 copies), Insurance information (if in Private Practice) (14 copies), 
Investigator’s Brochure (5 copies), CTN or CTX Form (1 original copy) 
 
 
Form Revised Jan 2003  
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University of Wollongong 
Client Participant Information Sheet 
Lake Macquarie Recovery Service Centre:  
 
Mental Health and Substance Abuse Problems 
 
Who is doing the study?  
Dr Peter Kelly, Prof Frank Deane and Mr Kane Mortlock will be conducting this research project. Aspects of 
this research will be used for Mr Mortlock’s doctorial thesis. 
 
What is the study about? 
The study aims to examine the proportion of people in residential drug and alcohol rehabilitation who also 
have a mental health problem. Studies have found that people with both drug and alcohol and mental health 
problems can do much worse than those with drug and alcohol problems alone. For this reason it is important 
to identify how many people in drug and alcohol treatment services also have mental health problems so more 
can be done to help this group. It will also examine people’s different reactions to music. We are looking at this 
because music has been found to effect people’s moods in different ways and may have the potential to be use-
ful in therapy.!
 
What do I need to do? 
The first thing you need to do is carefully read this ‘participant information sheet’ making sure you understand 
what is required.  In order to protect your privacy we will not request your written consent to participate in this 
study, instead by completing and returning this questionnaire you will be providing your consent to participate 
in this study. If you do not wish to participate in this study you can either: 
  
1. Discuss this with the Salvation Army staff 
  
2. Discuss this with one of the researchers 
  
3. Return the incomplete questionnaire in the envelope provided. 
  
It is anticipated that completion of this questionnaire will take approximately 60 minutes.  If you would like 
further information on the study you can also contact Dr Kelly or Prof Deane at the University of Wollongong 
by calling 02 4221 4207. 
 
Is there any risk or burden if I decide to participate? 
The main burden will be related to the time it takes to complete the assessment. There is a very small risk that 
you might think some of the questions in the questionnaires are too personal or distressing. Example items are: 
“Have you ever been advised to take medication for anxiety, depression, hearing voices, or for any other emo-
tional problem?” and to what extent do you “want to drink/use drugs so much I can taste it.” However, in addi-
tion to your right not to participate in the survey, you also have the right to refuse to answer any specific ques-
tions that you find too personal or distressing and if any of the questions cause you any distress the Salvation 
Army staff will also be available to assist you.!
Also because your name will not appear on any part of the questionnaire there will be no option to withdraw 
any information provided at a later date. If you choose not to participate in the study, this will in no way have 
an effect on your relationship with your support or treatment services or the University of Wollongong. Partic-
ipation is entirely voluntary.  
Are there any benefits expected? 
People often find that when they complete the questionnaires it helps them reflect on their progress and clarify 
what it is about treatment that is helping them.  Also the information from this study will hopefully contribute 
to improving the treatment program and complimenting already existing research. 
 
How will my information be collected and used? 
You will be required to complete a questionnaire which will involve completing a written survey.  Information 
from this survey will be kept confidential. All questionnaire material will be stored securely at the University of 
Wollongong. The information may be used for publication in scholarly research journals, reports to the Salva-
tion Army, student theses, and conference presentations. You will not be identifiable in any publications. 
 
What if I have more questions? 
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You may have additional questions that you wish to ask about the research before you decide whether to partic-
ipate. You can contact Dr Kelly or Prof Deane at the University of Wollongong by calling 02 4221 4207. If you 
have any concerns or complaints regarding the way in which the research is or has been conducted, you can 
contact the Secretary of the University of Wollongong Human Research Ethics Committee on Phone:  (02) 
4221 4457, Fax: (02) 4221 4338   email: research@uow.edu.au 
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Mental!Health!Screening!and!Emotional!Control!
!
1.! What!is!your!age?!………………..!
!
2.! How!many!weeks!have!you!been!in!the!program!for?!………………!
!
3.! What!gender!are!you?!(Circle)!!! ! 1.!Male!! 2.! Female!
!
4.! What!program!are!you!attending?!(circle)!
Gold Coast Brisbane Townsville Canberra Sydney Central Coast Morisset 
Blue 
Mountains 
 
5.! How long have you had drug and/or alcohol problems? ___________Years 
!
6.! In!the!12!months!before!you!entered!treatment!what!substances!had!you!used?!
(You!may!tick!multiple!drugs)!
! Heroin!! ! ! ! ! ! ! !1!
! Marijuana/Cannabis! ! ! ! ! ! !2!
Amphetamines!(e.g.!speed,!ice,!crystal!methyl)! ! !3!
! Alcohol! ! ! ! ! ! ! !4!
! Ecstasy! ! ! ! ! ! ! !5!
! Cocaine! ! ! ! ! ! ! !6!
! Other(s)! ! ! ! ! ! ! !7!
If!Other(s)!Please!Specify!
! _____________________________________________________________!
!
7.! What!do!you!consider!your!primary!drug!of!concern?!(Please!specify!just!one)!
____________________________________________ 
 
8.! Before entering treatment, how often would you take this drug? (tick) 
Once$a$month$ $ $ $ $ $ !1$
More$than$once$a$month$ $ $ $ $ !2$
At$least$once$a$week$ $ $ $ $ !3$
Daily$ $ $ $ $ $ $ $ !4$
More$than$once$a$day$ $ $ $ $ !5$
 
9.! Have you ever previously sought treatment for your current drug problem? 
YES! ! !1! !
NO! ! !2!
10.!Have you ever received treatment for a mental health problem? 
  YES  "1    
NO  "2 
11.!If YES, what diagnosis did you receive? ……………………… 
 
12.!How well is the service meeting your mental health needs currently? 
 
Not at all    Slightly    Moderately        Considerably   Extremely 
 
13.!Have you experienced any of the following drug-and-alcohol-related things previ-
ously? 
 
Relapse      Hospitalisation         Violence       Family difficulties      Homelessness 
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DAQ 
A craving refers to the thoughts and feelings associated with an urge or desire to drink or use drugs.  
The following questions in this section relate specifically the time since you’ve been in the residen-
tial treatment program. Please indicate your agreement to the following statements by circling the 
most appropriate number on the scale following the statement 
!
 Strongly disagree 
   Strongly 
agree 
1.  I want to drink/use drugs so much I can taste 
it. 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
2.  My desire to drink/ use drugs now seems 
overwhelming 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
3.  I would do almost anything to have a drink/ take 
some drugs right now 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
4.  I would feel as if all the bad things in my life 
had disappeared if I drank/used drugs now 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
5.  Even major problems in my life would not 
bother me if I drank/used drugs now 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
6.  I would feel less worried about my daily prob-
lems if I drank/used dugs now 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
7.  Drinking/using drugs would be satisfying now 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
8.  Drinking/using drugs would be pleasant now 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
!
!
!
 
TAS%20!
Please!rate!how!strongly!you!agree!with!the!following!statements.!
!
!
!
Strong%
ly!disa%
gree!
Disa%
gree!
Unsure! Agree! Strong%
ly!agree!
1.! I!am!often!confused!about!what!emotion!
I!am!feeling.! 1 2 3 4 5 
2.! It!is!difficult!for!me!to!find!the!right!words!
for!my!feelings.! 1 2 3 4 5 
3.! I!have!physical!sensations!that!even!
doctors!don’t!understand.! 1 2 3 4 5 
4.! I!am!able!to!describe!my!feelings!easily.! 1 2 3 4 5 
5.! I!prefer!to!analyse!problems!rather!than!
just!describe!them! 1 2 3 4 5 
6.! When!I!am!upset,!I!don’t!know!if!I!am!
sad,!frightened,!or!angry.! 1 2 3 4 5 
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!
!
Strong%
ly!disa%
gree!
Disa%
gree!
Unsure! Agree! Strong%
ly!agree!
7.! I!am!often!puzzled!by!sensations!in!my!
body! 1 2 3 4 5 
8.! I!prefer!to!just!let!things!happen!rather!
than!to!understand!why!they!turned!out!
that!way.!
1 2 3 4 5 
9.! I!have!feelings!that!I!can’t!quite!identify.! 1 2 3 4 5 
10.!Being!in!touch!with!emotions!is!essential.! 1 2 3 4 5 
11.!I!find!it!hard!to!describe!how!I!feel!about!
people.! 1 2 3 4 5 
12.!People!!tell!me!to!describe!my!feelings!
more.! 1 2 3 4 5 
13.!I!don’t!know!what’s!going!on!inside!me.! 1 2 3 4 5 
14.!I!often!don’t!know!why!I!am!angry.! 1 2 3 4 5 
15.!I!prefer!talking!to!people!about!their!daily!
activities!rather!than!their!feelings.! 1 2 3 4 5 
16.!I!prefer!to!watch!“light”!entertainment!
shows!rather!than!psychological!dramas.! 1 2 3 4 5 
17.!It!is!difficult!for!me!to!reveal!my!innerA
most!feelings,!even!to!close!friends.! 1 2 3 4 5 
18.!I!can!feel!close!to!someone,!even!in!
moments!of!silence.! 1 2 3 4 5 
19.!I!find!examination!of!my!feelings!useful!in!
solving!personal!problems.! 1 2 3 4 5 
20.!Looking!for!hidden!meanings!in!movies!
or!plays!distracts!from!their!enjoyment.! 1 2 3 4 5 
!
!
!
What!is!your!favourite!style!of!music?!………………………………..!
!
!
In!the!past,!to!what!extent!have!the!following!emotions!triggered!you!to!use!your!main!drug!of!
choice?!
!
!
!
Very!
small!
extent!
Small!
extent!
Unsure! Large!
extend!
Very!
large!
extent!
1.! Sadness! 1 2 3 4 5 
2.! Anger! 1 2 3 4 5 
3.! Anxiety! 1 2 3 4 5 
4.! Happiness!/!Joy! 1 2 3 4 5 
5.! Love! 1 2 3 4 5 
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!
!
Very!
small!
extent!
Small!
extent!
Unsure! Large!
extend!
Very!
large!
extent!
6.! Calmness! 1 2 3 4 5 
!
!
!
To!what!extent!is!music!capable!of!leading!you!to!experience!the!following!emotions?!
!
!
!
Very!
small!
extent!
Small!
extent!
Unsure! Large!
extend!
Very!
large!
extent!
7.! Sadness! 1 2 3 4 5 
8.! Anger! 1 2 3 4 5 
9.! Anxiety! 1 2 3 4 5 
10.!Happiness!/!Joy! 1 2 3 4 5 
11.!Love! 1 2 3 4 5 
12.!Calmness! 1 2 3 4 5 
!
!
MEQ!
This!questionnaire!concerns!the!place!of!music!in!your!life.!!Questions!concern!your!
thoughts!about!music,!your!feelings!about!it,!your!reactions!to!it,!and!how!it!relates!to!your!
activities.!!There!are!no!right!or!wrong!answers!to!these!questions.!!After!reading!each!
question!carefully,!indicate!how!true!it!is!of!your!experience!and!behaviour,!using!the!followA
ing!scale:!
!
 Very!
untrue 
Some%
what!
untrue 
Equally!
true!
and!un%
trueY!
unsure 
Some%
what!
true 
Very!
true 
1.! I!can!easily!improvise!on!an!inA
strument!without!having!music!
in!front!of!me. 
1 2 3 4 5 
2.! I!frequently!hear!songs!in!my!
head. 1 2 3 4 5 
3.! I!feel!more!integrated!(more!
“together”)!when!I!hear!certain!
kinds!of!music. 
1 2 3 4 5 
4.! I!often!sing,!hum,!or!whistle!
along!with!recorded!music. 1 2 3 4 5 
5.! I!would!never!want!to!listen!to!
the!same!piece!of!music!twice!
in!a!row. 
1 2 3 4 5 
6.! When!I’m!enjoying!music!with!
other!people!I!feel!like!we’re! 1 2 3 4 5 
! 163!
 Very!
untrue 
Some%
what!
untrue 
Equally!
true!
and!un%
trueY!
unsure 
Some%
what!
true 
Very!
true 
speaking!the!same!language. 
7.! I’ve!had!musical!experiences!
that!have!changed!my!whole!
mood. 
1 2 3 4 5 
8.! I!enjoy!singing!in!the!shower!or!
bath. 1 2 3 4 5 
9.! I!sometimes!spend!more!money!
than!I!can!afford!to!attend!a!
musical!performance. 
1 2 3 4 5 
10.!It!is!hard!for!me!to!keep!the!
beat!when!dancing. 1 2 3 4 5 
11.!Music!unites!my!mind!and!my!
body. 1 2 3 4 5 
12.!A!song!has!never!made!me!feel!
joyous. 1 2 3 4 5 
13.!I!like!listening!to!music!that!has!
a!message. 1 2 3 4 5 
14.!There’s!nothing!more!powerful!
than!singing!a!beloved!song!
with!other!people. 
1 2 3 4 5 
15.!Listening!to!music!is!a!very!priA
vate!experience!for!me. 1 2 3 4 5 
16.!I!wish!my!family!had!sung!toA
gether!more!when!I!was!growA
ing!up. 
1 2 3 4 5 
17.!I!have!perfect!pitch. 1 2 3 4 5 
18.!When!they!are!done!well,!I!find!
patriotic!songs!very!stirring. 1 2 3 4 5 
19.!I!wish!music!had!been!more!a!
part!of!my!childhood. 1 2 3 4 5 
20.!I!have!never!been!physically!
stirred!up!by!music. 1 2 3 4 5 
21.!Music!is!the!most!important!
thing!in!my!life. 1 2 3 4 5 
22.!Music!helps!me!forget!my!
cares. 1 2 3 4 5 
23.!Totally!new!tunes,!that!I’ve!
never!heard!before,!sometimes!
pop!into!my!head. 
1 2 3 4 5 
24.!I!can!hardly!resist!dancing!to!
certain!music. 1 2 3 4 5 
25.!Music!gives!me!a!sense!of!purA
pose!and!movement. 1 2 3 4 5 
26.!The!experience!of!music!brings!
me!closer!to!a!higher!power. 1 2 3 4 5 
27.!I!am!especially!response!to!the!
beat!or!rhythm!in!music. 1 2 3 4 5 
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 Very!
untrue 
Some%
what!
untrue 
Equally!
true!
and!un%
trueY!
unsure 
Some%
what!
true 
Very!
true 
28.!People!have!applauded!my!perA
formance!of!music. 1 2 3 4 5 
29.!I!enjoy!making!up!or!composing!
tunes,!songs!or!musical!pieces. 1 2 3 4 5 
30.!I!have!a!good!sense!of!pitch. 1 2 3 4 5 
31.!I!easily!get!“lost”!in!the!depth!of!
my!concentration!on!music. 1 2 3 4 5 
32.!I!often!find!myself!swaying!in!
tune!with!music!to!which!I’m!lisA
tening. 
1 2 3 4 5 
33.!Music!never!affects!my!feelings. 1 2 3 4 5 
34.!Music!has!no!place!in!my!life. 1 2 3 4 5 
35.!Music!helps!me!get!out!of!myA
self. 1 2 3 4 5 
36.!Certain!music!draws!me!strongA
ly!to!dance. 1 2 3 4 5 
37.!I!have!made!sacrifices!in!my!life!
in!the!pursuit!of!music. 1 2 3 4 5 
38.!I!follow!the!details!of!certain!
musical!performers’!lives. 1 2 3 4 5 
39.!I!love!some!kind!of!music. 1 2 3 4 5 
40.!Sometimes!I!spend!too!much!
money!on!musical!recordings!or!
music!videos. 
1 2 3 4 5 
41.!It’s!important!for!me!to!see!muA
sic!being!performed!and!not!just!
hear!it. 
1 2 3 4 5 
42.!Music!!helps!me!not!feel!so!
lonely. 1 2 3 4 5 
43.!Often!I!tap!my!feet!or!hands!
along!with!music!I’m!hearing. 1 2 3 4 5 
44.!I!am!better!able!to!face!the!
world!after!enjoying!music. 1 2 3 4 5 
45.!The!emotional!side!of!music!
makes!me!uncomfortable. 1 2 3 4 5 
46.!There!are!some!kinds!of!music!
that!I!really!detest. 1 2 3 4 5 
47.!I’ve!been!both!aroused!and!satA
isfied!by!a!musical!experience. 1 2 3 4 5 
48.!Music!gives!a!sense!of!order!to!
my!life. 1 2 3 4 5 
49.!I’m!pretty!good!at!improvising!
music,!either!in!my!head!or!on!
an!instrument. 
1 2 3 4 5 
50.!Hearing!a!song!will!sometimes! 1 2 3 4 5 
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 Very!
untrue 
Some%
what!
untrue 
Equally!
true!
and!un%
trueY!
unsure 
Some%
what!
true 
Very!
true 
bring!to!my!mind!a!period!of!my!
life. 
51.!Music!can!influence!my!emoA
tions. 1 2 3 4 5 
52.!Life!would!be!meaningless!to!
me!without!music. 1 2 3 4 5 
53.!I’ve!had!experiences!of!ecstasy!
while!listening!to!music. 1 2 3 4 5 
!
!
DERS!
Please!indicate!how!often!the!following!statements!apply!to!you!by!writing!the!appropriate!
number!from!the!scale!below!on!the!line!beside!each!item:!
!
! Almost!
never!
(0%10%)!
Some%
times!
(11%35%)!
About!
half!
time!
(36%65%)!
Most!of!
the!time!
(66%90%)!
Almost!
always!
(91%100%)!
1.! I!am!clear!about!my!feelings.! 1 2 3 4 5 
2.! I!pay!attention!to!how!I!feel.! 1 2 3 4 5 
3.! I!experience!my!emotions!as!
overwhelming!and!out!of!conA
trol.!
1 2 3 4 5 
4.! I!have!no!idea!how!I!am!feeling.!
! 1 2 3 4 5 
5.! I!have!difficulty!making!sense!
out!of!my!feelings.! 1 2 3 4 5 
6.! I!am!attentive!to!my!feelings.! 1 2 3 4 5 
7.! I!know!exactly!how!I!am!feeling.! 1 2 3 4 5 
8.! I!care!about!what!I!am!feeling.! 1 2 3 4 5 
9.! I!am!confused!about!how!I!feel.! 1 2 3 4 5 
10.!When!I’m!upset,!I!acknowledge!
my!emotions.! 1 2 3 4 5 
11.!When!I’m!upset,!I!become!anA
gry!with!myself!for!feeling!that!
way.!
1 2 3 4 5 
12.!When!I’m!upset,!I!become!emA
barrassed!for!feeling!that!way.! 1 2 3 4 5 
13.!When!I’m!upset,!I!have!difficulty!
getting!work!done.! 1 2 3 4 5 
14.!When!I’m!upset,!I!become!out!
of!control.! 1 2 3 4 5 
15.!When!I’m!upset,!I!believe!that!I!
will!remain!that!way!for!a!long!
time.!
1 2 3 4 5 
16.!When!I’m!upset,!I!believe!that!
I’ll!end!up!feeling!very!deA
pressed.!
1 2 3 4 5 
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! Almost!
never!
(0%10%)!
Some%
times!
(11%35%)!
About!
half!
time!
(36%65%)!
Most!of!
the!time!
(66%90%)!
Almost!
always!
(91%100%)!
17.!When!I’m!upset,!I!believe!that!
my!feelings!are!valid!and!imA
portant.!
1 2 3 4 5 
18.!When!I’m!upset,!I!have!difficulty!
focusing!on!other!things.! 1 2 3 4 5 
19.!When!I’m!upset,!I!feel!out!of!
control.! 1 2 3 4 5 
20.!When!I’m!upset,!I!can!still!get!
things!done.! 1 2 3 4 5 
21.!When!I’m!upset,!I!feel!ashamed!
with!myself!for!feeling!that!way.! 1 2 3 4 5 
22.!When!I’m!upset,!I!know!that!I!
can!find!a!way!to!eventually!feel!
better.!
1 2 3 4 5 
23.!When!I’m!upset,!I!feel!like!I!am!
weak.! 1 2 3 4 5 
24.!When!I’m!upset,!I!feel!like!I!can!
remain!in!control!of!my!behavA
iors.!
1 2 3 4 5 
25.!When!I’m!upset,!I!feel!guilty!for!
feeling!that!way.!
!
1 2 3 4 5 
26.!When!I’m!upset,!I!have!difficulty!
concentrating.! 1 2 3 4 5 
27.!When!I’m!upset,!I!have!difficulty!
controlling!my!behaviors.! 1 2 3 4 5 
28.!When!I’m!upset,!I!believe!that!
there!is!nothing!I!can!do!to!
make!myself!feel!better.!
1 2 3 4 5 
29.!When!I’m!upset,!I!become!irriA
tated!with!myself!for!feeling!that!
way.!
1 2 3 4 5 
30.!When!I’m!upset,!I!start!to!feel!
very!bad!about!myself.! 1 2 3 4 5 
31.!When!I’m!upset,!I!believe!that!
wallowing!in!it!is!all!I!can!do.! 1 2 3 4 5 
32.!When!I’m!upset,!I!lose!control!
over!my!behaviours.! 1 2 3 4 5 
33.!When!I’m!upset,!I!have!difficulty!
thinking!about!anything!else.! 1 2 3 4 5 
34.!When!I’m!upset,!I!take!time!to!
figure!out!what!I’m!really!feelA
ing.!
1 2 3 4 5 
35.!When!I’m!upset,!it!takes!me!a!
long!time!to!feel!better.! 1 2 3 4 5 
36.!When!I’m!upset,!my!emotions!
feel!overwhelming.! 1 2 3 4 5 
!
MHSF%III!
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Please&rate&Yes&or&No&to&the&following&questions.&Please&note,&each&item&refers&to&your&entire&life&history,&not&
just&your&current&situation,&this&is&why&each&question&begins&–&“Have&you&ever&….”&
&
1)! Have you ever talked to a psychiatrist, psychologist, therapist, social work-
er or counsellor about an emotional problem?& YES& NO&
2)! Have you ever felt you needed help with your emotional problems, or have 
you had people tell you that you should get help for your emotional prob-
lems?&
YES& NO&
3)! Have you ever been advised to take medication for anxiety, depression, 
hearing voices, or for any other emotional problem?& YES& NO&
4)! Have you ever been seen in a psychiatric emergency room or been hospital-
ised for psychiatric reasons?& YES& NO&
5)! Have you ever heard voices no one else could hear or seen objects or things 
which others could not see?& YES& NO&
6)! a) Have you ever been depressed for weeks at a time, lost interest or pleas-
ure in most activities, had trouble concentrating and making decisions or 
thought about killing yourself? 
b) Did you ever attempt to kill yourself? 
&
!
YES!
!
!
YES&
!
NO!
!
!
NO&
7)! Have you ever had nightmares or flashbacks as a result of being involved in 
some traumatic/terrible event? For example, warfare, gang fights, fire, do-
mestic violence, rape, incest, car accident, being shot or stabbed?&
YES& NO&
8)! Have you ever experienced any strong fears? For example, of heights, in-
sects, animals, dirt, attending social events, being in a crowd, being alone, 
being in places where it may be hard to escape or get help?&
YES& NO&
9)! Have you ever given in to an aggressive urge or impulse, on more than one 
occasion, that resulted in serious harm to others or led to the destruction of 
property?&
YES& NO&
10)!Have you ever felt that people had something against you, without them 
necessarily saying so, or that someone or some group may be influencing or 
trying to influence your thoughts or behaviour?&
YES& NO&
11)!Have you ever experienced any emotional problems associated with your 
sexual interests, your sexual activities, or your choice of sexual partner?& YES& NO&
12)!Was there ever a period in your life where you spent a lot of time thinking 
and worrying about gaining weight, becoming fat, or controlling your eat-
ing? For example, by repeatedly dieting or fasting, engaging in much exer-
cise to compensate for binge eating, taking enemas, or forcing yourself to 
throw up?&
YES& NO&
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13)!Have you ever had a period of time when you were so full of energy and 
your ideas came very rapidly, when you talked nearly non-stop, when you 
moved quickly from one activity to another, when you needed little sleep, 
and believed you could do almost anything?&
YES& NO&
14)!Have you ever had spells or attacks when you suddenly felt anxious, fright-
ened, uneasy to the extent that you began sweating, your heart began to beat 
rapidly, you were shaking or trembling, your stomach was upset, you felt 
dizzy or unsteady, as if you would faint?&
YES& NO&
15)!Have you ever had a persistent, lasting thought or impulse to do something 
over and over that caused you considerable distress and interfered with 
normal routines, work, or your social relations? Examples would include 
repeatedly counting things, checking and rechecking on things you had 
done, washing and rewashing your hands, praying, or maintaining a very 
rigid schedule of daily activities from which you could not deviate?&
YES& NO&
16)!Have you ever lost considerable sums of money through gambling or had 
problems at work, in school, with your family and friends as a result of your 
gambling?&
YES& NO&
17)!Have you ever been told by teachers, guidance counselors, or others that 
you have a special learning problem?& YES& NO&
!
!
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MENTAL!HEALTH!CONTINUUM!–!SHORT!FORM!(MHC!–!SF)!
The&following&questions&are&about&how&you&have&been&feeling&in&the&past&month.&Please&place&a&check&mark&in&
the&box&that&best&represents&how&often&you&have&felt&each&feeling.&
!
In!the!past!month,!how!often!
did!you!feel!…!!
!
!
NEVER!
(0)!
ONCE!
OR!
TWICE!
(1)!
ABOUT!
ONCE!A!
WEEK!
(2)!
2!OR!3!
TIMES!A!
WEEK!
(3)!
ALMOST!
EVERY!
DAY!
(4)!
!
EVERY!
DAY!
(5)!
&
1.&happy&
&
! ! ! ! ! !
&
2.&interested&in&life&
&
! ! ! ! ! !
&
3.&satisfied&
&
! ! ! ! ! !
&
4.&that&you&had&something&
important&to&contribute&to&
society&
&
! ! ! ! ! !
&
5.&that&you&belonged&to&a&
community&(like&a&social&group,&your&
neighbourhood,&your&city)&
&
! ! ! ! ! !
&
6.&that&our&society&is&becoming&a&betR
ter&place&for&people&
&
! ! ! ! ! !
&
7.&that&people&are&basically&
good&
&
! ! ! ! ! !
&
8.&that&the&way&our&society&
works&makes&sense&to&you&
&
! ! ! ! ! !
&
9.&that&you&liked&most&parts&of&your&
personality&
&
! ! ! ! ! !
&
10.&good&at&managing&the&
responsibilities&of&your&daily&life&
&
! ! ! ! ! !
&
11.&that&you&had&warm&and&
trusting&relationships&with&
others&
&
! ! ! ! ! !
&
12.&that&you&have&experiences&that&
challenge&you&to&grow&and&become&a&
better&person&
&
! ! ! ! ! !
&
13.&confident&to&think&or&
express&your&own&ideas&and&
opinions&
&
! ! ! ! ! !
&
14.&that&your&life&has&a&sense&of&direcR
tion&or&meaning&to&it&
&
! ! ! ! ! !
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&
&
7.&How&many&days&have&you&experienced&medical&problems&in!the!past!30!days?&&
&&&&&(Do&not&include&ailments&directly&caused&by&drugs/alcohol,&except&for&serious&ailments&& !
&&&&&that&would&continue&even&if&you&were&abstinent&–&for&example,&cirrhosis&of&the&liver,& &&&&&&&&&&&&&&&Number!of!Days&
&&&&&abscesses&from&needles,&etc.)&
&
8.&How&troubled&or&bothered&have&you&been&by&these&medical&problems&in!the!past!30!days?&
!!!!!!!!!!!!Not!at!all!!!!!!!!Slightly! !!!!!!Moderately! !!!!!!!!Considerably! !!!!!Extremely!
!
9.&How&important&to&you&now&is&treatment&for&these&medical&problems?&
!!!!!!!!!!!!Not!at!all!!!!!!!!!Slightly! !!!!!!Moderately! !!!!!!!!!Considerably! !!!!!!Extremely!
!
!
10.&&
In!the!past!30!days,!have&you&had&a&significant&
period&of&time&in&which&you&have:&
!
NO!
!
YES!
!
Only!when!high,!
or!in!withdrawal!
from!alcohol/drugs!
!
&
a.&Experienced&serious&depression,&hopelessness,&
&&&&loss&of&interest,&difficulty&with&daily&functioning?&
&
! ! !
&
b.&Experienced&serious&anxiety/tension,&uptight,&
&&&&unreasonably&worried,&inability&to&feel&relaxed?&
&
! ! !
&
c.&Experienced&hallucinations&–&saw&things&or&heard&
&&&&voices&that&were&not&there?&
&
! ! !
&
d.&Experienced&trouble&understanding,&concentrating,&
&&&&or&remembering?&
&
! ! !
&
11.&
!
In!the!past!30!days,!did&you&have&a&significant&period&(it&may&have&
been&the&direct&result&of&alcohol/drug&use)&in&which&you&have:&
!
YES!
!
NO!
!
&
a.&Experienced&trouble&controlling&violent&behaviour,&including&episodes&
&&&&of&rage,&or&violence?&
&
! !
&
b.&Experienced&serious&thoughts&of&suicide&(seriously&considered&a&plan&
&&&&for&taking&your&life)?&
&
! !
&
c.&Attempted&suicide?&
&
! !
&
&
&
12.&In!the!past!30!days,&how&many&days&have&you&experienced&these&
&&&&&&psychological&or&emotional&problems?& & & & & Number!of!Days&
&
&
13.&How&much&have&you&been&troubled&or&bothered&by&these&psychological&or&emotional&problems&&
&&&&&&&in!the!past!30!days?!
&
Not!at!all! !Slightly!!!!!!!!!!!!!!!!!Moderately! !!!!!!Considerably! !Extremely!
!
!
14.&How&important&to&you&now&is&treatment&for&these&psychological&or&emotional&problems?&
Not!at!all! !Slightly!!!!!!!!!!!!!!!!!Moderately! !!!!!!Considerably! !Extremely!
!
&
15.&In!the!past!30!days,&have&you&been&prescribed&medication&for&
&&&&&&any&psychological&or&emotional&problems?& & & & &NO!!!!!!! !!!!!!!!!!!!YES!
&
! 171!
If!completing!this!survey!raises!any!emotional!issues!with!you!we!strongly!encourage!that!
you!discuss!this!with!your!support!worker.!
!
Thank!you!for!completing!the!survey.!
 
!
!
!
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Appendix$D$
HE08/297!
!
17th!November!2008!
!
Chairperson!
Human!Research!Ethics!Committee!
University!of!Wollongong!
!
!
Ethics!Number:! HE08/297!
Project!Title:!!Mental)health)screening)within)residential)drug)and)alcohol)rehabilitation!
!
Thank&you&for&providing&a&prompt&response&to&our&application.&We&have&carefully&attended&to&each&aspect&of&
the&committees’&concerns&as&outlined&below.&
&
1.! Provide!a!longer!outline!of!the!purpose!of!the!study!on!the!information!sheet.!
&
The&following&passage&has&been&inserted&into&the&participant&information&sheet,&(attached&in&full&as&appendix&
A),&to&enlarge&upon&our&outline&of&the&purpose&of&the&study:&
!
What%is%the%study%about?%
The% study%aims% to%examine% the%proportion%of%people% in% residential%drug%and%alcohol% rehabilitation%who%also%
have%a%mental%health%problem.%Studies%have%found%that%people%with%both%drug%and%alcohol%and%mental%health%
problems%can%do%much%worse%than%those%with%drug%and%alcohol%problems%alone.%For%this%reason%it%is%important%
to% identify% how%many% people% in% drug% and% alcohol% treatment% services% also% have%mental% health% problems% so%
more%can%be%done%to%help%this%group.%It%will%also%examine%people’s%different%reactions%to%music.%We%are%looking%
at%this%because%music%has%been%found%to%effect%people’s%moods%in%different%ways%and%may%have%the%potential%to%
be%useful%in%therapy.%%
&
&
2.! Extend!the!amount!of!time!it!takes!to!complete!the!survey!on!the!information!sheet.!!
!
The&advice&on&the&estimated&amount&of&time&it&takes&to&complete&the&survey&has&been&extended&from&40&
minutes&to&60&minutes.&&
&
&
3.! Provide!examples!of!“sensitive!questions”!on!the!participant!information!sheet.!
&
The&participant&information&sheet&has&had&the&following&paragraph&added&that&includes&two&items&that&could&
be&construed&as&“sensitive”:&
&
There%is%a%very%small%risk%that%you%might%think%some%of%the%questions%in%the%questionnaires%are%too%personal%or%
distressing.%Example%items%are:%“Have%you%ever%been%advised%to%take%medication%for%anxiety,%depression,%hearG
ing%voices,%or%for%any%other%emotional%problem?”%and%to%what%extent%do%you%“want%to%drink/use%drugs%so%much%
I%can%taste% it.”%However,% in%addition%to%your%right%not%to%participate% in%the%survey,%you%also%have%the%right%to%
refuse% to%answer%any%specific%questions% that%you% find% too%personal%or%distressing%and% if%any%of% the%questions%
cause%you%any%distress%the%Salvation%Army%staff%will%also%be%available%to%assist%you.%
&
&
4.! To!ensure!clients!have!the!freedom!to!not!participate,!only!have!researchers!in!the!room!when!clients!
are!completing!the!surveys.&
&&
At&the&time&when&clients&are&completing&the&surveys&only&researchers&will&be&in&the&room.&
&
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In&addition& to& the&concerns& raised&by& the&committee&we&would& like& to&add&an&additional&2&questions& to& the&
survey&to&examine&the&participants’&perceptions&of&how&well&their&mental&health&needs&are&being&met&by&their&
drug&and&alcohol&treatment&service&currently&and&what,&if&any,&poorer&treatment&outcomes&traditionally&assoR
ciated&with&drug&and&alcohol&and&mental&illness&comorbidity&they&have&experienced&previously.&The&items&are&
as&follows:&
&
14.!How$well$is$the$service$meeting$your$mental$health$needs$currently?$
$
Not!at!all! !!!Slightly! !!!Moderately! !!!!!!!Considerably! !!Extremely!
$
15.!Have$you$experienced$any$of$the$following$drugKandKalcoholKrelated$difficulties$preK
viously?$
$
Relapse!!!!!!!Hospitalisation!!!!!!!!Violence! !Family!difficulties! !Homelessness!
&
We&would&appreciate&it&if&you&could&let&us&know&if&these&revisions&have&adequately,&addressed&the&CommitR
tee’s&concerns&as&soon&as&possible&in&order&to&finalise&dates&for&the&data&collection.&
&
Yours&sincerely,&
Professor&Frank&Deane&
University&of&Wollongong&
&
&
University!of!Wollongong!
Client!Participant!Information!Sheet!
Lake!Macquarie!Recovery!Service!Centre:!!
!
Mental!Health!and!Substance!Abuse!Problems!
!
Who!is!doing!the!study?!!
Dr!Peter!Kelly,!Prof!Frank!Deane!and!Mr!Kane!Mortlock!will!be!conducting!this!research!project.!AsA
pects!of!this!research!will!be!used!for!Mr!Mortlock’s!doctorial!thesis.!
!
What!is!the!study!about?!
The!study!aims!to!examine!the!proportion!of!people!in!residential!drug!and!alcohol!rehabilitation!who!also!
have!a!mental!health!problem.!Studies!have! found! that!people!with!both!drug!and!alcohol!and!mental!
health!problems!can!do!much!worse!than!those!with!drug!and!alcohol!problems!alone.!For!this!reason!it!
is!important!to!identify!how!many!people!in!drug!and!alcohol!treatment!services!also!have!mental!health!
problems!so!more!can!be!done!to!help!this!group.!It!will!also!examine!people’s!different!reactions!to!muA
sic.!We!are!looking!at!this!because!music!has!been!found!to!effect!people’s!moods!in!different!ways!and!
may!have!the!potential!to!be!useful!in!therapy.!
!
What!do!I!need!to!do?!
The first thing you need to do is carefully read this ‘participant information sheet’ making sure you understand 
what is required.  In order to protect your privacy we will not request your written consent to participate in this 
study, instead by completing and returning this questionnaire you will be providing your consent to participate 
in this study. If you do not wish to participate in this study you can either: !
1. Discuss this with the Salvation Army staff!
2. Discuss this with one of the researchers!
3. Return the incomplete questionnaire in the envelope provided. 
 
It is anticipated that completion of this questionnaire will take approximately 60 minutes.  If you would like 
further information on the study you can also contact Dr Kelly or Prof Deane at the University of Wollongong 
by calling 02 4221 4207.!
!
Is!there!any!risk!or!burden!if!I!decide!to!participate?!
The!main! burden!will! be! related! to! the! time! it! takes! to! complete! the! assessment.! There! is! a! very!
small! risk! that!you!might! think!some!of! the!questions! in! the!questionnaires!are! too!personal!or!disA
tressing.!Example! items!are:! “Have!you!ever!been!advised! to! take!medication! for!anxiety,!depresA
sion,! hearing! voices,! or! for! any! other! emotional! problem?”! and! to! what! extent! do! you! “want! to!
drink/use!drugs!so!much!I!can!taste!it.”!However,!in!addition!to!your!right!not!to!participate!in!the!surA
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vey,!you!also!have!the!right!to!refuse!to!answer!any!specific!questions!that!you!find!too!personal!or!
distressing!and! if!any!of! the!questions!cause!you!any!distress! the!Salvation!Army!staff!will!also!be!
available!to!assist!you.!
Also because your name will not appear on any part of the questionnaire there will be no option to withdraw 
any information provided at a later date. If you choose not to participate in the study, this will in no way have 
an effect on your relationship with your support or treatment services or the University of Wollongong. Partic-
ipation is entirely voluntary.  
Are!there!any!benefits!expected?!
People!often!find!that!when!they!complete!the!questionnaires!it!helps!them!reflect!on!their!progress!
and!clarify!what! it! is!about! treatment! that! is!helping!them.!!Also!the! information!from!this!study!will!
hopefully! contribute! to! improving! the! treatment! program! and! complimenting! already! existing! reA
search.!
!
How!will!my!information!be!collected!and!used?!
You!will!be!required!to!complete!a!questionnaire!which!will! involve!completing!a!written!survey.!!InA
formation!from!this!survey!will!be!kept!confidential.!All!questionnaire!material!will!be!stored!securely!
at! the!University!of!Wollongong.!The! information!may!be!used! for!publication! in!scholarly! research!
journals,!reports!to!the!Salvation!Army,!student!theses,!and!conference!presentations.!You!will!not!be!
identifiable!in!any!publications.!
!
What!if!I!have!more!questions?!
You! may! have! additional! questions! that! you! wish! to! ask! about! the! research! before! you! decide!
whether! to!participate.!You!can!contact!Dr!Kelly!or!Prof!Deane!at! the!University!of!Wollongong!by!
calling! 02! 4221! 4207.! If! you! have! any! concerns! or! complaints! regarding! the!way! in!which! the! reA
search!is!or!has!been!conducted,!you!can!contact!the!Secretary!of!the!University!of!Wollongong!HuA
man! Research! Ethics! Committee! on! Phone:! ! (02)! 4221! 4457,! Fax:! (02)! 4221! 4338! ! ! email:! re%
search@uow.edu.au!
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Appendix$E$
Research Office use only 
          HE 09/224  
 
UNIVERSITY OF WOLLONGONG/ILLAWARRA AREA HEALTH SERVICE 
 
Human Research Ethics Committee 
 
 
INITIAL APPLICATION FOR APPROVAL TO UNDERTAKE 
RESEARCH INVOLVING HUMAN PARTICIPANTS 
(A separate application is required for each project) 
Please answer questions in terms understandable to the layperson. 
 
1. Descriptive Title of Project:  
  
The!Salvation!Army!Recovery!Service!Centres:!Validation!of!Mental!Disorder!and!Mental!
Health!Screening!Measures!!
 
2. 7 line summary of project aims: 
  
This! project!will! first! examine! the! sensitivity,! specificity! and! overall! accuracy! of! a! number! of!
screening!measures!designed!to!detect!mental!disorder!amongst! individuals!with!alcohol!and!
other!drug!problems.!The!project!will!also!investigate!the!psychometric!validity!and!reliability!of!
a!measure! of!mental! health.!Results!will! be! used! to! inform! assessment,! treatment! planning!
and!treatment!outcome!measurement!within!substance!abuse!treatment!facilities.!
 
3. Name Position/Appointment Institution Qualifications 
 Chief Investigator(s)    (Academic or Professional) 
  
Kane!Mortlock!(BA,!LLB!(Hons),!BPsyc!(Hons))!
PhD!candidate!!
Illawarra!Institute!for!Mental!Health!
School!of!Psychology!
University!of!Wollongong! !
!
Prof!Frank!Deane!(PhD,!Dip.!Clin.!Psych)!
Director!
Illawarra!Institute!for!Mental!Health!
School!of!Psychology!
University!of!Wollongong!
!
Dr!Trevor!Crowe!(PhD)!
Research!Fellow!
Illawarra!Institute!for!Mental!Health!
University!of!Wollongong!
 
Address for Correspondence (1st named investigator): 
 
Illawarra!Institute!for!Mental!Health!
Building!22!!
University!of!Wollongong!
Wollongong,!NSW!2522!
 
Contact Phone Number: 0422!589!549 Fax:!(02)!4221!5585!!Email: ksm22@uow.edu.au 
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 Other Participating Researchers: (names/address/contact details of other researchers 
working on this project) 
!
Dr!Peter!Kelly,!Associate!Fellow,!Illawarra!Institute!for!Mental!Health,!Building!22,!University!of!
Wollongong,!NSW!2522. 
 
 
 
4.  Where will potential participants be approached by the researchers to seek their partici-
pation in the research and where will research activities involving participants be con-
ducted: 
  
Supervisors!and!caseworkers!of!the!Salvation!Army!Bridge!program!will!be!informed!of!the!
proposed!study!by!the!researchers.!!Clients!will!be!informed!of!the!study!in!their!“house”!meetA
ing!(located!in!the!residential!treatment!facility)!where!they!will!be!notified!of!a!sign!up!sheet!
available!to!sign!up!for!the!study.!!A!participant!information!sheet!(Appendix!A)!will!be!provided!
along!with!contact!details!so!that!the!clients!can!contact!the!researcher!if!there!are!any!further!
questions.!!This!will!allow!the!opportunity!for!the!client!to!refuse!to!participate!outside!of!direct!
contact!with!his/her!caseworker.!!The!chief!investigator!will!be!on!site!at!The!Salvation!Army!
Recovery!Service!Centres!to!conduct!the!research!and!will!be!the!only!other!person!present!in!
the!room!at!the!time!the!research!is!conducted.!!!
 
 
Purpose and Funding of Project 
5.a Is this: YES Staff Research  (University of Wollongong) 
   ______Staff Research  (Illawarra Area Health Service) 
   YES Student Research (Post grad. degree or subject) 
  Course undertaken: PhD (Psychology) 
  Unit/ Faculty/Department School of Psychology/HBS 
  Supervisor Prof Frank Deane & Dr Trevor Crowe 
  ______Other (Please specify e.g. for external people who want to research Uni   
  students or IAHS clients) 
 
5.b What is the source and amount of funding from all sources for this research? 
  
Source (Name of Organisation / Funding Scheme) Amount  
The Salvation Army  $397 000 
  
  
 
5.c Is there any affiliation or financial interest between the sponsor/funding body and the 
researcher(s) or supervisor associated with this research?  If Yes, Please declare. 
 
! NO!
 
5.d Are there any conditions placed on this research by the funding body? (please provide 
details) YES/NO 
 
! NO!
 
5.e Is a copy of the HREC approval to be forwarded to the Granting Body?  
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! YES!!
 
If YES, please advise of any deadlines: 
!
No!deadline,!but!provided!to!the!funding!body!before!the!research!is!commenced.!
 
6. Has this research project been reviewed by any other Institutional Ethics Committee? 
(for example multi-centre research)       
  
! NO!
  
 If YES, include a copy of any correspondence the sponsor or researcher has entered into 
with the other Ethics Committee(s) to this point. 
 
7. Research Categories 
 
 Please mark the research categories relevant to this research proposal. See guidelines for 
descriptions of the categories. At least one category should be marked for each grouping. 
For "Other", please specify. 
 
 If your research only involves participants and research procedures from a-d under  
 A Participants and B Research Procedures Used, it may be open to expedited review by 
the Chair of the HREC. In that case, submit only one copy of your application (please see 
guidelines regarding expedited review). 
  
A Participants  
 
a. Healthy members of the community 
b. University students   
c. Employees of a specific company/organisation  
d. Members of a specific community group, club or  association  
e. Clients of a service provider  
 
f. Health Service clients (e.g. users/clients of a health service) 
g. School children  
h. Hospital in-patients  
i. Clinical clients (e.g. patients)   
j. Aboriginal/Torres Strait Islander people  
k. Members of socially disadvantaged groups 
l. Cadavers/ cadaveric organs 
m. Other:            
 
Expected age(s) of participants – please circle one or more  
  
Children (under 14) Young people (14-18)  Adults (> 18)  
 
B Research procedures used 
  
a. Anonymous questionnaires/ surveys  
b. Coded (potentially identifiable) questionnaires/ surveys 
c. Identifiable questionnaires/ surveys 
d. Examination of student work, journals etc 
e. Examination of medical, educational, personnel or other confidential records 
f. Observation (overt) 
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g. Observation (covert) 
h. Interviews (structured or unstructured) 
i. Telephone interviews 
j. Procedures involving physical experiments (e.g. exercise, reacting to computer im-
ages) 
k. Procedures involving administration of substances (e.g. drugs, alcohol, food) 
l. Physical examination of participants (including eg. blood glucose, blood pressure 
and temperature monitoring) 
m. Collection of body tissues or fluid samples 
n. Surgical procedures 
 
o. Other:           
 
C Research areas 
 
a. Qualitative research  
b. Social Science research  
c. Humanities research  
d. Educational research 
 
e. Health research  
f. Psychological research  
g. Comparison or evaluation of drugs or surgical or other therapeutic devices  
h. Comparison or evaluation of clinical procedures 
i. Comparison or evaluation of counselling or training methods 
j. Investigation of the effects of an agent (drug or other substance) 
k. Investigation of bio-mechanical processes 
l. Biomedical research 
o.! Epidemiology 
p.! Genetic research 
 
o. Other:           
 
 
 
8.a Does the project involve the use of drugs?     
  
! NO!
 
 Is the research clarified as a:           
 CTN Trial                 CTX Trial               Other (Please detail)   
 
8.b Does the project involve the use of a surgical or other therapeutic device? (please detail)
  
! NO!
 
8.c If you answered YES to 8a. or 8b., is there any business or similar association between 
the researcher and the supplier of a drug or surgical or other therapeutic device to be 
used in the trial? (please detail). 
 
! N/A!
 
 If you answered YES to 8a. or 8b., please include the budget for this trial including in-
formation about capitation fees, payments to researchers, institutions or organisations 
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involved in the research, current and consequential costs and costs which may be in-
curred by participants. 
 
 Please include evidence of arrangements to ensure adequate compensation to participants 
for any injury suffered as a result of participation in the trial. (Indemnification forms 
and, if the research is being undertaken in a private practice, evidence of adequate and 
appropriate insurance coverage) 
 
! N/A!
 
 
 
9. Justify the design of your proposed research and describe what you want participants to 
do.   
 Please provide an explanation, in terms understandable by a non-expert reader.  For stu-
dent researchers, please provide (in no more than 2 pages) the background to this project 
(Attach extra sheets if necessary) 
 
The!current!research!is!in!two!parts.!!
!
Mental!disorder!screening!
!
The!Illawarra!Institute!for!Mental!Health!(iiMH)!has!been!contracted!by!The!Salvation!Army!to!
develop,!trial!and!integrate!mental!disorder!screening!tools!across!their!residential!sites!and!to!
improve!treatment!offered!to!clients!in!The!Salvation!Army!alcohol!and!other!drug!recovery!
services!generally.!The!Salvation!Army!provides!a!range!of!longAterm,!residential!treatment!
services!for!people!with!substance!abuse!problems.!Although!screening!for!coAoccurring!menA
tal!disorder!is!recommended!as!best!practice,!there!is!no!definitive!guidance!provided!by!existA
ing!research!as!to!which!mental!disorder!screening!instrument!should!used.!A!preliminary!
screening!instrument!has!been!instituted!as!a!temporary!measure!until!the!proposed!research!
can!report!on!which!instrument!is!most!accurate!at!identifying!mental!disorder!comorbidity!in!a!
residential,!alcohol!or!other!drug!recovery!service!population.!!
!
It!has!been!acknowledged!that!clients!with!comorbid!mental!disorders!and!substance!misuse!
have!received!poor!care!due!to!gaps!in!service!provision!(Adams,!2008r!Harris!&!Edlund,!
2005).!Not!treating!coAoccurring!disorders!“contributes!to!some!of!the!most!intractable!and!exA
pensive!social!problems”!(Davis!et!al.,!2006,!p.!263).!In!Australia!the!historical!inadequacy!of!
treatment!for!this!population!was!targeted!by!the!Australian!Government’s!National!ComorbidiA
ty!Initiative,!which!allocated!$17.9!million!over!seven!years!to!address!the!treatment!of!this!
population.!The!emphasis!of!this!initiative!under!which!funding!for!the!proposed!research!is!
auspiced!is!upon!the!importance!of!identifying!and!effectively!managing!clients!who!are!expeA
riencing!both!a!substance!use!disorder(s)!and!a!mental!disorder(s)!in!treatment!settings!(AusA
tralian!Institute!of!Health!and!Welfare,!2009).!
!
Problems!facing!the!significant!number!of!people!with!comorbidity!include!poorer!treatment!reA
sponse!and!an!inability!to!maintain!functional!stability!(Grella!&!Stein,!2006r!Ziedonis!&!Stern,!
2001),!higher!rates!of!relapse!(Swofford,!Kasckow,!SchellerAGilkey,!&!Inderbitzin,!1996),!more!
hospital!visits!(Haywood!et!al.,!1995),!increased!involvement!in!violence!(Swartz!et!al.,!1998),!
family!difficulties!and!limited!social!relationships,!increased!unemployment,!victimisation!
(Goodman,!Rosenberg,!Mueser,!&!Drake,!1997),!incarceration!(Abram!&!Teplin,!1991),!homeA
lessness!(Drake,!Osher,!&!Wallach,!1991),!HIV!(Adams,!2008r!Brunette,!Mueser,!&!Drake,!
2004r!Ziedonis!&!Stern,!2001)!and!Hepatitis!C!(Rosenberg!et!al.,!2001).!In!2005,!in!most!cases!
in!Australia!where!a!mental!or!behavioural!disorder!was!recorded!as!the!underlying!cause!of!
death,!the!abuse!of!psychoactive!substances!such!as!alcohol!and!heroin!was!also!involved!
(Australian!Institute!of!Health!and!Welfare,!2008).!
!
The!accurate!identification!of!mental!disorder!comorbidity!is!an!important!step!towards!improvA
ing!treatment!for!this!population!(Ziedonis!et!al.,!2005).!Yet!there!is!no!consensus!about!which!
screening!instrument!to!use!to! identify!mental!disorder!comorbidity! in!alcohol!and!other!drug,!
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residential,! treatment! service! populations! (Maisto! &! Kivlahan,! 2007).! There! is! no! adequate!
base! of! research! evidence! upon! which! to! build! a! consensus.! Clinicians! often! miss! the! coA
occurrence!of!mental!disorders!and!substance!use!disorders!because!of!an!absence!of!routine!
screening!(Donald,!Dower,!&!Kavanagh,!2005).!Few!screening!instruments!have!been!tested!
against!one!another!directly! in! the!same!population! to!obtain!data!on! their! relative!accuracy.!
Two!exceptions!are!studies!by!Sacks!et!al.,!(2007)!which!compared!two!instruments!in!a!prisA
on!population!and!by!Lee!et!al.,!(2007)!which!compared!two!different!instruments!in!an!AustralA
ian!population!but!changed!one!of! them! from!Likert! to!dichotomous!scoring!and! reported!no!
sensitivity,!specificity!or!accuracy!figures.!No!comparative!studies!of!all!the!major!screening!inA
struments!have!been!conducted! in!Australian!populations.!The! research!data! on!existing! inA
struments! has! been! obtained! separately! in! different! populations! and! only! one! of! them! has!
been!conducted!in!Australia!(see!the!abovementioned!Lee!et!al.,!2007).!!
!
One!aim!of! the!present! study! is! to!address! this! research!gap! to!help!determine! the!best! inA
strument!to!screen!for!mental!illness!comorbidity!in!Australian,!alcohol!and!other!drug,!residenA
tial!treatment!populations.!To!facilitate!this!aim!clients!will!be!administered!a!number!of!the!maA
jor!screening!instruments!designed!to!detect!mental!disorder.!A!semiAstructured,!clinical!diagA
nostic!interview!(SCIDA1)!will!then!also!be!administered!to!provide!a!criterion!measure!against!
which!to!evaluate!the!sensitivity!of!the!various!screening!instruments!at!identifying!mental!disA
order,!the!specificity!of!the!various!screening!instruments!at!correctly!ruling!out!those!who!are!
not!mentally!disordered,!and! the!overall!accuracy!of! the! instruments! (obtained!by!combining!
the!previous!two!elements).!Comparing!the!various!screening!instruments!directly!against!each!
other! in! a! single! population!will! provide! evidence! about!which!mental! disorder! screening! inA
strument! is!the!most!accurate!at! identifying!mental!disorder!comorbidity! in!Australian,!alcohol!
and!other!drug,!residential!recovery!services.!This!is!information!the!entire!addictionAtreatment!
industry!could!benefit!from.!
!
Mental health screening 
 
In!addition!to!the!accurate!identification!of!pathologyAfocused!mental!illness,!wellnessAoriented!
mental!health!is!also!being!recognized!as!an!important!construct!in!the!treatment!of!both!menA
tal! disorders! and! drug! and! alcohol! disorders! (Corrigan! &! Ralph,! 2005r! Davidson! &! White,!
2007r! Miller! &! Miller,! 2009).! The! latest! theoretical! models! proposed! as! a! framework! within!
which!to!treat!coAoccurring!disorders!include!wellnessAoriented!mental!health!concepts!in!addiA
tion!to!pathologyAfocused!mental!illness!concepts!(see,!for!e.g.,!Davidson!et!al.,!2008r!Gagne,!
White,!&!William,!2007).!The!Surgeon!General!of!the!United!States!of!America,!defined!mental!
health!as:!
the successful performance of mental function, resulting in productive activities, 
fulfilling relationships with other people, and the ability to adapt to change and to 
cope with adversity; from early childhood until late life, mental health is the 
springboard of thinking and communication skills, learning, emotional growth, re-
silience and self-esteem (US Department of Health and Human Services, 1999, p. 
6). 
Contrastingly,!mental!illness!is!
the term that refers collectively to all mental disorders. Mental disorders are health 
conditions that are characterised by alterations in thinking, mood or behaviour (or 
some combination thereof) associated with distress and/or impaired functioning 
(US Department of Health and Human Services, 1999, p. 6) 
 
Recent! empirical! research! conducted! by! Corey! Keyes! suggests! mental! illness! (illnessA
oriented!constructs!such!as!distress!and!deficits!in!functioning)!and!mental!health!(wellnessA
oriented!and!successfulAfunctioning!constructs!such!as!happiness!and!purpose!in!life)!are!difA
ferent! latent!constructs.!The! implication! is! that! treatment!aimed!at!mental!disorder!alone! is!
inadequate!as!a!prescription!to!obtain!mental!health!(2005).!Keyes!found!that!the!absence!of!
mental! illness!does!not!equate! to! the!presence!of!mental!health! in!epidemiological!populaA
tions!and!that!the!worst!psychosocial!dysfunction!was!suffered!by!those!both!mentally!ill!and!
low! on!mental! health! (termed! “flounderers”)! (2002,! 2005).! People! with! mental! illness,! but!
medium!to!high!mental!health!(described!as!the!“purely!mentally!ill”!and!“strugglers”)!suffered!
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much! less!psychosocial!dysfunction! (Keyes,!2002,!2005).!The! implications!of! this! research!
are!that!it!may!no!longer!be!enough!to!identify!which!clients!have!coAoccurring!mental!disorA
der.!Clients’!mental!health!may!also!need! to!be!assessed!and! the! information! fed! into! the!
treatment!planning!process.!!
!
It! is!possible! that! it! is! coAoccurring!disorder! clients’!mental! health! in! combination!with! their!
mental! illness!that! is!associated!with!their!psychosocial!dysfunction,!not! their!mental! illness!
alone.!It!may!be!possible!to!alleviate!significant!psychosocial!dysfunction!and!reverse!tradiA
tionally!poor!treatment!outcomes!by!raising!mental!health!irrespective!of!client!mental!illness!
status.!This!possibility!is!particularly!important!to!alcohol!and!other!drug,!residential!rehabiliA
tation!services!that!often!lack!the!expertise!to!administer!specific,!best!practice!interventions!
for!each!type!of!mental!disorder.!Measuring!mental!health,! in!a!clinical!population!may!proA
vide!the!data!necessary!to!provide!new!integrated!treatments!consistent!with!recent!advocaA
cy!and!theoretical!models!(see,!for!e.g.,!Davidson!et!al.,!2008r!Davidson!&!White,!2007r!MilA
ler!&!Miller,!2009).!!
!
The!first!step! is! to!assess! the!validity!and!reliability!of!Keyes’!measure! in!a!clinical!populaA
tion.!TestAretest!reliability!analyses!require!a!coded,!potentially!identifiable!method!so!that!the!
same!clients!can!be!administered!the!same!measure!on!two!separate!occasions.!!
 
Research!plan!
!
a)!Research!design!
!
A!crossAsectional!design!will!be!used.!Participants!will!be!interviewed!within!one!month!of!inA
take.!Each!participant!will!be! interviewed!over! two!separate!sessions!to! facilitate!testAretest!
data!and!guard!against!results!from!an!instrument!informing!an!interview!or!vice!versa.!AddiA
tionally,!some!archival!data!from!the!generic!intake!process!will!be!accessed!including!inforA
mation!gathered!using!the!full!Addiction!Severity!Index!5th!Edition!(McLellan!et!al.,!1995)!and!
the! Depression,! Anxiety! and! Distress! Scale! –! 21! (DASS,! Lovibond! &! Lovibond,! 1995).!
Measures!used!in!the!two!sessions!will!be!quantitative!selfAreport!questionnaires!and!a!semiA
structured!interview.!In!one!session!participants!will!be!interviewed!using!the!Structured!ClinA
ical! Interview! for! DSMAIVATR! Axis! I! Disorders,! Research! Version,! Patient! Edition! (First,!
Spitzer,!Gobbon,!&!Williams,! 2002),!which!may!be!audioArecorded! if! participant! consent! is!
given!so!that!an!interrater!reliability!analysis!can!be!conducted.!For!the!participants,!this!auA
dio!recording!will!be!an!optional!component!and!they!will!be!able!to!do!the!study!without!conA
senting!to!this!component.!The!Mental!Health!Continuum!–!Short!Form!will!also!be!adminisA
tered! for! the! first! time!during! this!session.! In! the!other!session!participants!will!be!adminisA
tered! the! following! instruments! as!mental! illness! screening! instruments:! the!MHSFAIII,! the!
Modified!Mini!Screen!(MMS,!Alexander,!Haugland,!Lin,!Bertollo,!&!McCorry,!2008),!and!the!
World! Health! Organisation’s! SelfAReporting! Questionnaire! (SRQ,! Beusenberg! &! Orley,!
1994),!part!of!the!Psycheck!package!(see!Lee!et!al.,!2007).!Participants!will!also!be!adminisA
tered!Ryff’s!54Aitem!Scales!of!Psychological!WellABeing,!the!WHO!WellAbeing!Index!(WHOA5,!
Bech,!1998,!2001),! the!Short!Depression!Happiness!Scale!(SHDS,!Joseph,!2004),!and! the!
Mental!Health!Continuum!–!Short!Form!for!a!second!time!to!test!the!validity!and!reliability!of!
the!Mental!Health!Continuum!–!Short!Form.!!
!
!
b)!Participants!
!
The!sample!will!consist!of!individuals!attending!the!Salvation!Army!Bridge!residential!rehabiliA
tation!program!located!in,!Lake!Macquarie!(n!=!104),!Sydney!(n!=!110),!Blue!Mountains!(n!=!
17),!and!Canberra!(n!=!40).!We!anticipate!at!least!70%!of!these!residents!to!participate.!!All!
individuals!will!be!diagnosed!with!an!alcohol!and/or!substance!misuse!problem.!Participants!
may!also!be!diagnosed!with!a!coAoccurring!mental!illness!problem!(e.g.!depression,!anxiety,!
psychotic!disorder).!
!
!
c)!Measures!
!
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The!measures!outlined!in!the!section!below!will!be!administered!in!conjunction!with!the!interA
view!and! it!anticipated! the!whole!procedure!will! take!approximately!2! to!2.5!hours! to!comA
plete.!
!
Background!Information!and!drug!and!alcohol!use!
!
Basic!demographic!information!will!be!collected.!This!will!include!age,!weeks!in!the!program,!
gender!and!The!Salvation!Army!centre! they!are!attending.! Information!gathered!separately!
during!the!intake!process!using!the!full!Addiction!Severity!Index!5th!Edition!(McLellan!et!al.,!
1995)!will!also!be!accessed!as!relevant!to!the!person’s!drug!and!alcohol!history.!This!will!inA
clude!the!length!of!time!the!person!has!had!a!substance!misuse!problem,!the!types!of!drugs!
the! person! has! used! in! the! previous! 12Amonths,! the! substance! the! person! considers! their!
primary!drug!of!choice,! frequency!of!drug!use!and!if! they!have!ever!received!treatment!beA
fore.!We!will!ask!clients!to!specify!any!previous!mental!illness!diagnoses,!how!well!their!curA
rent!service!is!meeting!their!mental!health!needs!and!if!they!have!suffered!any!of!the!poorer!
treatment!responses!and!outcomes!traditionally!associated!with!coAoccurring!AOD!and!menA
tal!illness!disorders!previously.!
!
Mental!Disorder!Screening!
!
Structured)Clinical)Interview)for)DSMDIVDTR)Axis)I)Disorders,)Research)Version,)Patient)EdiD
tion)(SCIDDIP,)First)et)al.,)2002)!–!The!Structured!Clinical!Interview!for!DSMAIV!Disorders!is!a!
semiAstructured!interview!for!making!the!major!DSMAIV!Axis!I!diagnoses.!The!SCIDAIP!is!diA
vided!into!six!selfAcontained!modules!that!can!be!administered!in!sequence:!mood!episodes,!
psychotic!symptoms,!psychotic!disorders,!mood!disorders,!substance!use!disorders,!anxiety!
disorders,!adjustment,!and!other!disorders.!The!SCIDAIP!is!widely!accepted!as!the!standard!
for!assessing!substance!use!and!mental!disorders!(Magruda,!Sonne,!Brady,!Quello,!&!MarA
tin,!2005).!A!screening!instrument!is!considered!to!be!accurate!if!it!concurs!with!the!SCIDAIP!
on!the!presence!or!absence!of!a!disorder!(Sacks,!Melnick,!Coen,!Banks,!Friedmann,!Grella,!
Knight!et!al.,!2007).!
)
)
Mental)Health)Screening)Form)–)III)(MHSFDIIIr!Carroll)&)McGinley,)2000))D!The!Mental!Health!
Screening!Form!–!III!is!designed!as!a!mental!illness!screening!device!for!clients!seeking!adA
mission!to!substance!abuse!treatment!programs.!Each!MHSFAIII!question!is!answered!either!
“yes”!or!“no.”!All!questions!reflect!the!respondent’s!entire!life!historyr!therefore!all!questions!
begin!with!the!phrase!“Have!you!ever...”.!The!MHSFAIII!features!a!“Total!Score”!line!to!reflect!
the!total!number!of!“yes”!responses.!The!maximum!score!on!the!MHSFAIII!is!18!(question!6!
has!two!parts).!This!feature!permits!programs!to!do!research!and!program!evaluation!on!the!
mental!illnessAchemical!dependence!interface!for!their!clients.!The!first!four!questions!on!the!
MHSFAIII! are! not! unique! to! any! particular! mental! illness! diagnosisr! however,! questions! 5!
through!17!reflect!symptoms!associated!with! the! following!diagnoses/diagnostic!categories:!
Q5,!Schizophreniar!Q6,!Depressive!Disordersr!Q7,!Posttraumatic!Stress!Disorderr!Q8,!PhoA
biasr!Q9,!Intermittent!Explosive!Disorderr!Q10,!Delusional!Disorderr!Q11,!Sexual!and!Gender!
Identity! Disordersr! Q12,! Eating! Disorders! (Anorexia,! Bulimia)r! Q13,! Manic! Episoder! Q14,!
Panic! Disorderr! Q15,! ObsessiveACompulsive! Disorderr! Q16,! Pathological! Gamblingr! and!
Q17,!Learning!Disorder!and!Mental!Retardation.!
!
Addiction)Severity)Index)5th)Edition)–)Psychiatric)Status)Domain)(McLellan)et)al.,)1995)!–!The!
Addiction!Severity!Index!is!the!most!widely!published!substance!abuse!assessment.!The!enA
tire!measure! is! being! administered! as! part! of! The!Salvation!Army! intake! protocol.! For! the!
purposes!of!the!mental!disorder!screening!aspect!of!this!study!we!will!be!using!the!‘PsychiatA
ric!Status’! section!of! the! interview.!Previous! research! indicates! that! the!ASI!provides!good!
sensitivity!and!specificity!to!identify!coAoccurring!mental! illness!problems!(Cacciola,!PecoraA
ro,!&!Alterman,!2008).!
)
Modified)Mini) Screen) (MMS,) Alexander,) Haugland,) Lin,) Bertollo,) &)McCorry,) 2008)! –! The!
Modified!Mini!Screen!is!designed!to!identify!people!with!mental!disorder!problems!who!are!in!
treatment! for! chemical! dependency,! including! speciality! sector! substance! abuse! treatment!
settings,!shelters,!jails!and!community!outreach!programs.!The!Modified!Mini!Screen!(MMS)!
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consists!of!22!items!that!ask!about!current!symptoms!for!major!depression,!dysthymia,!suiA
cidality,! hypomania,! panic,! agoraphobia,! social! phobia,! obsessive! compulsive! disorder,!
PTSD,!psychosis!and!generalized!anxiety.!
!
World) Health) Organisation’s) SelfDReporting) Questionnaire) (SRQ20,) Beusenberg) &) Orley,)
1994),)part)of) the)Psycheck)package)(see)Lee)et)al.,)2007)!–!The!SelfAReporting!QuestionA
naire!was!originally!designed!by!Harding!et!al.!(1980)!to!study!mental!illness!in!primary!care!
in!developing!countries.!The! items!were!extracted! from!preAexisting!psychiatric! instruments!
(Ghubash,!Daradkeh,!ElARufaie,!&!AbouASaleh,!2001).!The!SRQ20!became!formally!recomA
mended!by!the!World!Health!Organization!in!1994!as!a!screen!for!common!mental!disorders!
(depression!and!anxiety)!in!primary!health!care.!
)
Mental!Health!Screening!
!
Mental) Health) Continuum) –) Short) Form) (Keyes,) 2009)) D! The! Mental! Health! Continuum! –!
Short!Form!is!a!measure!of!mental!health!that!consists!of!14!items.!It!measures!the!degree!
of!(1)!Emotional!Well!Being!(items!1–3)!as!defined!in!terms!of!positive!affect/satisfaction!with!
lifer! (2)!Social!Well!Being! (items!4–8)!as!described! in!Keyes’s! (1998)!model!of!Social!Well!
Being!(one!item!on!each!of!the!dimensions!of!social!acceptance,!social!actualization,!social!
contribution,! social! coherence! and! social! integration)r! and! (3)! Psychological! Well! Being!
(items!9–14)!as!described!in!Ryff’s!(1989)!model!(including!one!item!on!each!of!the!dimenA
sions! of! autonomy,! environmental!mastery,! personal! growth,! positive! relations!with! others,!
purpose!in!life!and!selfAacceptance).!The!MHC–SF!allows!a!diagnosis!to!be!made!of!the!level!
of! mental! health! an! individual! enjoys! from! languishing!mental! health! to! flourishing!mental!
health.!
!
Ryff)Scales)of)Psychological)WellDBeing)–)54)(PWBD54,)Ryff,)1989)!–!Ryff’s!Scales!of!PsyA
chological! WellABeing! include! 6! subscales.! The! subscales! are! autonomy,! environmental!
mastery,!personal!growth,!positive!relations!with!others,!purpose!in!life,!and!selfAacceptance.!
!
WHO)WellDbeing)Index)(WHOD5,)Bech,)1998,)2001)!–!The!World!Health!Organisation!(WHO)!
Five!WellAbeing!Index!was!derived!from!a!larger!rating!scale!developed!for!a!WHO!project!on!
quality!of!life!in!patients!suffering!from!diabetes.!During!the!first!psychometric!evaluation,!10!
of! the!original!28! items!were!selected!due! to! the!homogeneity! they!had!shown!across! the!
various!European! countries! participating! in! this! study! (Bech,!Gudex,! &!Staehr,! 1996).! BeA
cause!it!was!thought!positive!psychological!wellAbeing!has!to!include!positively!worded!items!
only,!these!10!items!were!then!reduced!to!five!items!(WHOAFive)!which!still!covered!positive!
mood! (good! spirits,! relaxation),! vitality! (being!active! and!waking!up! fresh!and! rested),! and!
general!interests!(being!interested!in!things).!
!
Short) Depression)Happiness) Scale) (SDHS,) Joseph,) Linley,) Harwood,) Lewis,) &)McCollam,)
2004)!–!The!SDHS!is!a!6Aitem!short! form!of! the!25Aitem!statistically!bipolar,!selfAreport!DeA
pression!Happiness!Scale!designed!for! the!rapid!assessment!of!depression!and!happiness!
conceived!of!as! two!poles!on!a!single!continuum.!Three! items!are!positive!and!three! items!
are!negative.)
!
Depression)Anxiety)Stress)Scale)–)21)(DASSD21,)Lovibond)&)Lovibond,)1995)))–!The!DASSA
21!is!a!shortened!form!of!the!42Aitem!Depression!Anxiety!Stress!Scale.!DASS!items!can!be!
reliably!grouped!into!three!scales:!Depression,!Anxiety!and!Stress.!The!Depression!Scale!inA
cludes! items! that! measure! symptoms! associated! with! dysphoric! mood! (e.g.,! sadness! or!
worthlessness).!The!Anxiety!Scale!measures!symptoms!related!to!physical!arousal,!panic!atA
tacks!and!fear.!The!Stress!Scale! includes! items!that!measure!tension,! irritability!and!a! tenA
dency! to!overreact! to!stressful!events! (Antony,!Bieling,!Cox,!Enns,!&!Swinson,!1998).!This!
measure! is!being!administered!as!part!of!The!Salvation!Army! intake!protocol!and! the!data!
collected!will!be!accessed!for!the!purposes!of!this!study.!
!
See!Appendix!C!for!copies!of!all!the!written!measures!for!this!study!including!those!used!in!
the!intake!process.!!
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10.  Please provide a brief statement of the ethical considerations relevant to the proposed 
research; specifically in relation to the participants’ welfare, rights, beliefs, perceptions, 
customs and cultural heritage both individual and collective. (Attach an extra sheet if 
necessary) 
 
Informed)consent)–) It! is! important! that!clients!are!aware!of! their! freedom!of!choice!to!particiA
pate!or!refuse!participation!in!this!study.!!For!this!to!be!made!certain!clients!will!be!approached!
about! this! study! through! the!Salvation!Army!staff! so!clients!do!not! feel!pressured!by! the! reA
searchers!to!participate.!!Salvation!Army!staff!will!be!instructed!to!reinforce!to!the!clients!that!
participation!is!voluntary!and!there!will!be!no!negative!repercussions!for!refusing!to!participate.!!
If! potential! participants! express! an! interest! in! participating! then! a! time! to!meet! with! the! reA
searchers! will! be! arranged.! At! the! time! of! the! appointment,! prior! to! commencing,! the! inforA
mation!form!will!again!be!reviewed!and!signed!consent!obtained.!This!provides!a!second!ocA
casion!for!the!potential!participant!to!be!fully! informed!about!what! is!required!for!participation!
and!to!refuse!to!participate!if!they!choose.!The!Consent!Form!is!Appendix!B!to!this!document.!
!
Confidentiality! –! The! surveys!will! be! collected! directly! by! researchers! from! the!University! of!
Wollongong!and!no!individual!data!will!be!given!to!the!case!managers!or!the!service.!!The!reA
searchers!will!be!on!site!to!collect!the!data.!!All!information!will!be!stored!securely!at!the!UniA
versity!of!Wollongong.!All!individuals!will!be!provided!with!a!unique!identifier!so!that!once!data!
is!entered! into! the!statistical!package! there!will!be!no! identifying! information.!Questionnaires!
with!identifying!information!will!have!all!names!removed!and!replaced!with!the!unique!identifier.!
After!data!has!been!entered!into!the!statistical!packages!all!questionnaires!will!be!scanned!for!
storage!without!names!and!original!paper!versions!will! be!destroyed.! If!participants!agree! to!
have!their!interviews!audio!taped!(optional),!then!after!interrater!reliability!analyses!have!been!
conducted!the!audio!recordings!will!be!destroyed.!
 
11. Referring to the categories of participants to be involved in this project identified in ques-
tion 7, above, What is the rationale for selecting participants from this/these group/s?  
 
We! are! interested! in! identifying! coAoccurring! mental! illness! problems! and! levels! of! mental!
health!within!residential!drug!and!alcohol! rehabilitation!programs.!As!outlined! in! the! introducA
tion!this!is!to!better!identify!and!then!treat!comorbid!problems.!The!study!will!use!clients!in!this!
population!who!are!currently!attending!these!programs.!
 
 
12. How will potential participants be approached initially and informed about the project? 
Please explain in detail and include copies of any letters, advertisements or other re-
cruitment information. (e.g. direct approach to people on the street, mail-out to potential 
participants through an organisation, posters or newspaper advertisements, etc) 
 
The!Salvation!Army!staff!(predominantly!program!managers)!will!be!informed!of!the!proposed!
study!by!one!of!the!researchers.!
!
Clients!will! initially!be! informed!of! the!study!by!The!Salvation!Army!staff.!A!participant! inforA
mation!sheet!(Appendix!A)!will!be!provided!with!contact!details!so!if!a!client!has!further!quesA
tions! they! can! contact! the! researcher.! A! sign! up! sheet!will! also! be! provided! so! clients!who!
chose!to!can!volunteer!to!participate!in!the!study.!
!
We!believe!the!safest!approach!to!clients!will!be!through!Salvation!Army!staff.!!The!staff!will!be!
instructed!to!reinforce!to!the!clients!that!participation!is!voluntary!and!there!will!be!no!negative!
repercussions!for!refusing!to!participate.!!Also!clients!will!be!given!the!option!of!refusing!particA
ipation! through! the!researchers,! in! the! instance! they!don’t!want! to! refuse! through! their!caseA
worker.!
!
Once!we!have!preliminary!agreement,!the!researcher!will!arrange!to!meet!with!the!participant,!
at! that! time! the! information!sheet!will!again!be! reviewed,!an!opportunity! to!ask! further!quesA
tions!will!be!provided!and!the!consent!form!will!be!signed!if!the!participant!wants!to!proceed.!
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13. How many participants in total do you anticipate will be involved in the project? If the 
research has several stages involving different participants, please provide the total num-
ber of participants expected as well as the number of participants involved in each stage. 
 
It!is!our!intention!that!a!minimum!of!100!clients!participate!in!this!study.!A!maximum!of!150!cliA
ents!would!be!interviewed.!
!
14.!Participant Consent  
Attach copies of any letters of invitation, information packages, consent forms, 
proxy/substitute consent forms, debriefing information, identification cards, contact de-
tail cards, etc. 
 
See!Appendix!B!for!a!copy!of!the!Consent!Form.!
  
14 a. Is it anticipated that all participants will have the capacity to consent to their participa-
tion in the research?          
 
YES!
 
 If NO, please explain why (e.g. children, incompetent participants, etc.) and explain how 
proxy or substitute consent will be obtained from the person with legal authority to con-
sent on behalf of the participant (see Guidelines).  
 
14 b. For participants who have the capacity to consent, how does the process ensure that in-
formed consent is freely obtained from the participant? 
 
To! enter! the! Bridge! program! clients! will! have! undergone! a! supervised! detoxification! proA
gramme!prior!and!will!have!already!been!assessed!as!having!appropriate!psychological!stabilA
ity.!As!previously!noted,!the!consent!process!allows!clients!to!refuse!consent!through!discussA
ing!participation!with!Salvation!Army!staff!and! the! researchers.!The!Salvation!Army!staff!will!
emphasize!clients’! right! to!refuse!to!participate! in! the!program!and!will!assure!clients! that!no!
negative!ramifications!will!follow!them!doing!so.!Further,!when!the!researchers!first!meet!with!
the! participants,! information! about! the! study!will! again! be! reviewed! and! signed! consent! obA
tained.!This!provides!a!second!opportunity!for!questions!and!the!option!to!decline!participation.!
 
14 c. Will written consent from participants be obtained?  
 
YES!
 
 If NO, please explain why it would be inappropriate or unethical to seek written evidence 
of consent to this project. 
 
15. Are any participants in a dependent relationship with the researcher, the institution or 
the funding body (for example the researcher’s clinical clients or students; employees of 
the institution; recipients of services provided by the funding body)? If so, what steps will 
be taken to ensure that participants are free to participate or refuse to participate in the 
research? 
 
The!clients!will!be!in!a!clinical!relationship!with!the!Salvation!Army!staff!who!will!inform!them!of!
the!study.!As!noted!it!will!be!clearly!emphasised!that!participation!is!voluntary.!In!addition,!the!
client!will!be!provided!with!an!option!of!contacting!(or!asking!to!be!contacted!by)!the!researchA
ers!so! they!have! the!opportunity! to! refuse! to!participate!without!having! to!do!so!directly!with!
the!caseworker.!!!
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16. How does the project address the participants’ freedom to discontinue participation? 
Will there be any adverse effects on participants if they withdraw their consent and will 
they be able to withdraw data concerning themselves if they withdraw their consent?  
 
Participants!will!be!able! to!withdraw! their!data!at!any!point!because! they!will!be! identifiable.!
Clients!will!be!informed!of!this!in!their!participant!information!sheet!before!participating.!!
 
18.! Does the project involve withholding relevant information from participants or deceiving 
them about some aspect of the research?  
 
NO.!
 
If YES, what is the justification for this withholding or deception and what steps will be 
taken to protect the participants’ interest in having full information about their partici-
pation? 
 
 
18. Will participants be paid or offered any form of reward or benefit (monetary or other-
wise) for participation in the research?  If so, please detail and provide a justification for 
the payment, reward or benefit.  
 
NO. 
 
19. Confidentiality: 
 What measures will be taken to protect the privacy of individual subjects in terms of the 
test results and other confidential data obtained (both in recording the data and in its 
publication)?  
 
After!data!is!entered!names!from!questionnaires!will!be!removed!and!unique!codes!used.!!IniA
tially,!names!need!to!be!used!since!contact!will!be!faceAtoAface!for!the!interview!and!there!will!
be!a!testAretest!component!to!the!study!requiring!that!time!1!and!time!2!data!be!linked.!Once!
all!data! is!entered! into!statistical!packages,!only!unique!codes!will!be!on! the!data.!QuestionA
naires!will!be!scanned!with! the!use!of!unique! identifiers!and!names!removed.!Original!paper!
versions!of!questionnaires!used! for! research!purposes!will! be!destroyed.!Only!grouped!data!
will!be!reported!in!any!publications!or!presentations!and!no!individual!will!be!identifiable.!Once!
audio!recorded!interviews!have!been!assessed!by!an!independent!rater!to!determine!interrater!
reliability!they!will!be!destroyed.!
 
20. Will information collected from data or interview be published? 
 
YES.!
 
 If YES, please indicate what form this will take (Please note that any further use of in-
formation which may identify a participant is conditional upon the participant’s permis-
sion for such use):  
 
No!individual!identifying!data!will!appear!in!any!reports!from!the!study.!Data!will!be!published!
in!group!form!only.!The!data!will!be!used!for!the!purposes!of!research!student!theses!and!poA
tentially!publication! in!scholarly! journals!and!conference!presentations.!A! report!may!also!be!
written!for!the!Salvation!Army.!
 
 
21. Will any part of the research activities be placed on an audiotape, film, photograph or 
video-tape? 
 
YES.!
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 To what purpose will the audiotape, film, photograph or video-tape be used?    
 
Some!Structured!Clinical!Interviews!for!Diagnoses!will!be!audio!recorded!so!that!the!reliability!
of!the!interviewer!can!be!rated!against!additional!clinicians!and!reported!on!as!part!of!the!reliaA
bility!of! the!research.!This!will!be!an!“optional”!component.!Participants!will!be!able!to!do!the!
study!without!doing!this!audioArecorded!component.! ! !
      
 For what audience(s) will the audiotape, film, photograph or video-tape be exhibited? 
 
Only!trained,!experienced!research!clinicians!will!review!the!audio!recordings!for!the!purposes!
of!establishing!interrater!reliability.! ! ! ! ! ! !  
22.  How will the data (including questionnaires, surveys, computer data, tapes, transcripts 
and specimens) be held securely, during and on completion of the project?  
 
Confidential!data!will!be!stored!securely!at!the!Illawarra!Institute!for!Mental!Health,!it!will!be!
stored!in!locked!filing!cabinets!and!at!the!completion!of!the!project!will!be!held!in!a!locked!storA
age!room.!
 
 Please confirm that original data will be held securely for a minimum of 5 years (15 years 
for clinical research).   
 
Clinical!research!data!will!be!securely!stored!for!15!years.!
 
 If NO, please give reasons why it would be unethical to store the data for this period. 
 
23. Does the project involve the use of invasive procedures (e.g. blood sampling) or the risk of 
physical harm or emotional distress? 
 
YES!
 
 If YES, give details:  
 
Clients!may!experience!mild!distress!from!answering!questions!about!cravings!for!drugs!or!alA
cohol,!or!by!questions!about!mental!disorders.! 
 
Explain how the risks of harm or distress will be minimised. In the case of risks of emo-
tional distress, what provisions have been made for an exit interview or the necessity of 
counselling? 
   
As! part! of! their! assessment! and! treatment! process,! all! participants! would! have! had! similar!
questions!asked!of!them!previously.!In!this!sense!they!will!not!be!surprised!by!any!of!the!quesA
tions!in!the!research!protocol.!In!the!unlikely!event!that!emotional!distress!occurs!in!response!
to!some!of!the!study!questions!there!will!be!provision!for!participants!to!meet!with!one!of!the!
counselling!staff!who!are!available!at!the!treatment!centre.!
 
24. Does this project involve obtaining information (e.g. data) of a private nature from any 
Commonwealth/State/Local Government Department or any other Agency, including 
health records from Area Health Services.   
 
NO!
 
 If YES, which Department (s)/Agency?  
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 Please include copies of any correspondence regarding permission to access this infor-
mation from a responsible officer of the Agency and complete a Privacy Guideline Form 
(available from Ethics Officer). 
 
25. Does the research intend to determine whether illegal activity has occurred or anticipate 
that participants may reveal information about criminal activity ?   
 
YES!
 
 If YES, how do you propose to respond to the legal issues raised? 
!
It! is!not!an!aim!of!this!research!to!examine!serious!criminal!activity,!but! it! is!possible!that!cliA
ents!may!identify!serious!crimes!that!they!have!committed!during!the!course!of!the!interview.!
To!minimise!the!risk!to!the!individual!client!the!following!statement!will!be!included!on!the!conA
sent!form!and!participants!will!be!reminded!about!this!issue!at!the!time!of!the!interviews.!
!
“It!is!not!a!component!of!this!research!to!examine!your!involvement!in!any!serious!criminal!acA
tivities.!If!you!choose!to!discuss!any!serious!criminal!activity!you!should!avoid!identifying!any!
specific! individuals!who!may!have!committed!crimes! in!any!way.!Serious!criminal!activity!coA
vers! offences! such! as! drug! trafficking,! serious! assaults,! sexual! assaults,! child! abuse! or! neA
glect,! murder! and! manslaughter.! It! does! not! cover! minor! possession! of! drugs.!As! this! re%
search!is!concerned!with!substance!use!the!researchers!will!not!report!any!illegal!drug!
use.”!
!!
  
   
26. Period of Research Clearance Requested (Please specify as near as possible 'start' and 
'finish' dates for the conduct of research):      
   
 FROM:   1/11/09 TO:  1/11/10 
 
27. Any research project that involves the collection of data should be designed so that it is 
capable of providing information that can be analysed to achieve the aims of the project. 
Usually, although not always, this will involve various important statistical issues. It is 
important that the design and analysis be properly planned in the early stages of the pro-
ject. You should seek statistical advice. The University of Wollongong has a Statistical 
Consulting Service that provides such advice to research students and staff undertaking 
research. 
 
 Are statistical issues relevant to this project?         
 
YES!
 
 If so, have you discussed this project with the Statistical Consulting Service?     
           
The!statistical!consultants!in!the!School!of!Psychology!have!been!and!will!again!be!consulted!
regarding!the!design!and!analysis!of!this!study.!
 
28. Does this project involve the collection or use of personal health information or infor-
mation relating to the provision of a health service to an individual? This includes gen-
eral information such as a gymnasium would collect as well as information collected for a 
medical purpose.  
 If so, you need to complete the Initial Application Form Part 2 – Privacy Addition for 
Health Information. For additional information regarding this please read the document 
‘Health Records and Privacy Act’ and the NSW Privacy Commissioners’ Statutory 
guidelines on research. Both documents are available from the HREC webpage.  
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YES!
 
 
29.  Comments. If you would like to make any comment about the application or the applica-
tion process please do so. 
   
  
 DECLARATION BY CHIEF INVESTIGATOR 
 
 I, the undersigned, have read the current National Statement on Ethical Conduct in Re-
search Involving Humans: 
  http://www.health.gov.au/nhmrc/publications/synopses/e35syn.htm 
and accept responsibility for the conduct of the research activities detailed in this appli-
cation in accordance with the principles contained in the National Statement and any 
other conditions laid down by the University of Wollongong's Human Research Ethics 
Committee. 
 Chief Investigator's signature/s: 
  Date:   
  
 If the Chief Investigator is a student include: 
 Supervisor's signature: 
 
  Date:   
 
Signature/s of other researcher/s: (The first named researcher will assume responsibility 
for the project in the absence of the Chief Investigator) 
 
  Date:   
 
 
DECLARATION BY HEAD OF UNIT 
 
As Head of Unit I have responsibility for ensuring that Occupational Health and Safety 
(OHS) issues surrounding research in the Unit are addressed.  
 
(please tick all relevant boxes) 
 
___ I am satisfied that a general risk assessment for the research project addressed in this 
application has been completed adequately 
___ I will ensure that a risk assessment specific to this application will be completed prior to 
commencing the activities described in this application 
___  I will ensure that there exist appropriate mechanisms to address potential OHS issues 
that may arise and I have responsibility for implementing those mechanisms 
___ I will ensure that mechanisms exist for ongoing assessment of the OHS issues related to 
this research 
___ This research involves use of radiation, chemicals or biohazards. A Risk Assessment has 
been conducted and is attached to this application 
 
 Head of Unit’s Signature.................................................Date........................ 
 
 
  
NOTE:  RESEARCH MUST NOT COMMENCE UNTIL APPLICATION HAS BEEN 
FULLY APPROVED. 
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CHECKLIST  
Applications should be sent to the Ethics Officer, Human Research Ethics Committee, Office of 
Research, University of Wollongong, Northfields Ave, Wollongong  NSW  2522 
 
 
 Original Ethics Application plus appropriate number of copies (See Guidelines) 
 
 Consent Form(s)  
 
 Participant Information Sheet/Package 
 
 Copies of Questionnaire(s)/Survey(s) or Interview Questions 
 
 Copies of all documents and other material used to inform potential participants  
 about the research including advertisements and letters of invitation. 
 
 Evidence of permission to conduct research in locations not associated with the  
 University of Wollongong 
 
 Evidence of approval/rejection by other HREC(s), including comments and re-
quested alternations to the protocol  
 
 Any form requiring signature by the HREC (one copy) 
 
 For Clinical Trials : Application Form (original +14 copies),  Patient  
 Information Package (14 copies), Consent Forms (14 copies), Indemnity Form (14  
copies), Protocols (14 copies),  Advertisement (14 copies), Summary Sheet (14 cop-
ies), Budget (14 copies), Insurance information (if in Private Practice) (14 copies), 
Investigator’s Brochure (5 copies), CTN or CTX Form (1 original copy) 
 
 
Form Revised Jan 2003  
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Appendix$F$
NSW HEALTH 
HEALTH ETHICS BRANCH 
PRIVACY ADDITION TO HREC APPLICATION FORM 
!
!
!
The Health Records and Information Privacy Act 2002 commences on 1 September 2004.  The Act creates a scheme to regulate the collec-
tion, use and disclosure of personal health information.  It requires personal health information to be handled in accordance with 15 Health 
Privacy Principles (HPPs) set out in the Act.  It is necessary for you to complete this part of the application form in order to ensure: 
 
•! You and the [name of institution] comply with the Act; 
•! This HREC can properly assess your research under the Act; 
•! This HREC can meet its statutory obligations to report to the Privacy 
Commissioner on its activities under the Act. 
 
Please read the Statutory Guidelines made under the Act entitled Health Rec-
ords and Information Privacy Act 2002 (NSW): Statutory Guidelines on Research 
which can be found on the website of Privacy NSW. This website can be ac-
cessed through www.lawlink.nsw.gov.au.  Reading these documents will assist 
you in completing this section of the application form. 
 
 
Q1. Does this project involve the collection, use, or disclosure of personal health 
information which is identified, or from which the identity of the person can be 
reasonably ascertained? 
 
√! Yes!–!you!must!complete!this!section!of!the!application!form.!Go!to!question!2.!
 
No – you do not need to complete this section of the application form. Go to [insert 
next section of your standard HREC application form] 
 
Q2. Could the purpose of this project be served by collecting, using or disclosing 
de-identified information? 
 
Yes!–!you!should!collect,!use!or!disclose!deEidentified!information!only.!If!you!do!so,!you!do!
not!need!to!complete!this!section!of!the!application!form.!
 
√ No – Go to question 3. 
 
 
Q3. Why can’t the purpose of the project be achieved using de-identified information? 
 
√ The proposed project involves linkage of data. 
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Scientific defects in the project would result if de-identified information 
was used. Please provide details. 
 
 
 
 
 
 
 
 
 Other. Please provide details. 
 
 
 
 
 
 
 
 
Go to question 4. 
 
Q4. Are you proposing to collect, use or disclose the health information with the 
consent of the individual(s) concerned? 
 
√! Yes!–!you!can!collect,!use!or!disclose!the!health!information!relying!on!the!‘consent!exempE
tion’!in!HPP!10!or!HPP!11.!Go!to!question!12.!
 
 No – Go to question 5. 
 
Best!practice!tip:!Wherever!possible,!you!should!seek!the!consent!of!the!person.!!Use!or!disclosure!authorised!by!the!person!is!alE
most!always!to!be!preferred,!provided!the!consent!is!freely!given!and!informed.!
 
Q5. From which organisations/bodies are you collecting personal health infor-
mation?  Please specify each individual hospital, other area health services and 
any other organisations.  If known, please name the individual custodian of this 
information and the personnel in the organisation who generally have access to 
the information. 
 
 
 
 
 
 
 
 
Go to question 6. 
 
Q6. Is the information being collected reasonably necessary for the project, be-
ing collected for a lawful purpose (HPP1), relevant to the project, and not exces-
sive (HPP 2)? 
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Yes!–!go!to!question!7.!
 
 No – you must comply with HPP 1 and HPP 2. Refer to the Act. 
 
 
Q7. Was the health information originally collected for the primary purpose of 
this project? 
 
Yes!–!you!can!use!or!disclose!the!health!information!for!the!project!relying!on!HPP!10!or!HPP!
11.! ! You!do!not!need! to! complete! any!more!questions! from! this! section!of! the! application!
form.!Go!to![insert'the'next'section'of'your'standard'HREC'application'form]!
 
  No – Go to question 8. 
 
Q8. Is this project directly related to the primary purpose for which the health 
information was collected and would the person reasonably expect you to use or 
disclose their health information for the purposes of this project? 
 
Yes!–!please!provide!details!of!how!it!is!directly!related!!
!
 
 
 
 
 
 
 
 
!
You!can!use!or!disclose!the!health!information!for!the!project!relying!on!the!‘direct!relation!exE
emption’!in!HPP!10!or!HPP!11.! !You!do!not!need!to!answer!any!more!questions!from!this!secE
tion! of! the! application! form.! Go! to! [insert' the' next' section' of' your' standard'HREC' application'
form]!
  
No – Go to question 9. 
 
Best practice tip: It is unlikely that many research activities will come within this exemption, however some compilation or analysis of 
statistics activities might come within it.  Using health information to compile statistics about the number of patients treated for a particular 
disease within a hospital, for example, would arguably come within this exemption. 
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Q9. Is the use or disclosure for the project authorised, required, permitted or reasonably con-
templated under another law? 
 
Yes!–!Please!provide!details.!
!
!
!
!
!
!
!
You!can!use!or!disclose!the!health!information!relying!on!the!exemption!in!HPP!10(2)!or!HPP!
11(2).!!You!do!not!need!to!answer!any!more!questions!from!this!section.!!Go!to![insert'next'sec9
tion'of'your!standard'HREC'application'form]'
 
  No – Go to question 10. 
 
Q10. Why is it impracticable to obtain the consent of the individual to collect, use or disclose their 
health information?  
 
 The size of the population involved in the research. 
 
The proportion of individuals who are likely to have moved or died since 
the health information was originally collected. 
 
The risk of introducing potential bias into the research, thereby affecting 
the generalisability and validity of the results. 
 
The risk of creating additional threats to privacy by having to link infor-
mation in order to locate and contact individuals to seek their consent. 
 
The risk of inflicting psychological, social or other harm by contacting in-
dividuals with particular conditions in certain circumstances. 
 
The difficulty of contacting individuals directly when there is no existing or 
continual relationship between the organisation and the individuals. 
 
The difficulty of contacting individuals indirectly through public means, 
such as advertisement and notices. 
 
Other – please give details. 
 
 
 
 
 
 
 
Go to question 11. 
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Q11. Please provide reasons why the collection, use or disclosure of this 
information is in the public interest, and why the public interest in 
the project substantially outweighs the public interest in the pro-
tection of privacy. 
 
 
 
 
 
 
 
 
NB: In determining whether the public interest in the project substantially outweighs the public interest in the protection of 
privacy, the HREC will consider the matters listed below.  Please make reference to relevant factors in your reasons. 
 
(a)! The degree to which the project is in the public interest 
(b)! The degree to which the project is likely to contribute to: 
(i)! the identification, prevention or treatment of illness, injury or disease; or 
(ii)! scientific understanding relating to health; or 
(iii)! the protection of the health of individuals and/or communities; or 
(iv)! the improved delivery of health, disability or aged care services; or 
(v)! enhanced scientific knowledge or understanding; or 
(vi)! enhanced knowledge within the fields of social science and the humanities relating to health; 
(c)! Any likely benefits to individuals, to the category of persons to which the individual(s) belong, or the wider 
community that will arise from the project being undertaken in the manner proposed; 
(d)! In considering benefits to the category of persons to which the individual(s) belong, specific consideration 
should be given to any likely benefits to individuals that belong to certain categories where the information 
may be of a particularly personal or sensitive nature; for example: 
(i)! children and young people; or 
(ii)! persons with intellectual or psychiatric disability; or 
(iii)! persons highly dependant on medical care; or 
(iv)! persons in dependant or unequal relationships; or 
(v)! persons who are members of collectivities; or 
(vi)! Aboriginal and Torres Strait Islander peoples; or 
(vii)! Persons whose information relates to their mental or sexual health 
(viii)! Persons who are incarcerated 
(e)! whether the project design can be satisfied without needing to apply HPP 10(1)(f) or 11(1)(f) and the defects 
in the project that might arise if the project was not conducted in the manner proposed; 
(f)! the cost of not undertaking the project (to government, the public, the health care system, etc.); 
(g)! the public importance of the project; 
(h)! whether the risk of harm to an individual whose health information is to be collected, used or disclosed in the 
project is minimal 
(i)! the standards of conduct to be observed in the project, including: 
(i)! The project design and the scientific or other credentials of those involved in conducting that 
project; 
(ii)! If the project involves contact with participants, the procedures or controls that will apply to 
ensure participants are treated with integrity and sensitivity, including whether questions to be 
asked or procedures to be employed are intrusive; 
(iii)! Whether access to health information is restricted to appropriate personnel involved in con-
ducting the proposed study [you are asked to respond to this in question 13]; 
(iv)! The procedures that are to be followed to ensure that the information will not be published in 
a form that identifies particular individuals or from which an individuals or from which an in-
dividual’s identity can be reasonably ascertained [you are asked to respond to this in question 
12]; and 
(v)! The procedures that are to be followed at the completion of the project to ensure that all data 
containing health information are at least as secure as they were in the sources from which the 
data was obtained, including the date when the data will be destroyed or returned. These pro-
cedures must be in accordance with HPP 5 [you are asked to respond to this in question 13].  
 
Go to question 12. 
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Q12. Please confirm that information which identifies individuals or from which an individu-
al’s identity can reasonably be ascertained, will not be published in any generally availa-
ble publication? 
 
√ Confirmed – publication of such information is not permissible under the Act  
 
Q13. Describe in detail the security standards that will be applied to the storage of, and access 
to, the health information during the project and the proposed method of disposal of the health 
information at the completion of the project. 
 
The!surveys!will!be!collected!directly!by!researchers!from!the!University!of!Wollongong!and!no!
individual!data!will!be!given!to!the!case!managers!or!the!service.!!The!researchers!will!be!on!
site!to!collect!the!data.!!All!information!will!be!stored!securely!at!the!University!of!Wollongong.!
Questionnaires!with! identifying! information!will! have!all! names! removed!and! replaced!with!a!
unique!identifier.!All!individuals!will!be!provided!with!this!unique!identifier!so!that!once!data!is!
entered!into!the!statistical!package!there!will!be!no!identifying!information.!After!data!has!been!
entered! into! the! statistical! packages! all! questionnaires! will! be! scanned! for! storage! without!
names!and!original!paper!versions!will!be!destroyed.! If!participants!agree! to!have! their! interA
views!audio!taped!(optional),!then!after!interrater!reliability!analyses!have!been!conducted!the!
audio!recordings!will!be!destroyed. 
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Office use only: 
 
•! If “no” was ticked in response to question 4, mark here      - This project 
should be counted for reporting question 5. 
 
•! If the applicant was required to complete question 10 and following, mark 
here    - This project should be counted in determining the number of pro-
posals to be listed next to “yes” in reporting question 6. 
 
•! Mark which boxes the applicant ticked in question 3. 
 
  The proposed project involves linkage of data. 
 
Scientific defects in the project would result if de-identified infor-
mation was used  
 
  Other. Give brief description………………………………………………………………. 
 
This information should be used to answer reporting question 8. 
 
•! Mark which boxes the applicant ticked in question 10  
 
  The size of the population involved in the research. 
  
The proportion of individuals who are likely to have moved or died 
since the health information was originally collected. 
 
The risk of introducing potential bias into the research, thereby af-
fecting the generalisability and validity of the results. 
 
The risk of creating additional threats to privacy by having to link in-
formation in order to locate and contact individuals to seek their con-
sent. 
 
The risk of inflicting psychological, social or other harm by contacting 
individuals with particular conditions in certain circumstances.  
 
The difficulty of contacting individuals directly when there is no exist-
ing or continual relationship between the organisation and the indi-
viduals. 
 
The difficulty of contacting individuals indirectly through public 
means, such as advertisement and notices. 
 
Other –give brief details………………………………………………………………………. 
 
This information should be used to answer reporting question 9. 
 
•! Note the outcome of the HREC decision 
 
 Approved including privacy aspects. 
Rejected for reasons including privacy aspects. 
Rejected for other reason. 
 
Count!this!project!for!the!purposes!of!reporting)question)10,!only!if!the!first!box!is!marked.!
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Appendix$G$
HE09/224!
!
21st!August!2009!
!
Chairperson!
Human!Research!Ethics!Committee!
University!of!Wollongong!
!
!
Ethics!Number:! HE09/224!
Project!Title:! The)Salvation)Army)Recovery)Service)Centres:)Validation)of)Mental)
Disorder)and)Mental)Health)Screening)Measures!
!
Thank&you&for&providing&a&prompt&response&to&our&application.&We&have&carefully&attended&to&the&Committees’&
concern&as&outlined&below.&
&
5.! Please!state!clearly!in!the!‘risks’!section!of!the!Participant!Information!Sheet!that!if!participants!do!re^
veal!information!about!criminal!activity!which!has!a!mandatory!reporting!requirement!the!researchers!
will!have!to!report!it.!
&
The&following&passage&has&been&inserted&into&the&Participant&Information&Sheet&‘risks’&section,&(attached&in&full&
as&appendix&A),&to&address&the&Committee’s&concern:&
!
It!is!not!a!component!of!this!research!to!examine!your!involvement!in!any!serious!criminal!activities.!If!
you!choose!to!discuss!any!serious!criminal!activity!you!should!avoid!identifying!any!specific!individuA
als!who!may!have!committed!crimes! in!any!way.!Serious!criminal!activity!covers!offences!such!as!
drug!trafficking,!serious!assaults,!sexual!assaults,!child!abuse!or!neglect,!murder!and!manslaughter.!
It!does!not!cover!minor!possession!of!drugs.!As!this!research!is!concerned!with!substance!use!
the!researchers!will!not!report!any!illegal!drug!use.!If!you!reveal!information!about!criminal!activiA
ty!that!has!a!mandatory!reporting!requirement,!however,!(for!e.g.,!current!criminal!activity!that!is!putA
ting!a!child!or!children!at!risk!of!harm),!the!researchers!will!have!to!report!it.!
&
We&would&appreciate& it& if& you&could& let&us&know& if& this& revision&has&adequately&addressed& the&Committee’s&
concerns&as&soon&as&possible&in&order&to&finalise&dates&for&the&data&collection.&
&
&
Yours&sincerely,&
&
&
&
&
&
Professor&Frank&Deane&
University&of&Wollongong&
&&
!
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Appendix$H$
University of Wollongong 
Client Participant Information Sheet 
 
The Salvation Army Recovery Service Centres: 
Validation of Mental Disorder & Mental Health Screening Measures 
 
Who is doing the study?  
Mr Kane Mortlock, Prof Frank Deane and Dr Trevor Crowe will be conducting this research project. Aspects 
of this research will be used for Mr Mortlock’s doctoral thesis. 
 
 
What is the study about? 
The study aims to examine the reliability of some tests that could be used in the service in the future. Some of 
these tests are designed to identify people who have mental illness (e.g., depression). Studies have found that 
people with both drug and alcohol and mental illness can have more difficulty recovering than people with 
drug and alcohol problems alone. For this reason it is important to identify those people who also have mental 
illness so more can be done to help this group. This study aims to find out which questionnaires work best at 
identifying people who have mental illness. So several short questionnaires designed to identify whether you 
have mental illness problems will be administered along with an interview against which these questionnaires 
will be compared. As an additional, optional component, this interview may also be audio recorded to allow a 
second trained rater to double-check the reliability of the interview conclusions. You may choose to still partic-
ipate in the interview without having it audio recorded. The study also has some other short questionnaires that 
examine positive, wellness-oriented mental health constructs such as satisfaction with life, community belong-
ing and whether you feel in control of your life. This part of the study is being done because treatments that 
concentrate upon positive goals and strengths have the potential to be useful in therapy. 
 
What do I need to do? 
The first thing you need to do is carefully read the rest of this ‘participant information sheet’ making sure you 
understand what is required. If you do not wish to participate in this study you can simply not put your name 
down on the signup sheet. There will be no negative consequences for not participating in this study. It is 
entirely voluntary. If you sign up to participate, you will be contacted by Mr Kane Mortlock to arrange times 
to do two sessions a couple of days apart within one month of your start date in the program. These two ses-
sions will take approximately 2.5 hours in total. There will be a written consent form to sign before the first 
session. You will be asked to complete some questionnaires and an interview with Mr Kane Mortlock. If you 
would like further information you can contact Mr Kane Mortlock or Prof Frank Deane at the University of 
Wollongong by calling 02 4221 4207. 
 
Is there any risk or burden if I decide to participate? 
The main burden will be related to the time it takes to complete the two interviews. There is a very small risk 
that you might think some of the questions in the questionnaires or interview too personal or distressing. Many 
of the questions ask you about how you have been feeling emotionally. An example item is: “Have you ever 
been advised to take medication for anxiety, depression, hearing voices, or for any other emotional problem?” 
However, in addition to your right not to participate at all, even if you do decide to participate, you also have 
the right to refuse to answer any specific questions. If any of the questions cause you any distress the Salvation 
Army staff will also be available to assist you.  
 
It is not a component of this research to examine your involvement in any serious criminal activities. If you 
choose to discuss any serious criminal activity you should avoid identifying any specific individuals who may 
have committed crimes in any way. Serious criminal activity covers offences such as drug trafficking, serious 
assaults, sexual assaults, child abuse or neglect, murder and manslaughter. It does not cover minor possession 
of drugs. As this research is concerned with substance use the researchers will not report any illegal drug 
use. If you reveal information about criminal activity that has a mandatory reporting requirement, however, (for 
e.g., current criminal activity that is putting a child or children at risk of harm), the researchers will have to re-
port it. 
 
Are there any benefits expected? 
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People often find that when they complete the questionnaires it helps them reflect on their progress and clarify 
what it is about treatment that is helping them.  Also the information from this study will hopefully contribute 
to improving the treatment program for you and everyone who goes through it. You will be making a contribu-
tion to our understanding of how to best identify when people have mental health problems in addition to their 
substance misuse problems. This will assist in development of better treatment programs. 
 
 
How will my information be collected and used? 
Your information will be collected via some written questionnaires and an interview. We would also like per-
mission to obtain information obtained from your initial intake assessment when you first came into The Salva-
tion Army recovery programs. Your information will be kept confidential. It will be de-identified by attaching a 
special code to it so your name is not on it and you cannot be identified from it. All questionnaire material will 
be stored securely at the University of Wollongong in locked filing cabinets. The information from all the par-
ticipants as a whole may be used for publication in scholarly research journals, reports to the Salvation Army, 
student theses, and conference presentations. You will not be personally identifiable in any of these publica-
tions. Only group information will be published. If you also agree to have your interview tape recorded, after 
these tapes have been assessed by a second rater, they will be destroyed. 
 
What if I have more questions? 
You may have additional questions that you wish to ask about the research before you decide whether to partic-
ipate. You can contact Mr Kane Mortlock or Prof Frank Deane at the University of Wollongong by calling 02 
4221 4207. If you have any concerns or complaints regarding the way in which the research is or has been con-
ducted, you can contact the Secretary of the University of Wollongong Human Research Ethics Committee on 
Phone:  (02) 4221 4457, Fax: (02) 4221 4338   email: research@uow.edu.au 
!
!
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Appendix$I$
!
Client!Participant!Consent!Form!
!
The!Salvation!Army!Recovery!Service!Centres:!
Validation!of!Mental!Disorder!and!Mental!Health!Screening!Measures!
!
The!researchers!are:!Mr!Kane!Mortlock,!Prof!Frank!Deane!(Supervisor)!&!Dr!Trevor!Crowe!(Supervisor).!
!
I!have!been!given!information!about!the!study!‘The!Salvation!Army!Recovery!Service!Centres:!Validation!of!
Mental!Disorder!and!Mental!Health!Screening!Measures’.!I!have!discussed!the!project!with!The!Salvation!
Army!staff!and!have!been!offered!the!opportunity!to!discuss!the!research!project!with!the!chief!researcher!
(Mr!Mortlock)!who!is!conducting!this!research.!
!
I!understand!that,!if!I!consent!to!participate!in!this!project!I!will!be!asked!to:!
!
•! Authorise!access!to!my!intake!questionnaire!datar!
•! Attend!two!research!sessionsr!
o! Complete!questionnairesr!
o! Complete!an!interviewr!and!
o! Authorise!audio!recording!of!that!interview!(Optional)!
!
I! have! been! advised! of! the! potential! risks! and! burdens! associated! with! this! research,! which! include!
completion! of! questionnaires! that!may! contain! personal! questions! and! to! not! divulge! the! details! of! any!
serious!criminal!activity.!I!have!been!given!an!opportunity!to!contact!the!researchers!and!ask!any!questions!
I!may!have!about!the!research!and!my!participation.!!
I!understand!that!my!participation!in!this!research!is!voluntary.!I!am!free!to!refuse!to!participate!and!I!am!
free!to!withdraw!from!the!research!at!any!time.!My!refusal! to!participate!or!withdrawal!of!consent!will!not!
affect!my! relationship!with! The!Salvation!Army! or! the!University! of!Wollongong.! I! understand! that! I! can!
consent! to! the! research! without! consenting! to! the! interview! being! audio! recorded.! I! understand! that!
consenting! to! the! interview!being!audio!recorded! is!an!optional!component!and! that! I!can!consent! to! the!
research!without!consenting!to!this!optional!component!if!I!choose.!)
!
I! understand! that! the! data! collected! from!my!participation!will! be! deAidentified,! (made! so! you! cannot! be!
identified!by!it),!collated!with!other!participants’!data!and!that!I!will!not!be!identifiable!in!any!reports!of!this!
study.!I!understand!that!the!results!may!be!reported!in!journal!publications,!organisational!reports,!research!
theses,!and!conference!presentations,!and!I!consent!for!it!to!be!used!in!that!manner.!
)
If! I! have!any!enquiries!about! the! research,! I! can!contact!Mr!Mortlock!or!Prof!Deane!at! the!University!of!
Wollongong!by!calling!02!4221!4207.!If!I!have!any!concerns!or!complaints!regarding!the!way!the!research!
is!or!has!been!conducted,! I!can!contact! the!Ethics!Officer,!Human!Research!Ethics!Committee,!Office!of!
Research,! University! of! Wollongong! on! Phone:! ! (02)! 4221! 4457,! Fax:! (02)! 4221! 4338! ! ! email:! re%
search_services@uow.edu.au.!
!
By! signing! below! I! am! indicating!my! consent! to! participate! in! the! research! titled! ‘The! Salvation! Army!
Recovery!Service!Centres:! Validation! of!Mental!Disorder! and!Mental!Health! Screening!Measures’!
conducted!by!Mr!Mortlock,!Prof!Deane!and!Dr!Crowe!as! it! has!been!described! to!me! in! the!Participant!
Information!Sheet!and!discussed!with!The!Salvation!Army!staff.!!
!
I!understand!that!if!I!tick!the!checkbox!next!to,!“I!also!consent!to!the!interview!being!audio!recorded”,!I!am!
indicating!consent!to!that!optional!component!of!the!research!as!well.!!
!
!!!I!consent!to!the!interview!being!audio!recorded.!
!
Sign:! ! ! ! ! ! ! ! ! ! !
!
Name!(please!print):_________________________________!!!!!!!!!Date:!___________!
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Appendix$J$
UNIVERSITY!OF!WOLLONGONG!RESEARCH!STUDY:!
MENTAL!HEALTH!SCREENING!QUESTIONAIRE!
!
Requirements:!
•! Participants!1A2!weeks!into!program!!
•! Agree!to!participate!in!study!
•! Agree!to!2!interviews!2!days!apart!
•! First!interview:!~1.5!hours!(45mins!to!2!hours!max)!
•! Second!interview:~45!minutes!(30!mins!to!1!hour!max)!
•! People!tested!on!Monday!are!reAtested!on!Wednesday!
•! People!tested!on!Tuesday!are!reAtested!on!Thursday!!
!
!
!
!
!
!
Time! Monday!8!March!2010! Time! Tuesday!9!March!2010!
9.00!–!
10.00!
1.! 9.00!–!
11.00!
4.!
10.30!–!
11.30pm!
2.! 12.30!–!
2.30!
5.!
1.00!–!
2.00pm!
3.! 2.30!–!
4.30!
6.!
!
!
!
!
!
!
Time! Wednesday!10!March!2010! Time! Thursday!11!March!2010!
9.00!–!
10.00!
1.! 9.00!–!
11.00!
4.!
10.30!–!
11.30pm!
2.! 12.30!–!
2.30!
5.!
1.00!–!
2.00pm!
3.! 2.30!–!
4.30!
6.!
!
!
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Appendix$K$
MENTAL!HEALTH!CONTINUUM!–!SHORT!FORM!(MHC!–!SF)!
!
The&following&questions&are&about&how&you&have&been&feeling&in&the&past&month.&Please&place&a&
check&mark&in&the&box&that&best&represents&how&often&you&have&felt&each&feeling.&
!
In!the!past!month,!how!often!
did!you!feel!…!&
&
&
NEVER!
(0)&
ONCE!
OR!
TWICE!
(1)&
ABOUT!
ONCE!A!
WEEK!
(2)&
2!OR!3!
TIMES!A!
WEEK!
(3)&
ALMOST!
EVERY!
DAY!
(4)&
&
EVERY!
DAY!
(5)&
&
1.&happy&
&
& & & & & &
&
2.&interested&in&life&
&
& & & & & &
&
3.&satisfied&
&
& & & & & &
&
4.&that&you&had&something&
important&to&contribute&to&
society&
&
& & & & & &
&
5.&that&you&belonged&to&a&
community&(like&a&social&group,&
your&neighbourhood,&your&city)&
&
& & & & & &
&
6.&that&our&society&is&becoming&a&
better&place&for&people&
&
& & & & & &
&
7.&that&people&are&basically&
good&
&
& & & & & &
&
8.&that&the&way&our&society&
works&makes&sense&to&you&
&
& & & & & &
&
9.&that&you&liked&most&parts&of&
your&personality&
&
& & & & & &
&
10.&good&at&managing&the&
responsibilities&of&your&daily&
life&
&
& & & & & &
&
11.&that&you&had&warm&and&
trusting&relationships&with&
others&
&
& & & & & &
&
12.&that&you&have&experiences&
that&challenge&you&to&grow&and&
become&a&better&person&
&
& & & & & &
&
13.&confident&to&think&or&
express&your&own&ideas&and&
opinions&
&
& & & & & &
&
14.&that&your&life&has&a&sense&
of&direction&or&meaning&to&it&
&
& & & & & &
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SELF!REPORTING!QUESTIONNAIRE%20!
!
!
First:!Please!circle!the!“YES”!box!if!you!have!had!this!symptom!in!the!last!30!days.!
!
!
!
1.!Do!you!often!have!headaches?!
!
YES! NO! !
!
2.!Is!your!appetite!poor?!
!
YES! NO! !
!
3.!Do!you!sleep!badly?!
!
YES! NO! !
!
4.!Are!you!easily!frightened?!
!
YES! NO! !
!
5.!Do!your!hands!shake?!
!
YES! NO! !
!
6.!Do!you!feel!nervous,!tense!or!worried?!
!
YES! NO! !
!
7.!Is!your!digestion!poor?! YES! NO! !
!
8.!Do!you!have!trouble!thinking!clearly?!
!
YES! NO! !
!
9.!Do!you!feel!unhappy?!
!
YES! NO! !
!
10.!Do!you!cry!more!than!usual?!
!
YES! NO! !
!
11.!Do!you!find!it!difficult!to!enjoy!your!daily!activities?!
!
YES! NO! !
!
12.!Do!you!find!it!difficult!to!make!decisions?!
!
YES! NO! !
!
13.!Is!your!daily!work!suffering?!
!
YES! NO! !
!
14.!Are!you!unable!to!play!a!useful!part!in!life?!
!
YES! NO! !
!
15.!Have!you!lost!interest!in!things?!
!
YES! NO! !
!
16.!Do!you!feel!like!you!are!a!worthless!person?!
!
YES! NO! !
!
17.!Has!the!thought!of!ending!your!life!been!on!your!mind?!
!
YES! NO! !
!
18.!Do!you!feel!tired!all!the!time?!
!
YES! NO! !
!
19.!Do!you!have!uncomfortable!feelings!in!your!stomach?!
!
YES! NO! !
!
20.!Are!you!easily!tired?!
!
YES! NO! !
!
!
!
Second:!Please!look!back!over!the!questions.!For!every!one!you!have!answered!“YES”,!
please!put!a!tick!in!the!final!column!if!you!had!that!problem!at!a!time!when!you!were!NOT!
using!alcohol!or!other!drugs.!
!
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MODIFIED!MINI!SCREEN!
!
!
!
1.!Have!you!been!consistently!depressed!or!down,!most!of!the!day,!nearly!
every!day,!for!the!past!2!weeks?!
!
YES! NO!
!
2.!In!the!past!2!weeks,!have!you!been!less!interested!in!most!things!or!less!
able!to!enjoy!the!things!you!used!to!enjoy!most!of!the!time?!
!
YES! NO!
!
3.!Have!you!felt!sad,!low!or!depressed!most!of!the!time!for!the!last!two!
years?!
!
YES! NO!
!
4.!In!the!past!month,!did!you!think!that!you!would!be!better!off!dead!or!wish!
you!were!dead?!
!
YES! NO!
!
5.!Have!you!ever!had!a!period!of!time!when!you!were!feeling!up,!hyper!or!
so!full!of!energy!or!full!of!yourself!that!you!got!into!trouble!or!that!other!
people!thought!you!were!not!your!usual!self?!(Do!not!consider!times!when!
you!were!intoxicated!on!drugs!or!alcohol).!
!
YES! NO!
!
6.!Have!you!ever!been!so!irritable,!grouchy!or!annoyed!for!several!days,!
that!you!had!arguments,!verbal!or!physical!fights,!or!shouted!at!people!outA
side!your!family?!Have!you!or!others!noticed!that!you!have!been!more!irriA
table!or!overreacted,!compared!to!other!people,!even!when!you!thought!
you!were!right!to!act!this!way?!
!
YES! NO!
!
7a.!Have!you!had!one!or!more!occasions!when!you!felt!intensely!anxious,!
frightened,!uncomfortable!or!uneasy!even!when!most!people!would!not!feel!
that!way?!
7b.!If!yes,!did!these!intense!feelings!get!to!be!their!worst!within!10!min?!
If!the!answer!to!both!a!and!b!is!YES,!score!the!question!YES!
If!the!answer!to!either!a!or!b!is!NO,!score!the!question!NO!
!
YES! NO!
!
8.!Do!you!feel!anxious,!frightened,!uncomfortable!or!uneasy!in!situations!
where!help!might!not!be!available!or!escape!might!be!difficult?!
!
YES! NO!
!
9.!Have!you!worried!excessively!or!been!anxious!about!several!things!over!
the!past!6!months?!
If!NO!to!Question!9,!answer!NO!to!Question!10!and!proceed!to!Question!
11!
!
YES! NO!
!
10.!Are!these!worries!present!most!days?!
!
YES! NO!
!
11.!In!the!past!month,!were!you!afraid!or!embarrassed!when!others!were!
watching!you,!or!when!you!were!the!focus!of!attention?!Were!you!afraid!of!
being!humiliated?!
!
YES! NO!
!
12.!In!the!past!month,!have!you!been!bothered!by!thoughts,!impulses,!or!
images!that!you!couldn’t!get!rid!of!that!were!unwanted,!distasteful,!inapA
propriate,!intrusive!or!distressing?!
!
YES! NO!
!
13.!In!the!past!month,!did!you!do!something!repeatedly!without!being!able!
to!resist!doing!it?!
!
YES! NO!
!
14.!Have!you!ever!experienced!or!witnessed!or!had!to!deal!with!an!exA
tremely!traumatic!event!that!included!actual!or!threatened!death!or!serious!
injury!to!you!or!someone!else?!
!
YES! NO!
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!
15.!Have!you!reAexperienced!the!awful!event!in!a!distressing!way!in!the!
past!month?!
!
YES! NO!
!
16.!Have!you!ever!believed!that!people!were!spying!on!you,!or!that!someA
one!was!plotting!against!you,!or!trying!to!hurt!you?!
!
YES! NO!
!
17.!Have!you!ever!believed!that!someone!was!reading!your!mind!or!could!
hear!your!thoughts,!or!that!you!could!actually!read!someone’s!mind!or!hear!
what!another!person!was!thinking?!
!
YES! NO!
!
18.!Have!you!ever!believed!that!someone!or!some!force!outside!of!yourself!
put!thoughts!in!your!mind!that!were!not!your!own,!or!made!you!act!in!a!way!
that!was!not!your!usual!self?!Or,!have!you!ever!felt!that!you!were!posA
sessed?!
!
YES! NO!
!
19.!Have!you!ever!believed!that!you!were!being!sent!special!messages!
through!the!TV,!radio,!or!newspaper?!Did!you!believe!that!someone!you!
did!not!personally!know!was!particularly!interested!in!you?!
!
YES! NO!
!
20.!Have!your!relatives!or!friends!ever!considered!any!of!your!beliefs!
strange!or!unusual?!
!
YES! NO!
!
21.!Have!you!ever!heard!things!other!people!couldn’t!hear,!such!as!voices?!
!
YES! NO!
!
22.!Have!you!ever!had!visions!when!you!were!awake!or!have!you!ever!
seen!things!other!people!couldn’t!see?!
!
YES! NO!
!
!
!
RYFF!SCALES!OF!PSYCHOLOGICAL!WELL%BEING!54!
!
The!following!set!of!questions!deals!with!how!you!feel!about!yourself!and!your!life.!!Please!remember!that!
there!are!no!right!or!wrong!answers.!
!
!
Circle!the!number!that!best!describes!your!
present!agreement!or!disagreement!with!
each!statement.!
Strongly!
Disagree!
Disagree!
Somewhat!
Disagree!
Slightly!
Agree!
Slightly!
Agree!
Somewhat!
Strongly!
Agree!
1.!!Sometimes!I!change!the!way!I!
act!or!think!to!be!more!like!those!
around!me.!!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
2.!!In!general,!I!feel!I!am!in!charge!
of!the!situation!in!which!I!live.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
3.!!I!am!not!interested!in!activities!
that!will!expand!my!horizons.!!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
4.!!When!I!look!at!the!story!of!my!
life,!I!am!pleased!with!how!things!
have!turned!out.!!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
5.!!Maintaining!close!relationships!
has!been!difficult!and!frustrating!for!
me.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
6.!!I!am!not!afraid!to!voice!my!opinA
ions,!even!when!they!are!in!opposiA
tion!to!the!opinions!of!most!people.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
7.!!The!demands!of!everyday!life!
often!get!me!down.!!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
8.!!I!live!life!one!day!at!a!time!and!
don’t!really!think!about!the!future.!!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
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Circle!the!number!that!best!describes!your!
present!agreement!or!disagreement!with!
each!statement.!
Strongly!
Disagree!
Disagree!
Somewhat!
Disagree!
Slightly!
Agree!
Slightly!
Agree!
Somewhat!
Strongly!
Agree!
9.!!In!general,!I!feel!confident!and!
positive!about!myself.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
10.!!I!often!feel!lonely!because!I!
have!few!close!friends!with!whom!to!
share!my!concerns.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
11.!!My!decisions!are!not!usually!
influenced!by!what!everyone!else!is!
doing.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
12.!!I!do!not!fit!very!well!with!the!
people!and!the!community!around!
me.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
13.!!I!tend!to!focus!on!the!present,!
because!the!future!nearly!always!
brings!me!problems.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
14.!!I!feel!like!many!of!the!people!I!
know!have!gotten!more!out!of!life!
than!I!have.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
15.!!I!enjoy!personal!and!mutual!
conversations!with!family!members!
or!friends.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
16.!!I!tend!to!worry!about!what!other!
people!think!of!me.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
17.!!I!am!quite!good!at!managing!
the!many!responsibilities!of!my!daily!
life.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
18.!!I!don’t!want!to!try!new!ways!of!
doing!things!A!my!life!is!fine!the!way!
it!is.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
19.!!Being!happy!with!myself!is!
more!important!to!me!than!having!
others!approve!of!me.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
20.!!I!often!feel!overwhelmed!by!my!
responsibilities.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
21.!!I!think!it!is!important!to!have!
new!experiences!that!challenge!
how!you!think!about!yourself!and!
the!world.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
22.!!My!daily!activities!often!seem!
trivial!and!unimportant!to!me.!!!!!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
23.!!I!like!most!aspects!of!my!perA
sonality.!!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
24.!I!don’t!have!many!people!who!
want!to!listen!when!I!need!to!talk.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
25.!!I!tend!to!be!influenced!by!peoA
ple!with!strong!opinions.!!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
26.!!When!I!think!about!it,!I!haven’t!
really!improved!much!as!a!person!
over!the!years.!!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
27.!!I!don’t!have!a!good!sense!of!
what!it!is!I’m!trying!to!accomplish!in!
life.!!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
28.!!I!made!some!mistakes!in!the!
past,!but!I!feel!that!all!in!all!everyA
thing!has!worked!out!for!the!best.!!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
29.!!I!generally!do!a!good!job!of!
taking!care!of!my!personal!finances!
and!affairs.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
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Circle!the!number!that!best!describes!your!
present!agreement!or!disagreement!with!
each!statement.!
Strongly!
Disagree!
Disagree!
Somewhat!
Disagree!
Slightly!
Agree!
Slightly!
Agree!
Somewhat!
Strongly!
Agree!
30.!!I!used!to!set!goals!for!myself,!
but!that!now!seems!like!a!waste!of!
time.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
31.!!In!many!ways,!I!feel!disapA
pointed!about!my!achievements!in!
life.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
32.!!It!seems!to!me!that!most!other!
people!have!more!friends!than!I!do.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
33.!!I!enjoy!making!plans!for!the!
future!and!working!to!make!them!a!
reality.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
34.!!People!would!describe!me!as!a!
giving!person,!willing!to!share!my!
time!with!others.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
35.!!I!have!confidence!in!my!opinA
ions,!even!if!they!are!contrary!to!the!
general!consensus.!!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
36.!!I!am!good!at!juggling!my!time!
so!that!I!can!fit!everything!in!that!
needs!to!be!done.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
37.!!I!have!a!sense!that!I!have!deA
veloped!a!lot!as!a!person!over!time.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
38.!!I!am!an!active!person!in!carryA
ing!out!the!plans!I!set!for!myself.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
39.!!I!have!not!experienced!many!
warm!and!trusting!relationships!with!
others.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
40.!!It’s!difficult!for!me!to!voice!my!
own!opinions!on!controversial!matA
ters.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
41.!!I!do!not!enjoy!being!in!new!sitA
uations!that!require!me!to!change!
my!old!familiar!ways!of!doing!
things.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
42.!!Some!people!wander!aimlessly!
through!life,!but!I!am!not!one!of!
them.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
43.!!My!attitude!about!myself!is!
probably!not!as!positive!as!most!
people!feel!about!themselves.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
44.!!I!often!change!my!mind!about!
decisions!if!my!friends!or!family!disA
agree.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
45.!For!me,!life!has!been!a!continuA
ous!
process!of!learning,!changing,!and!
growth.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
46.!!I!sometimes!feel!as!if!I’ve!done!
all!there!is!to!do!in!life.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
47.!!I!know!that!I!can!trust!my!
friends,!and!they!know!they!can!
trust!me.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
48.!!The!past!had!its!ups!and!
downs,!but!in!general,!I!wouldn’t!
want!to!change!it.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
49.!!I!have!difficulty!arranging!my!
life!in!a!way!that!is!satisfying!to!me.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
! 211!
Circle!the!number!that!best!describes!your!
present!agreement!or!disagreement!with!
each!statement.!
Strongly!
Disagree!
Disagree!
Somewhat!
Disagree!
Slightly!
Agree!
Slightly!
Agree!
Somewhat!
Strongly!
Agree!
50.!!I!gave!up!trying!to!make!big!
improvements!or!changes!in!my!life!
a!long!time!ago.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
51.!!When!I!compare!myself!to!
friends!and!acquaintances,!it!makes!
me!feel!good!about!who!I!am.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
52.!I!judge!myself!by!what!I!think!is!
important,!not!by!the!values!of!what!
others!think!is!important.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
53.!!I!have!been!able!to!build!a!
home!and!a!lifestyle!for!myself!that!
is!much!to!my!liking.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
54.!!There!is!truth!to!the!saying!that!
you!can’t!teach!an!old!dog!new!
tricks.!
!
1!
!
2!
!
3!
!
4!
!
5!
!
6!
!
!
!
!
!
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MENTAL!HEALTH!SCREENING!FORM%III!
&
Instructions:&In&this&program,&we&help&people&with&all&their&problems,&not&just&their&addictions.&This&
commitment&includes&helping&people&with&emotional&problems.&Our&staff&is&ready&to&help&you&to&
deal&with&any&emotional&problems&you&may&have,&but&we&can&do&this&only&if&we&are&aware&of&the&
problems.&Any&information&you&provide&to&us&on&this&form&will&be&kept&in&strict&confidence.&It&will&not&
be&released&to&any&outside&person&or&agency&without&your&permission.&If&you&do&not&know&how&to&
answer&these&questions,&ask&the&staff&member&giving&you&this&form&for&guidance.&Please&note,&each&
item&refers&to&your&entire&life&history,&not&just&your&current&situation,&this&is&why&each&question&beR
gins&–&“Have&you&ever&….”&
&
&
1)! Have&you&ever&talked&to&a&psychiatrist,&psychologist,&therapist,&social&worker&
or&counselor&about&an&emotional&problem?&
YES& NO&
2)! Have&you&ever&felt&you&needed&help&with&your&emotional&problems,&or&have&
you&had&people&tell&you&that&you&should&get&help&for&your&emotional&probR
lems?&
YES& NO&
3)! Have& you& ever& been& advised& to& take& medication& for& anxiety,& depression,&
hearing&voices,&or&for&any&other&emotional&problem?&
YES& NO&
4)! Have&you&ever&been&seen&in&a&psychiatric&emergency&room&or&been&hospitalR
ised&for&psychiatric&reasons?&
YES& NO&
5)! Have&you&ever&heard&voices&no&one&else&could&hear&or&seen&objects&or&things&
which&others&could&not&see?&
YES& NO&
6)! a)&Have&you&ever&been&depressed&for&weeks&at&a&time,&lost&interest&or&pleasR
ure& in&most& activities,& had& trouble& concentrating& and&making& decisions& or&
thought&about&killing&yourself?&
b)&Did&you&ever&attempt&to&kill&yourself?&
&
&
YES&
&
YES&
&
NO&
&
NO&
&
7)! Have&you&ever&had&nightmares&or&flashbacks&as&a&result&of&being&involved&in&
some&traumatic/terrible&event?&For&example,&warfare,&gang& fights,& fire,&doR
mestic&violence,&rape,&incest,&car&accident,&being&shot&or&stabbed?&
YES& NO&
8)! Have& you& ever& experienced& any& strong& fears?& For& example,& of& heights,& inR
sects,&animals,&dirt,&attending&social&events,&being& in&a&crowd,&being&alone,&
being&in&places&where&it&may&be&hard&to&escape&or&get&help?&
YES& NO&
9)! Have&you&ever&given&in&to&an&aggressive&urge&or&impulse,&on&more&than&one&
occasion,&that&resulted&in&serious&harm&to&others&or&led&to&the&destruction&of&
property?&
YES& NO&
10)!Have& you& ever& felt& that& people& had& something& against& you,&without& them&
necessarily&saying&so,&or&that&someone&or&some&group&may&be&influencing&or&
trying&to&influence&your&thoughts&or&behaviour?&
YES& NO&
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11)!Have& you& ever& experienced& any& emotional& problems& associated&with& your&
sexual&interests,&your&sexual&activities,&or&your&choice&of&sexual&partner?&
YES& NO&
12)!Was&there&ever&a&period&in&your&life&where&you&spent&a&lot&of&time&thinking&
and&worrying& about& gaining&weight,& becoming& fat,& or& controlling& your& eatR
ing?&For&example,&by& repeatedly&dieting&or& fasting,&engaging& in&much&exerR
cise& to& compensate& for&binge&eating,& taking&enemas,&or& forcing& yourself& to&
throw&up?&
YES& NO&
13)!Have& you&ever& had& a&period&of& time&when& you&were& so& full& of& energy& and&
your& ideas& came&very& rapidly,&when&you& talked&nearly&nonRstop,&when&you&
moved&quickly& from&one&activity& to&another,&when&you&needed& little& sleep,&
and&believed&you&could&do&almost&anything?&
YES& NO&
14)!Have&you&ever&had&spells&or&attacks&when&you&suddenly&felt&anxious,&frightR
ened,& uneasy& to& the&extent& that& you&began& sweating,& your&heart& began& to&
beat& rapidly,&you&were&shaking&or& trembling,&your&stomach&was&upset,&you&
felt&dizzy&or&unsteady,&as&if&you&would&faint?&
YES& NO&
15)!Have&you&ever&had&a&persistent,&lasting&thought&or&impulse&to&do&something&
over& and& over& that& caused& you& considerable& distress& and& interfered& with&
normal&routines,&work,&or&your&social&relations?&Examples&would&include&reR
peatedly&counting&things,&checking&and&rechecking&on&things&you&had&done,&
washing& and& rewashing& your& hands,& praying,& or& maintaining& a& very& rigid&
schedule&of&daily&activities&from&which&you&could&not&deviate?&
YES& NO&
16)!Have& you& ever& lost& considerable& sums& of&money& through& gambling& or& had&
problems&at&work,&in&school,&with&your&family&and&friends&as&a&result&of&your&
gambling?&
YES& NO&
17)!Have& you& ever& been& told& by& teachers,& guidance& counselors,& or& others& that&
you&have&a&special&learning&problem?&
YES& NO&
!
THE!SHORT!DEPRESSION^HAPPINESS!SCALE!(SDHS)!!
©&Stephen&Joseph&2000&&
A&number&of&statements&that&people&have&made&to&describe&how&they&feel&are&given&below.&Please&
read&each&one&and&tick&the&box&which&best&describes&how&frequently&you&felt&that&way&in&the&past&
seven&days,&including&today.&Some&statements&describe&positive&feelings&and&some&describe&negative&
feelings.&You&may&have&experienced&both&positive&and&negative&feelings&at&different&times&during&the&
past&seven&days.&
&
& Never& Rarely& Sometimes& Often&
(1)&I&felt&dissatisfied&with&my&life& & & & &
(2)&I&felt&happy& & & & &
(3)&I&felt&cheerless& & & & &
(4)&I&felt&pleased&with&the&way&I&am& & & & &
(5)&I&felt&that&life&was&enjoyable& & & & &
(6)&I&felt&that&life&was&meaningless& & & & &
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&
SELF!REPORTING!QUESTIONNAIRE%5!
!
First:!Please!circle!the!“YES”!box!if!you!have!had!this!symptom!in!the!last!30!days.!
!
!
1.!Do!you!feel!that!somebody!has!been!trying!to!harm!you!in!some!
way?!
!
YES! NO! !
!
2.!Are!you!a!much!more!important!person!than!people!think?!
!
YES! NO! !
!
3.!Have!you!noticed!any!interference!or!anything!else!unusual!with!
your!thinking?!
!
YES! NO! !
!
4.!Do!you!ever!hear!voices!without!knowing!where!they!come!from!or!
which!other!people!cannot!hear?!
!
YES! NO! !
!
5.!Have!you!ever!had!any!fits,!convulsions,!falls!to!the!ground,!with!
movements!of!the!arms!and!legs,!biting!of!the!tongue!or!loss!of!conA
sciousness?!
!
YES! NO! !
!
Second:!Please!look!back!over!the!questions.!For!every!one!you!have!answered!“YES”,!
please!put!a!tick!in!the!final!column!if!you!had!that!problem!at!a!time!when!you!were!NOT!
using!alcohol!or!other!drugs.!
!!
!
!
!
!
THE!WHO!(FIVE)!WELL^BEING!INDEX!(1998!VERSION)!!
&
Please&indicate&for&each&of&the&five&statements&which&is&closest&to&how&you&have&been&feeling&over&
the&last&two&weeks.&Notice&that&higher&numbers&means&better&wellRbeing.&
&
Example:&If&you&have&felt&cheerful&and&in&good&spirits&more&than&half&of&the&time&during&the&last&two&
weeks,&put&a&tick&in&the&box&with&a&number&3&next&to&it&for&question&1&below.&
&
Over%the%last%two%weeks:%
All&of&the&
time&
Most&of&
the&time&
More&than&
half&of&the&
time&
Less&
than&
half&of&
the&time&
Some&of&
the&
time&
At&no&
time&
(1)&I&have&felt&cheerful&and&in&
good&spirits&  5!  4!  3!  2!  1!  0!
(2)!I!have!felt!calm!and!relaxed!  5!  4!  3'  2'  1'  0'
(3)!I!have!felt!active!and!vigorous!  5!  4!  3'  2'  1'  0'
(4)!I!woke!up!feeling!fresh!and!
rested!  5!  4!  3'  2'  1'  0'
(5)!My!daily!life!has!been!filled!
with!things!that!interest!me!  5!  4!  3'  2'  1'  0'
!
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Appendix(L(
ADDICTION(SEVERITY(INDEX(PSYCHIATRIC(STATUS(DOMAIN(
(
How(many(times(have(you(been(treated(for(any((
psychological(or(emotional(problems:(
(
P1∗'''In'a'hospital'or'inpatient'setting?'
'
P2∗(('Outpatient/private'patient?'
(((((((((((•(Do'not'include'substance'abuse,'employment,''
or'family'counseling.'''
(((((((((((•(Treatment'episode'='a'series'of'continuous''
'''''''''''''visits'or'treatment'days,'not'the'number'of'visits.'
'
'
P3.'''''Do'you'receive'financial'support'for'a'psychiatric''
'''''''''''disability?''Can'be'from'government'or'employer,'etc.' '''''''''''''' ' ' '''
' ' ' ' ' ' ' ' 0GNo'''1GYes'
'
Have(you(had(a(significant(period(of(time((that(was(not(a(direct((
result(of(alcohol/drug(use)(in(which(you(have:(
' ' ' ' ' ' 0MNo(((1MYes(
' ' ' ' ' ''''(Past(30(Days(((((Lifetime'
P4.'''''Experienced'serious'depressionG'
''''''''''sadness,'hopelessness,'loss'of'interest?'
'
'
P5.'''''Experienced'serious'anxiety/tension'
''''''''''uptight,'unreasonably'worried,''
''''''''''inability'to'feel'relaxed?'
'
'
P6.'''''Experienced'hallucinationsGsaw'things/''
''''''''''heard'voices'that'others'didn’t'see/hear?'
'''''''''''Code'other'psychotic'symptoms'here'also.'
'
'
P7.'''''Experienced'trouble'understanding,'
''''''''''concentrating,'or'remembering?'
'
(
Note:''Patient'can'be'under'the'influence'of'alcohol/drugs'for'these'questions.'
Have(you(had(a(significant(period(of(time((regardless(of(alcohol(and(drug(use)(in(which(you(
have:'' '
''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''0MNo(((1MYes((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
' ' ' ' ' Past(30(Days(((((Lifetime'
P8.'''''Experienced'trouble'controlling''
''''''''''violent'behavior'including'episodes'of''
''''''''''rage,'or'violence?'
( '
P9.'''''Experienced'serious'thoughts'of'suicide?'
( •(Patient'seriously'considered'a'plan'for''
'''taking'his/her'life.'''
'''
P10.'''Attempted'suicide?'
( •(Include'actual'suicidal'gestures'or''
'''attempts.'
' (('
'
P11.''Has'a'health'care'provider'recommended''
''''''''''you'take'any'medications'for''
''''''''''psychological'or'emotional'problems?'
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(
((((((((((•(Recommended'for'the'patient'by'a'physician'or'other'health'care''
''''''''''''provider'as'appropriate.''Record'"Yes"'if'a'medication'was''
''''''''''''recommended'even'if'the'patient'is'not'taking'it.'
'
'
'
(
P12.''How'many'days'in'the'past'30'have'you'experienced''
these'psychological'or'emotional'problems?'
( •(This'refers'to'problems'noted'in'Questions'P4GP10.'
'
For(Questions(P13MP14,(ask(the(patient(to(use(the(Patient(Rating(scale(
(
P13.''How'troubled'or'bothered'have'you'been'by'these''
psychological'or'emotional'problems'in'the'past'30'days?'
( •(Patient'should'be'rating'the'problem'days'from'Question'P12.'
'
P14.''How'important'to'you'now'is'treatment'for''
'''''''' ''these'psychological'or'emotional'problems?'
(
Note:(The(patient(is(rating(their(need(for(you/your(program(to(provide(or(refer(them(to(psychologiM
cal/psychiatric(services,(above(and(beyond(treatment(they(may(already(be(getting(somewhere(else.(
(
CONFIDENCE(RATING(
Is(the(above(information(significantly(distorted(by:(
P22'''Patient's'misrepresentation?' ' ''''''''''''''0GNo'1GYes'
'
P23.''Patient's'inability'to'understand?' ''''''''''''''0GNo'1GYes'
(
PSYCHIATRIC(STATUS(COMMENTS(
(Include'question'number'with'your'comments)'
_____________________________________________________(
(
Specify(Diagnoses(if(known:(_____________________________(
(
_____________________________________________________(
(
_____________________________________________________(
(
_____________________________________________________(
(
_____________________________________________________(
'
________________________________________________________________________________(
(
_____________________________________________________(
(
(
CLOSING(ITEM(
'
G12.(Special(Code(M(If(ASI(is(not(completed:(
1.'Interview'terminated'by'interviewer'
2.'Patient'refused'to'finish'interview'
3.'Patient'unable'to'respond'(language'or'intellectual'barrier,'under'
''''the'influence,'etc.')'
'
Code'“N”'if'Interview'completed.'
'
((
'
'
'
'
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Appendix(M(
'
STRUCTURED(CLINICAL(INTERVIEW(FOR(DSMMIVMTR(AXIS(I(DISORDERS(
'
Patient(Edition(((January(2007)(
'
S(C(I(D(M(I(/(P((
'
'
Michael'B.'First,'M.D.b'Robert'L.'Spitzer,'M.D.b'
Miriam'Gibbon,'M.S.W.b'and'Janet'B.W.'Williams,'D.S.W.'
'
'
Study:' __________________________________' Study'No.:' __''__''__''__'
'
Subject:' __________________________________' I.D.'No.:' __''__''__''__'
'
Rater:' __________________________________' Rater'No.:' __''__''__'
'
' ' Date'of'Interview:' __''__''__''__''__''__'
' Mo.' Day' Year''''
' P1'
'
P2'
'
'
P3'
'
P4'
Sources'of'information'(check'all'that'apply):' ' __'Subject'
__'Family/friends/associates'
__'Health'professional/chart/referral'note'
' P5'
P6'
P7'
Edited'and'checked'by:'__________________________________' Date:_______________'
''
'
' '
'
'
'
'
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